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Temozolomide (TMZ) is the standard of care treatment for patients diagnosed with glioblastoma 
multiforme. However, median survival of patients diagnosed with glioblastoma is only increased 
by 2.5 months when treated with TMZ and radiotherapy, compared with radiotherapy alone. 
Furthermore, current literature suggests that 60-75% of patients experience no clinical benefit 
from TMZ and a further 15-20% of these patients develop clinically significant toxicity, which can 
make further treatment unsafe. Therefore, there is an inherent need for a chemotherapeutic 
agent that is safer and more effective for patients with high-grade glioma. 
 
A comprehensive review of the literature indicated that position 8 on the imidazole ring of TMZ, 
held significant promise in terms of improving the activity of the molecule. Numerous studies 
have demonstrated a degree of success investigating both ester and amide analogues of TMZ. 
However, to date, modifications at position 8 of the imidazole ring of TMZ have not been fully 
explored. Consequently, the aim of the current study was to synthesise a series of novel ester 
and amide analogues of TMZ, with the aim of improving our understanding of structure activity 
relationships at this position, thus, improving activity of the molecule. 
 
Novel ester and amide analogues of TMZ, were synthesised using two routes. One utilising 
reactions between TMZ acyl chloride and various alcohols and amines, the other utilising 
dehydrating agents, dicyclohexylcarbodiimide and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, to achieve direct coupling of TMZ acid to various alcohols 
and amines. Novel analogues were characterised using 1H and 13C nuclear magnetic resonance 
(NMR) spectroscopy, infrared spectroscopy, high resolution mass spectrometry (HMRS) and 
melting point analysis. Upon characterisation, the novel analogues were assessed for their 
cytotoxic potency against the high-grade glioma cell lines, U87-MG, 1321-N1 and GOS-3. 
Additionally, the human glial cell line, SVGp12 was included as a control. Cells were incubated 
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for 144 hours with various concentrations of drug before assessing viability with CellTitreGlo©, 
to obtain the IC50.  
 
Antiproliferative determination of novel esters and amides analogues of TMZ revealed that 
phenolic ester analogues of TMZ displayed increased potency, up to 5-fold, against specified 
HGG cell lines. The promising activity displayed by phenolic TMZ esters prompted further 
investigations against patient-derived primary glioblastoma cultures, obtained from The Royal 
Preston Hospital. Primary cultures, BTNW914 and BTNW374, were revealed to be MGMT 
positive and MGMT negative by pathology staff at the hospital, using Immunohistochemical 
analysis. Lead phenolic TMZ esters were found to decrease viability in primary cells at clinically 
obtainable concentrations, irrespective of O6-alkylguanine DNA alkyltransferase (MGMT) 
expression. Furthermore, TMZ was found to be ineffective against the same primary cells at 
clinically relevant concentrations, suggesting that the novel phenyl ester analogues of TMZ have 
potential as chemotherapeutics agents for the treatment of glioblastoma. 
 
Porcine liver esterase was used to assess the stability of the ester linkage of lead analogues, 
using HPLC as a means of analysis. Results from this work suggest a potential marked fragility of 
the ester bond in lead analogues with half-lives ranging from 3.2 – 13.7 minutes. 
 
In conclusion, the lead phenolic TMZ esters described in the present study have been shown to 
exhibit improved in-vitro activity against HGG cells, compared with TMZ. It is hoped that this 
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Neuroglial cells, more commonly referred to as glial cells, account for the majority of cells in the 
central nervous system (CNS), outnumbering nerve cells by a ratio of approximately 3:1. Glial 
cells were named in the early 19th century from the belief that these cells acted as the “glue” 
that held the nervous system together. The presumption that glial cells acted as glue was born 
from early visualisation of brain tissue, where these cells appeared to cover all the space 
between neurons in the brain. This appearance led early scientists to believe that glial cells 
provided a scaffold for the neurons. However, it is now widely recognised that glial cells have a 
variety of different functions Purves et al. (2001). Glial cells differ from nerve cells since they are 
not directly involved in synaptic interactions, instead they work to support neuron signalling 
(Kettenmann and Ransom, 2013).  
 
Figure 1.1: A graphical illustration summarising the cells of the CNS. Green – astrocytes; Blue – microglia; 




Glial cells of the mature CNS are classified as microglial cells or macroglial cells. As the name 
suggests, microglial cells are the smallest of these subtypes and function as the brain’s immune 
cells of the brain. In the resting healthy brain tissue these cells are highly mobile and work to 
actively detect brain insults and to monitor synaptic integrity (Purves et al., 2001). In early 
postnatal development, microglial cells interact with neurons to help develop neuronal 
pathways influencing maturation of the brain. Macroglial cells include a number of specialised 
cells each with different functions. Such examples of macroglial cells found in the CNS are 
oligodendrocytes whose function is to myelinate axons; astrocytes whose function is to support 
neuron signalling; and ependymal cells which maintain homeostasis in the brain (Figure 1.1) 
(Kettenmann and Ransom, 2013; Wolburg et al., 2015). Cancers originating from glial cells, more 
commonly referred to as gliomas, are the most common primary brain tumour diagnosed in the 














1.2. Glioma and Glioblastoma Multiforme 
Glioma is a general term used to describe primary brain tumours originating from glial cells 
including oligodendrocytes, astrocytes and ependymal cells (Wolburg et al., 2015). While the 
global incidence of glioma is relatively low, the prognosis of the malignancy is extremely poor, 
with only half of patients responding positively to treatment (Ernest and Sontheimer, 2009). 
Although gliomas account for a very small proportion of cancers diagnosed in adults, the poor 
prognosis of the condition means that gliomas are the second largest cause of cancer-related 
deaths in children and the single largest cause of cancer related deaths in adult men (aged 20-
39) (Liu et al., 2018). Gliomas are also most prevalent in individuals over 55 years of age, a group 
that tends to have the poorest prognosis (Figure 1.2) (Ernest and Sontheimer, 2009).  
A summary of survival rates for glioma, grades I-IV, is shown in Table 1.1. The most common and 
aggressive type of glioma is glioblastoma multiforme (GBM), a tumour of astrocytic lineage and 
classified as grade IV by the World Health Organisation (WHO) (Louis et al., 2016). 
 
Figure 1.2: Average Number of New Brain Tumour Cases per Year and Age-Specific Incidence Rates per 100,000 




GBM accounts for 54% of all gliomas and remains an incurable disease with very poor prognosis 
(Ostrom et al., 2013). In 2016 the classification of GBMs was updated by the WHO. Currently 
GBMs are assessed for mutations in the IDH1 gene, coding for cytosolic NADP+ dependent 
isocitrate dehydrogenase (Louis et al., 2016). The IDH status of GBMs is used to distinguish 
between primary and secondary tumours as well as being a useful predictor for treatment 
response (Combs et al., 2011; Choi and Curry, 2017). GBMs are classified into three main sub 
types by the WHO; glioblastoma IDH wild type (primary); glioblastoma IDH mutant (secondary); 
and glioblastoma NOS (Glioblastoma NOS refer to a glioblastoma where full IDH evaluation 
cannot be performed (Louis et al., 2016)). Primary IDH wild type GBMs occur predominantly in 
older patients (mean age 62 years).  Whereas secondary IDH mutant GBMs are much more 
common in the younger cohorts (mean age 46 years), these tumours are usually a result of the 
development of lower-grade astrocytomas or oligodendrogliomas (Ohgaki et al., 2004; Ohgaki 
and Kleihues, 2007; Ohgaki and Kleihues, 2009).  
 
Table 1.1: Survival rates and grading of diffuse astrocytic and oligodendroglial tumours. (Liu et al., 2012). 
WHO Grade Glioma Median Survival 
I Pilocytic astrocytoma 10 years + 
II Diffuse astrocytoma; Oligodendroglioma 5-10 years 
III Anaplastic astrocytoma; Anaplastic oligodendroglioma  2-5 years 







Age-adjusted incidence rates of GBM range from 0.59 to 3.69 persons per 100,000 persons, 
across different countries (Arora et al., 2009; Gausia et al., 2009; Dobes et al., 2011; Liu et al., 
2012; Thakkar et al., 2014). Thakkar et al., 2014 indicated that the incidence of GBMs is 
significantly higher in developed countries. This phenomenon is likely accounted for by poor 
access to health care and different diagnostic practices resulting in under reporting of GBMs in 
developing countries (Fisher et al., 2007). It is well documented that GBM predominantly occurs 
in males compared to females (Thakkar et al., 2014). However, although primary GBMs are 3 
times more common in men; secondary GBMs are actually 1.5 times more common in women 
(Sturm et al., 2014). Age also plays an important factor in the incidence rates of GBM with the 
majority of diagnoses occurring in elderly patients. The median age of diagnosis is 64 years, with 
peak incidence between the ages of 75-84 years (Ostrom et al., 2013). As the incidence rate in 
children under the age of 19 years is much less common, epidemiological studies traditionally 
combine diffuse intrinsic pontine glioma, anaplastic astrocytomas with GBMs, under the 
umbrella of high grade gliomas (HGG) (Sturm et al., 2014). HGGs affect 0.8 per 100,000 children 
per year, representing the most common group of CNS neoplasms in this age group (Thakkar et 
al., 2014). 
Limited information is available for the etiology of brain tumours, including GBM (Hanif et al., 
2017). Hochberg et al., 1990, failed to show a significant increase in GBM incidence as a result 
of various lifestyle behaviours, such as smoking, drugs, excessive alcohol consumption or high 
N-nitroso exposure through diet (Hochberg et al., 1990). There is, however, evidence that 
supports that intracranial radiation exposure significantly increases the incidence of GBM (Hanif 
et al., 2017). Following 116 cases of GBM that were directly caused by radiation exposure it was 
estimated/calculated that the overall risk of developing GBM as a direct result of radiotherapy 
was 2.6% (Salvati et al., 2003; Hanif et al., 2017). This represents a significant increase in 
incidence when compared with the <0.01% global incidence of GBMs. Within the paediatric 
cohort, it has been shown that there is an increased risk of glioma after therapeutic intracranial 
radiation exposure, which is both dose and age dependent (Hanif et al., 2017). Exposure to 
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atomic bomb radiation in Nagasaki and Hiroshima also increased the incidence of gliomas 
(Prasad and Haas-Kogan, 2009). However, no direct evidence has been presented that shows an 
increase in the risk of developing GBM through exposure to routine diagnostic radiation 
exposure in both the adult and paediatric cohorts (Prasad and Haas-Kogan, 2009). Therefore 
there is an assumption that the manifestation of GBM is usually a result of sporadic genetic 
mutation within the astrocytes of the brain leading to tumour development. It should also be 
noted that in approximately 10% of cases, patients have been found to have a genetic 
predisposition to developing GBM, but the gene/genes responsible are yet to be identified 
(Fisher et al., 2007; Backes et al., 2014). A meta-analysis conducted by Linos et al., 2007 found a 
significant decrease in the risk of developing glioma in patients suffering from allergies (Linos et 
al., 2007). This has been hypothesised to be as a result of stimulation of immune surveillance 
mechanisms helping prevent gliomas, such as GBMs from developing (Bondy et al., 2008).  
Human cytomegalovirus (HCMV) has also been associated with a significant increase in the risk 
of GBM development. HCMV is known to exhibit tropism for glial cells, inducing upregulation of 
specific proteins; intermediate-early proteins IE1 and IE2, chemokine receptor homologue US28 
and glycoprotein gB (Cobbs et al., 2014). These proteins have the ability to activate mitogenesis, 
angiogenesis, inflammation, apoptosis and mutagenesis. Activation of these pathways results in 
gene products that work to deregulate key signalling pathways STAT3 and Akt, compromising 
glial cells and increasing their susceptibility to malignant transformation (Soroceanu et al., 
2015). 
The current standard treatment of care for GBM involves surgical resection followed by 
postoperative radiotherapy and adjuvant chemotherapy (Stupp et al., 2005). Despite the 
intensive treatment regimen the prognosis for patients with GBM is still very poor. Surgical 
resection plays a pivotal role in the treatment of GBM (Manrique-Guzman et al., 2017). The 
resection of malignant glial tissue has historically been the initial approach for the treatment of 
brain tumours, reducing tumour mass and harvesting tissue used for diagnosis (Sanai and 
32 
 
Berger, 2009). The first multivariate analysis investigating survival benefit of surgical resection 
with radiotherapy in GBM, found that at least 89% of the tumour must be resected for the 
patient to gain a significant survival benefit (Lacroix et al., 2001). Furthermore, resection of >98% 
of the tumour resulted in 13 months median survival of the patient. In contrast resection of 
<98% of the tumour only resulted in 8.8 months median survival (Lacroix et al., 2001). Although 
it is clear that maximal resection of GBM increases median survival, it is often difficult to achieve 
due to the diffuse nature of GBMs and the tendency for tumours to develop close to important 
anatomical features (Manrique-Guzman et al., 2017). In practise, some studies show treatment 
of GBM by surgical resection without radiotherapy to exhibit median survival as low as 1.9 
months. Consequently, other treatment strategies are employed in order to further increase 
patient survival (Lanzetta and Minniti, 2010). 
Following maximal surgical resection, dependant on the size and location of the tumour, 
patients begin postoperative radiotherapy. Typically radiotherapy commences once craniotomy 
wounds heal, usually 4 weeks after surgery (Davis, 2016). Historically, whole-brain radiotherapy 
was the standard in radiotherapy for GBM treatment, however clinically significant toxicities 
caused by whole-brain irradiation resulted in the need for a more sophisticated approach (Shih 
et al., 2015). Currently, three-dimensional conformal beam or intensity-modulated radiotherapy 
is the standard of care method. This strategy allows radiation to be delivered specifically to the 
tumour reducing side-effects associated with whole brain radiotherapy. GBM reoccurrence 
often takes place within 2 cm of the original tumour and consequently tumours are irradiated 
with an additional 2-3 cm margin (Shih et al., 2015). The typical total dose administered to a 
patient diagnosed with GBM is 60 Gy, which is delivered 5 days per week over a period of 6 
weeks in 1.8 – 2 Gy fractions (Barani and Larson, 2015). Doses of 60 Gy are well established to 
deliver maximal benefit to patients. Doses above 60 Gy have resulted in increased toxicity 
without any increase to patient survival rates (Barani and Larson, 2015). Prior to 2005, the 
standard treatment of GBM included surgical resection followed by radiotherapy, resulting in 
median survival of 12.1 months (Stupp et al., 2005). However, the inclusion of temozolomide 
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(TMZ; 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide, 1), an imidazotetrazine 
prodrug, into the treatment regimen alongside surgical resection and RT, increases median 
survival by 2.5 months (Stupp et al., 2005). The relative effectiveness of TMZ is attributed in-





















1.3. Imidazotetrazine Prodrug Discovery and Temozolomide 
TMZ 1 is part of a family of drugs known as imidazotetrazines. Shown in Figure 1.3, this class of 
drug contains several nitrogen atoms throughout their core which give rise to a number of 
unique properties. Imidazotetrazines have often been described in the literature as being 
derived from dacarbazine (DTIC) 3 (Newlands et al., 1997). DTIC itself was introduced in the 
1970s to treat melanoma, following successful in vivo investigations (Mizuno and Decker, 1976). 
However, the drug displayed limited effectiveness during clinical trials due to poor distribution 
of the active metabolite 5(3-methyl-1-triazeno) imidazole-4-carboxamide (MTIC), (discussed in 
section 1.4), proven by in-vivo micro dialysis (Newlands et al., 1997). This effect was later known 
to a result of liver enzymes being required to convert the DTIC prodrug into its active metabolite 
(Sankar et al., 1999). 
 
 
Figure 1.3: Chemical structures of: Temozolomide 1; Mitozolomide 2; DTIC 3. 
 
The first imidazotetrazine prodrugs were synthesised at Aston University by the Malcom F. G. 
Stevens research group. The original publication, “Antitumor imidazotetrazines 1”, sought to 
utilise the versatile reactivity observed in cyclic and acyclic N-N-N linkages to give rise to small 
molecules with selective antitumor effects, using the chemical structure of DTIC as a starting 
point (Stevens et al., 1984). Similar to DTIC 3, imidazotetrazines also degrade in vivo to the 
corresponding MTIC analogue 12. However, degradation of imidazotetrazines to MTIC occurs 
spontaneously at physiological pH and does not require liver enzymes, resulting in an improved 
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bio-distribution of the active MTIC (Newlands et al., 1997). Imidazotetrazines 1, 2 were found to 
have a number of advantageous properties such as excellent bioavailability, stability at acidic 
pH, oral administration suitability, as well as being able to clear the BBB due to the lipophilic 
nature of the imidazotetrazine core, making them excellent candidates for potential brain 
tumour chemotherapeutics (Newlands et al., 1997). The first imidazotetrazine to enter clinical 
trials was mitozolomide 2 (Stevens et al., 1984). However, the drug induced life-threatening 
myelosuppression in patients and was quickly removed from testing (McKeage et al., 1992). The 
adverse side effects observed were attributed to DNA crosslinking properties of the chloroethyl 
diazonium ion (Neijt et al., 1989; Smyth et al., 1989). As a result, attention focused on the 3-
methyl derivative, TMZ 1. TMZ was obtained through substitution of the chloroethyl group on 
the tetrazinone ring by a methyl group (Stevens et al., 1984; Lunt et al., 1987). TMZ differed 
from mitozolomide since its cytotoxic effect was generated through methylation of DNA rather 
than DNA cross-linking (Denny et al., 1994). Clinical trials using TMZ, showed the drug was able 
to generate similar antitumor effects without eliciting the life-threatening side-effects 
associated with mitozolomide (Hegi et al., 2005; Stupp et al., 2005). 
Summarised in Scheme 1.1, the initial synthesis of imidazotetrazines the involved conversion of 
commercially available 5-aminoimidazole-4-carboxamide 4 (AIC) to the corresponding 
diazoimidazole 5 using sodium nitrite. The diazoimidazole 5 was then carefully treated in the 
absence of light with an isocyanate to yield the desired imidazotetrazine 1 (Stevens et al., 1984). 
Although Scheme 1.1 yielded the desired imidazotetrazines in favourable yields, attempts were 
made to produce a scheme that obviated the need for isocyanates, due shortages of this 
compound as a result of the 1984 Bhopal disaster (Wang et al., 1998; Varma and Varma, 2005). 
During the disaster, methyl isocyanate, needed for the synthesis of TMZ (Scheme 1.1), was 
accidently released to an estimated 200,000 inhabitants living near the manufacturing plant, 
killing approximately 20,000 people. Consequently, the TMZ precursor was all but removed from 





Scheme 1.1: Original synthesis of imidazotetrazines described by Stevens et al., 1984, (TMZ example). 
Reagents: (i) Sodium nitrite, aq. hydrochloric acid; (ii) methyl isocyanate, dichloromethane, 25 oC, 20 
days. 
 
Due to the difficulties of sourcing and shipping industrial quantities of methyl isocyanate, 
isolation of the potentially dangerous and unstable 5-diazo-1H-imidazole-4-carboxamide 5 and 
the 20 day synthesis time (Scheme 1.1), a new synthesis, more suited to industry was developed 
(Stevens et al., 1984). Schering-Plough Corporation, now merged with Merck, initially licensed 
TMZ and currently have two patented procedures for its industrial scale synthesis, which obviate 
the use of isocyanates (Moody and Wheelhouse, 2014; Schering-Plough, 2005).  The first of 
these routes, Scheme 1.2, utilises the commercially available AIC 4 as the starting material, 
consistent with the original route described in scheme 1.1. AIC 4 is treated with 4-nitrophenyl 
chloroformate to yield the corresponding carbamate 6. Substitution of the 4-nitrophenyl ester 
group of carbamate 6 is achieved through treatment with methyl hydrazine, resulting in the 
formation of a semicarbazide 7. Cyclisation is achieved through oxidation of intermediate 7 by 
treating it with tetrabutyl ammonium iodide and periodic acid, yielding TMZ 1 (Kuo, 2005). 
Although this route avoids the use of methyl isocyanate, the use the highly toxic reagent methyl 






Scheme 1.2: Industrial synthetic route to TMZ, patented by Schering-Plough. Reagents: (i) 4-nitrophenyl 
chloroformate, triethylamine, dichloromethane; (ii) methylhydrazine, dimethylformamide; (iii) tetrabutyl 




Scheme 1.3: Alternate industrial synthetic route to TMZ, patented by Schering-Plough. Reagents: (i) 
sodium nitrite, acetic acid, lithium chloride, water; (ii) conc. sulphuric acid. 
 
Schering-Plough’s second patented route to TMZ, outlined in scheme 1.3, involves a multi-step 
synthesis to yield a tert-butyl protected imidazole urea 8 (Kuo et al., 2006). Treatment of 
compound 8 with sodium nitrite and acetic acid causes cyclisation forming the tetrazine ring 9. 
The tert-butyl group is then removed by either conc. sulphuric acid or hydrochloric acid / 
Commented [OI1]: Add yields 
Commented [OI2]: Add yields 
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dioxone (Han et al., 2001; Kuo et al., 2006). Although ultimately more cumbersome, Scheme 1.3 
yields TMZ while avoiding the use of methyl isocyanate and methyl hydrazine incorporating 
improved safety procedures (Moody and Wheelhouse, 2014). However, despite the two 
schemes patented by Schering-Plough, the method of choice for small-scale research remains 
coupling diazoimidazoles 5 with isocyanates to form the imidazotetrazine core 1 (Stevens et al., 


















1.4. Mechanism of Action of Temozolomide 
TMZ requires an aqueous environment to become biologically active (Agarwala and Kirkwood, 
2000). To elicit cytotoxicity the molecule must first be hydrolysed to 5-(3-dimethyl-1-triazenyl) 
imidazole-4-carboxamide 12 (MTIC). MTIC 12 undergoes further degradation to produce a 
methyl diazonium ion 13 which is responsible for methylation of the DNA (Scheme 1.4) 
(Newlands et al., 1997). The first step in the mechanism involves a base catalysed addition of 
water to the C4 terminus on the tetrazinone ring 1, forming an unstable tetrahedral 
intermediate 2 (Scheme 1.4). Mechanistic studies conducted by Mirzaei et al., 2015 confirm a 
preference for the C4-N5 bond to break over the C4-N3 bond during ring opening (scheme 1.4) 
(Mirzaei et al., 2015). This is followed by spontaneous decarboxylation at N5, (11 - Scheme 1.4). 
MTIC 12 further degrades through acid catalysed fragmentation of the triazene to afford AIC 4 
and the methyl diazonium ion 13 (Scheme 1.4). Although the methyl diazonium 13 ion exists in 
equilibrium with diazomethane 14, it is the methyl diazonium ion that methylates DNA, 
generating cytotoxicity (Newlands et al., 1997).  
Figure 1.4 shows the fate of each of the atoms that make up TMZ. The imidazole containing AIC 
is excreted in the urine following degradation (red), the carbonyl at position 4 on the tetrazinone 
ring is lost as CO2 during biological activation under physiological conditions (blue) and N2 and 
N3 are lost as N2 (green) during methylation of DNA (Figure 1.4) (Newlands et al., 1997; 
Nuthalapati et al., 2018). Due to the mechanism of action, TMZ is considered as a carrier 









Figure 1.4: Structure of temozolomide showing the biological fate of each atom. Atoms excreted in the 
urine following degradation are shown in red. N2 and N3 are lost as N2 following methylation of DNA, 









As previously stated, TMZ undergoes hydrolytic degradation in order to become biologically 
active. The cytotoxic methyl diazonium ion 13 (scheme 1.4) is responsible for methylation of 
DNA, inducing a cytotoxic response (Denny et al., 1994). Methylation of DNA by the diazonium 
ions occurs mainly in guanine rich sequences of DNA; at guanine-N7 17, (70%), occasionally at 
adenine-N3 19, (9%), and at guanine-O6 16, (6%), (Figure 1.5) (Zhang et al., 2012).  
 
 
Figure 1.5: Mechanism of methylation of guanine 15 and adenine 18 producing O6-methyl guanine 16, 




Newlands et al., 1997, describes how methylation tends to occur in the centre of the sequences 
of three or more consecutive guanines. These results were replicated when other alkylating 
agents of low molecular weight were used. This phenomenon was attributed to the steric and 
electronic environment of the DNA. It was found that three consecutive guanine nucleotides 
give rise to an electron rich environment, and that a run of 3 or more consecutive guanines 
works to disrupt the double helix shape of the DNA (B-form), leading to an increase in the size 
of the major groove (Denny et al., 1994). The increase in the size of the major groove results in 
a better steric access for the methyl diazonium ion which explains the preference of the sites 
being methylated (Denny et al., 1994). 
 
 
Figure 1.6: Normal base pairing between guanine and cytosine. 
 
The mechanism by which the electrophilic methyl diazonium ion methylates nucleophilic sites 
on adenine and guanine bases is shown in Figure 1.5 (Wyatt and Pittman, 2006). Methylation at 
guanine-N7 17 and adenine-N3 19 are readily recognised and repaired by base excision repair 
(BER) pathways, so do not readily contribute to cytotoxicity (Monti et al., 2004). However, 
methylation at guanine-O6 16 is not as readily repaired by BER and so has greater potential to 
generate cytotoxicity (Fahrer and Kaina, 2013). Normal base pairing between guanine 15 and 
cytosine 20, is shown in Figure 1.6 (Watson and Crick, 1953). Hydrogen bonds that dictate base 
pairing usually exist between positions 1, 2 and 6 on guanine 15 and positions 2, 3 and 4 on 
cytosine 20, respectively, (Figure 1.6). Methylation at O6 on guanine, producing O6-methyl 
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guanine 16 (O6-MeG), disrupt hydrogen bonding with cytosine 20 resulting in a preference for 
bonding with thymine 21, (Figure 1.7) (Williams and Shaw, 1987). 
 
 
Figure 1.7: Base pairing between methyl guanine and thymine. 
 
The pathway of TMZ-triggered apoptosis in cells, as a result of methylation of guanine, is 
summarised in Figure 1.8. Mismatch between thymine and O6-MeG is recognised by mismatch 
repair proteins (MMR), prompting the removal of thymine from the replication fork (Roos et al., 
2007). In the absence of O6-methylguanine-DNA methyltransferase (MGMT) the guanine 
methylation is not repaired, resulting in reinsertion of thymine into the replication fork. This 
futile cycle of insertion and deletion persists until the replication fork collapses, inducing a 
double stranded break (Karran and Bignami, 1994; Hampson et al., 1997). Once a sufficient 
number of double stranded breaks have occurred, the Ataxia telangiectasia mutated (ATM) and 
ATM and RAD3-related (ATR) - Chk1 pathways are activated leading to stabilisation of p53, 




















1.5. Therapeutic Limitations  
The average improvement in the survival of patients with high-grade GBM treated with TMZ and 
radiotherapy is 2.5 months, when compared with treatment using radiotherapy alone (14.6 
months vs 12.1 months, respectively) (Stupp et al., 2005). The improvement of 2.5 months can 
be, at best, described as modest. Hegi et al. (2008) found that 60% of all newly treated patients 
with GBM receive no benefit from treatment with TMZ (Hegi et al., 2005). Moreover, the study 
conducted by Stupp et al. (2005) did not include patients over the age of 70 or patients who 
were not capable of independent living, patient cohorts accounting for 20% and 10% of newly 
diagnosed GBM cases, respectively. Patients within these cohorts are likely to be those with the 
poorest survival rates and were not included in these studies. It is evident from the literature 
published that although TMZ does provide a modest improvement for some patients this is not 
the case for all patients, highlighting the need for an effective alternate therapy (Chamberlain, 
2010). 
TMZ resistance is one of the principle reasons the majority of patients derive little or no clinical 
benefit from TMZ treatment. MGMT expression is a major indicator of TMZ resistance and is 
known to be the sole enzyme responsible for the repair of O6-methyl adducts on methyl guanine 
(Silber et al., 2012). Structure-functionality studies reveal that the enzyme repairs DNA lesions 
by binding to the minor groove of DNA detecting O6-MeG (Tubbs et al., 2007). The methylated 
base is transferred to the active site of MGMT via a base-flipping mechanism. Once in the active 
site, MGMT is a reagent in a stoichiometric reaction where the methyl adduct is covalently 
transferred to a cysteine residue in the active site (Figure 1.9) (Tubbs et al., 2007). MGMT is 
unique to all other human DNA-repair proteins since once the methyl adducts are transferred 
to the active site, the enzyme spontaneously degrades. The suicide-repair mechanism of MGMT 
means resistance is dependent on the rate of methylation of TMZ compared with rate of MGMT 
synthesis by the cell (Romani et al., 2018). Consequently, the use of MGMT competitive 
inhibitors such as O6-benzylguanine, has been used to increase susceptibility to TMZ treatment, 
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however to date these efforts have been unsuccessful (Mrugala and Chamberlain, 2008; Kaina 
et al., 2010).  
 
 
Figure 1.9: O6-Methyl guanine repair by MGMT. During repair the potentially cytotoxic methyl adduct is 
transferred to a cysteine 145 in the active site of MGMT. (Adapted from: Tubbs et al. (2007)). 
 
Multiple studies have linked the high expression of MGMT in GBM to TMZ resistance. MGMT 
expression has been shown to relate to levels of methylation in the MGMT promoter (van 
Nifterik et al., 2010). High levels of methylation within the MGMT promoter region usually result 
in low levels of protein expression and consequently result in TMZ sensitivity. Consequently, it 
is generally accepted that TMZ resistance can be best predicted by the methylation status of the 
MGMT promoter as well as MGMT protein expression levels in the cell/tumour (van Nifterik et 
al., 2010; Uno et al., 2011). However, some cells, such as cells of the T98G cell line, are MGMT 
methylated but express high levels of MGMT and confer TMZ resistance. It has been suggested 
that the resistance observed in the T98G cell line is due to the expression of alkylpurine-DNA-N-
glycolase (APNG) as well as MGMT expression (Agnihotri et al., 2012). The APNG protein is a 
member of the BER machinery and is responsible for the repair of N3-methyl adenine and N7-
methyl guanine. It has also been shown in patients presenting GBMs that express APNG, have a 
significantly poorer prognosis than those without (Agnihotri et al., 2012). Similarly, studies 
investigating patient MGMT promoter methylation status and TMZ sensitivity, found a 
correlation between methylation and TMZ sensitivity. However, a significant number of patients 
were found to have a MGMT hypomethylated promoter yet be sensitive to TMZ (Stupp et al., 
2005; Hegi et al., 2008). Bocangel et al., failed to find a link between MGMT expression and TMZ 
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susceptibility in 7 human glial primary cultures. In this case the authors attributed TMZ 
resistance to non-functional p53 response to DNA damage and not to MGMT expression 
(Bocangel et al., 2002). Although MGMT promoter methylation status and MGMT protein 
expression is a useful predictor of TMZ sensitivity for patients, it is clear that multiple proteins 
play a role.  
Known toxicities of TMZ include thrombocytopenia, lymphopenia, neutropenia and the 
development of myelodysplastic syndrome. Gerber et al., 2007 showed that of 52 newly 
diagnosed GBM patients, approximately 15-20% went on to develop thrombocytopenia when 
treated with TMZ and radiotherapy. The development of thrombocytopenia can prevent the 
safe administration of further chemotherapy, ultimately reducing patient survival. Similarly, 
Stupp et al., 2007 found that 15% of patients discontinued chemotherapy due to the 
development of neutropenia or thrombocytopenia. Interestingly, evidence suggests that the 
development of TMZ toxicity is subject to a significant gender bias. It was found that the 
development of lymphopenia occurred in 45% of women treated with TMZ, compared to 6% of 
men (Armstrong et al., 2008). A study conducted by Grossman et al., 2011, found 57% of patients 
treated with TMZ and radiotherapy went on to develop lymphopenia. Development of 
lymphopenia bears clinical significance as it is thought to increase a patients’ susceptibility to 
opportunistic infections. Pneumocystis pneumonia represents the most clinically-significant of 
these infections, often leading to co-administration of antipneumoncystis antiparasitic drugs 
(Grossman et al., 2011).  
Additionally, the guidelines on assessing cost effectiveness of drugs was established by The 
National Institute of Health of Care Excellence (NICE). Cost effectiveness of drugs is expressed 
as the cost per Quality Adjusted Life-Year (QALY) gained. A QALY takes into account the quantity 
of life gained as well as the quality of that life through the following: Quality of life (0-1 scale 
where 1 is equal to perfect health and 0 is equal to death) multiplied by the quantity of life.  The 
cost effectiveness threshold for drugs in the U.K. is between £20,000 and £30,000 per QALY 
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gained, (Garside et al., 2007). Cost effectiveness analysis of TMZ has shown incremental costs 
to be £35,861 per QALY. However, a lack of an effective alternative therapy for GBM results in 
TMZ remaining as the first line treatment, despite the relative costs outweighing patient 
benefits, (Messali et al., 2013).  
As a direct consequence of both the poor clinical performance of TMZ and its subsequent poor 
cost effectiveness, there is a need for an alternative chemotherapeutic that is more effective 
and safe for patients diagnosed with GBM, (Chamberlain, 2010). The remainder of this chapter 
will focus on the efforts that have been made so far to optimise the activity of TMZ in the hope 















1.6. Structural Modifications to Optimise Cytotoxicity of Temozolomide  
There have been several attempts to optimise the anti-tumour activity of TMZ by modifying its 
chemical structure. In a study conducted by Lunt et al., 1987, modifications at position 3 of the 
tetrazine ring were made (Lunt et al., 1987) (figure 1.3). This is a particularly important position 
on the molecule as it is the site that ultimately bonds to DNA. All ethyl and large alkyl 
modifications at this position resulted in a significant loss of antitumor activity against TXL5 
lymphoma implanted mice. The study found that significant antitumor activity was restricted to 
TMZ 1 and mitozolomide 2. It is evident from the results of this study that modifications at 
position 3 result in compounds that are either too potent for clinical use, as is the case with 
mitozolomide, or do not exhibit significant antitumor activity, such as the 3-ethyl, 3-alkyl and 3-
benzyl modifications (Lunt et al., 1987). Modifications at position 3 may also disrupt the 
mechanism of imidazotetrazines which could result in undesirable DNA crosslinking leading to 
potentially fatal side effects, as is the case with mitozolomide (Neijt et al., 1989; Smyth et al., 
1989). 
One such novel modification made at position 3 was described by Garelnabi et al., 2012. The 
monofunctional 22 and bifunctional analogues 23 of TMZ from this study are displayed in Figure 
1.10. These analogues where tested against colon, non-small-cell lung carcinoma, pancreatic 
and TMZ resistant cell lines. Both analogues exhibit significantly greater cytotoxic effects when 
compared with TMZ, regardless of MGMT status. The increased cytotoxicity and success of 
bifunctional analogues 23 in MGMT positive cells is a result of crosslinking of DNA. As a result, 





Figure 1.10: Structure of monofunctional temozolomide analogue, 22; and bifunctional temozolomide 
analogue, 23. (Garelnabi et al., 2012). 
 
 
Changes to the imidazotetrazine structure have also included modifications to the core of the 
molecule. Due to the way in which TMZ and other imidazotetrazines exhibit their mechanism of 
action, the conformation of the tetrazine ring is vital for ring opening and conversion to MTIC. 
However, much less detail is known about the role of the imidazole ring during the mechanism 
of action (Moody and Wheelhouse, 2014). A study conducted by Cheng et al., 1986 analysed the 
effects of modifying the imidazole ring of mitozolomide and TMZ that involved synthesising a  
pyrazolo analogue 24 of the two drugs, (Figure 1.11). However, during testing on P388 leukaemia 
cell lines it was found that the pyrazolo analogue of TMZ was completely inactive. The 
mitozolomide pyrazolo analogue however, retained some potency and showed good toxicity 








Figure 1.11: Structures of pyrazolo 24; pyrrolo 25 and indolo 26 analogues of temozolomide. (Cheng et al., 
1986; Diana et al., 2002; Barraja et al., 2004) 
 
Other modifications to the core of the molecule have been investigated including pyrrole 25 and 
indolo 26 analogues (Figure 1.11). However, these modifications resulted in very limited efficacy 
against a small number of cell lines. Drugs that did exhibit growth inhibitory activity were found 
to work by a different mechanism of action when compared with TMZ, i.e. not methylation. 
However, the exact mechanism by which these analogues elicit a mechanism of action was not 
reported (Diana et al., 2002; Barraja et al., 2004). These studies indicate the importance of the 
imidazole and the tetrazine ring to the activity of the imidazotetrazines.  
Modifications of imidazotetrazines at positions 6 and 8 on the imidazole ring have also been 
investigated (Figure 1.12). Lunt et al., 1987 was the first to characterise modifications to these 
positions during structure activity relationship (SAR) analysis of imidazotetrazines. Modifications 
at position 6 included a broad range of alkyl groups. Of these analogues it was found that larger 
alkyl groups were significantly less cytotoxic, compared to smaller alkyl groups. This effect was 
attributed to the large alkyl group preventing ring-opening at position 5 due to steric hindrance, 
thus thwarting nucleophilic attack by water required for the conversion of TMZ to MTIC, which 
subsequently accounted for the loss of activity of the large 6-alkyl modification (Lunt et al., 
1987). Therefore, for optimal cytotoxicity, it is important that position 6 contains only hydrogen 





Figure 1.12: Structure of temozolomide showing imidazotetrazine positions. 
 
Modifications at position 8 of the imidazole ring, however, have shown encouraging results. It 
should be noted that early analogues, synthesised by Lunt et al. (1987), were derived from 
mitozolomide, not TMZ. The presence of a 2-chloroethyl group at position 3 on the tetrazinone 
ring (mitozolomide) produced acute myelosuppression, and was therefore not approved (Neijt 
et al., 1989; Smyth et al., 1989). The same study by Lunt et al. (1987) found that increasing the 
size of the amide at position 8, decreased the cytotoxicity of the drug. However, functional 
groups such as sulfonyl compounds increased cytotoxicity, prompting further research regarding 
modifications at position 8 of the imidazole ring of TMZ. To date, the role of position 8 of the 
imidazole ring is much less understood. It has been hypothesised that this position could possibly 
play a role in a number of different mechanisms that contribute to the activity of 
imidazotetrazines, these include: exerting a level of control of the conversion to MTIC via ring 
opening at position 5; increasing the stability of MTIC and the AIC intermediates; adjusting 
transport and uptake properties of the drug into tumour cells or modifying the non-covalent 




Figure 1.13: General structures of ester and amide analogues synthesised by Liu et al. (2010). 
 
Building on the initial work carried out by Lunt et al., 1987; Liu et al., 2010 synthesised a number 
of ester 27 and amide 28 analogues at position 8 of the imidazole ring of TMZ. These analogues 
exhibited a wide range of antitumor activity, which made definitive structural activity 
relationships difficult to conclude. Ester modifications resulted in analogues that had increased 
water solubility ranging from 80-110-fold, compared with TMZ. Ester analogues exhibited 
comparable cytotoxicity to TMZ against PC-3, LNCaP, T47D, MDA-MB-231, DU145, HT29 and 
HCT-15 cell lines and significantly greater cytotoxicity against HL-60 cells (Liu et al., 2010). 
Interestingly, the esters that were chosen for analysis in this study all contained amine groups, 
however, this strategy was not justified. Other modifications at position 8 were carried out by 
Langnel et al., 2000. These modifications involved the substitution of the amide group at 
position 8 of the imidazole ring with various 8-cyano-imiazotetrazines using a novel synthetic 
route. However, the activity of these modified imidazotetrazines was not reported, which may 
indicate a lack of cytotoxicity displayed by these drugs, similar to what was deduced by Lunt et 
al., 1987. Suppasansatorn et al., 2006 synthesised a number of TMZ analogues with simple chain 
ester groups at position 8 with a view to produce analogues that could be suitable for topical 
administration for melanoma treatment. The hexyl ester analogue was the most promising 
analogue from this study (Suppasansatorn et al., 2006). Studies conducted by Arrowsmith et al., 
1999 and 2002 explored the addition of small linear peptide motifs at position 8 of the imidazole 
ring, designed to bind to both the major and minor grooves of DNA, however, both studies 
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concluded limited success, with no significant increase in in vitro antitumor activity (Arrowsmith 
et al., 1999; Arrowsmith et al., 2002).   
 
 
Figure 1.14: Structure of NEO212 27. (Chen et al., 2015). 
 
More recently, the conjugation of perillyl alcohol at position 8 has yielded some success. Perillyl 
alcohol is a naturally occurring alcohol that exhibits anticancer activity against a number of cell 
lines including TMZ resistant GBM cultures (Chen et al., 2015). Despite encouraging activity of 
the perillyl alcohol, it did not enter clinical practice due to dose-limiting intestinal toxicity. The 
structure of the perillyl alcohol conjugate of TMZ (NEO212) 29 is shown in Figure 1.14. NEO212 
29 holds particular promise due to its cytotoxicity against GBM cell lines that are resistant to 
TMZ and is more potent than the alcohol (Cho et al., 2014). The effectiveness of NEO212 in vitro 
could be attributed to increased cell membrane permeability due to the lipophilic nature of the 
resulting conjugates allowing improved access to the site of action (Chen et al., 2015). It should 
be noted that the increase in cytotoxicity of the drug suggests a different mechanism of action 
from that of TMZ, and could be attributed to the generation of a cytotoxic AIC-perillyl alcohol 
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degradant, rather than the methylation of DNA via the methyl diazonium ion, currently, this has 
not been confirmed. 
 
Figure 1.15: Structure of 8-phenyl TMZ 28 and 8-(5-methyloxazole) TMZ 29. (Svec et al., 2018). 
 
Recently the hydrolytic stability of 3-methylimidazotetrazines, in response to position 8 
modifications, has been investigated (Svec et al., 2018). This area of research is of particular 
interest since currently it is unknown if the rate of prodrug activation of TMZ is optimal to 
maximise therapeutic efficacy (Wesolowski et al., 2010). Although TMZ has a half-life 1.8 hours 
in physiological conditions, position-8-modified analogues exhibit half-lives that range from 20 
mins for compound 30 to 3 h for compound 31 (Figure 1.15) (Tisdale, 1987; Svec et al., 2018). 
TMZ analogues that undergo rapid degradation, such as analogue 30, were shown to exhibit 
limited efficacy in-vivo. The lack of efficacy was attributed to the analogue activating too early, 
preventing the accumulation of the methyldiazonium ion within the tumour microenvironment. 
Interestingly, analogue 31 exhibited a half-life of 3 h and enhanced brain distribution (Svec et 
al., 2018). These results indicate that modifications at position 8 have the potential to affect the 
electronic properties of the bicyclic ring, in addition to enhanced bio-distribution of the drug, 
which may lead to analogues with improved therapeutic properties. Similarly, the Nottingham 
University research group, headed by Malcolm Stevens, reported C8-imidazolyl 32 and C8-
methylimidazole 33 TMZ analogues that elicit activity independent of MGMT status (Figure 
1.16). Interestingly, these analogues were found to initiate G2/M arrest in cells independent of 
Commented [OI3]: 30 and 31 
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both MGMT and MMR status. The research group established that analogues 32 and 33 undergo 
hydrolytic degradation similar to that of TMZ and were able to methylate similar DNA adducts 
(Yang et al., 2019). This suggests the increased activity was due to either sheer volume DNA 
alkylation overcoming the respective repair mechanisms or an additional mechanism of action 
playing a part. The coupling of TMZ to γ-carboline through amide and amino ethyl linkers has 
been found to improve brain permeation (Rai et al., 2016). This is supported by the findings of 
Wollowitz and Kataisto (2009) and Sweetlove (2012) who found TMZ analogues containing γ-














1.7. Summary and Aims 
1.7.1. Summary 
TMZ is the standard of care chemotherapeutic agent used to treat patients with GBM. However, 
despite this, TMZ provides little benefit to these patients due to systemic toxicity generated 
through myelosuppression and MGMT mediated resistance. Although NICE guidelines deem 
TMZ to be a non-cost-effective drug, it is still provided to patients on the NHS as there is no 
effective alternative. Due to the limited patient benefit and poor cost-effectiveness of TMZ, 
there is a substantial need for an alternative chemotherapeutic agent for the treatment of GBM. 
Efforts to increase the efficacy of TMZ through co-administration with MGMT inhibitors have to-
date been unsuccessful. Attempts to optimise the activity of TMZ through structural 
modifications have provided mixed success. Modifications at position 3 on the tetrazine ring 
have produced analogues that are either too toxic for clinical use or analogues that are inactive. 
SARs have established that a single hydrogen is optimal for activity at position 6 and that 
modifications to the imidazotetrazine core disrupts hydrolytic degradation by inhibiting prodrug 
activation through imidazotetrazine ring opening. It is well established that the amide group 
present on the imidazole ring is not essential for activity and remains purely as an artefact from 
its initial synthesis. Therefore, modifications to position 8 modifications holds the most promise 
for optimising the activity of TMZ. Recent research suggests the substitution of the amide group 
at position 8 by specific esters appears to increase activity of the molecule. However, as yet no 
definitive SARs have been deduced. Modifications to TMZ at position 8 can also increase brain 
permeation as well as effecting the rate of prodrug activation, which has the potential to 







The aim of the following work is to further explore the possibilities of optimising the activity of 
TMZ by further modifying position 8 of the imidazole tetrazine ring. Evidence to date shows that 
position 8 plays an important role in the activity of TMZ and by modifying this position, the 
activity of the drug can be altered. It is speculated that analogues with increased cytotoxic 
activity could have the potential to become superior cost-effective alternatives to TMZ for 
patients suffering from GBM. 
This study aims: 
• To successfully synthesise and characterise novel ester and amide analogues of TMZ 
using high resolution mass spectrometry, nuclear magnetic resonance spectroscopy, 
infrared spectroscopy and melting point analysis.  
• To evaluate the antiproliferative activity of novel analogues against U87-MG, 1321-N1, 
GOS-3 and SVG-p12 cell lines.  
• To evaluate antiproliferative effects of the most promising novel analogues against 
MGMT negative and MGMT positive patient-derived primary cells.  
• To evaluate the stability of the most promising novel analogues. This will include stability 
at physiological pH as well as the integrity of ester and amide bonds when subjected to 
porcine liver esterase.  
This thesis will be presented in specialised individual chapters. Chapter 2 will cover the design 
and synthesis of TMZ analogues. Chapter 3 will investigate the antiproliferative effects of TMZ 
analogues and identify any potential lead analogues. Chapter 4 will investigate the stability of 
lead analogues after exposure to an esterase enzyme, monitored by HPLC. Chapter 5 will discuss 





























It was initially postulated that a H bond donor at position 8 of the imidazole ring of TMZ was 
central to activity (Figure 2.1) (Lowe et al., 1992; Denny et al., 1994). However, since the 
understanding of the relationship between imidazotetrazine structural modifications and 
activity has grown, it has become increasingly apparent that modifications at position 8 on the 
imidazole ring may be tolerated and have the potential to yield analogues with increased 
antiproliferative activity (Suppasansatorn et al., 2006; Liu et al., 2010; Garelnabi et al., 2012; 
Ramirez et al., 2015; Yang et al., 2019). As a result, it is now generally accepted position 8 has 
potential in terms of improving the efficacy of imidazotetrazines, however, the amide remains 




Figure 2.1: Structure of temozolomide showing positions. 
 
Structural modifications of TMZ provide a number of challenges to the synthetic chemist. The 
imidazotetrazine ring opening occurs at physiological pH through base catalysed addition of 
water to C4=O (Scheme 2.1) (Denny et al., 1994). However, degradation may also occur in acidic 
conditions, albeit at a much slower rate or as a result of exposure to protic solvents (Stevens et 




Scheme 2.1: Degradation of temozolomide under physiological conditions. 
 
TMZ is reported to have a half-life of around 1.8 hours at pH 7.4 (Denny et al., 1994). However, 
in acidic conditions (<pH 4) stability is markedly improved to around 24 hours (Kim et al., 2001). 
Although the stability of TMZ is greatly improved under acidic conditions degradation persists 
albeit at a much slower rate. 
TMZ also degrades as a result of exposure to protic solvents such as ethanol and methanol. The 
mechanism of degradation is hypothesised to be due to nucleophilic attack of the hydroxyl group 
on the protic solvent on the carbonyl at C4, eliciting ring opening similar to that depicted in 
Scheme 2.1. (Stevens et al., 1984). Due to the relative instability of the imidazotetrazine core, 
schemes of synthesis must be designed to avoid neutral/basic conditions and protic solvents in 
order to maximise yields. The remainder of this chapter will focus on the design, synthesis and 
characterisation of novel temozolomide analogues.  
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2.2. Rational Design of Temozolomide Analogues  
2.2.1. Literature Review of Previous Modifications and Identifying a Suitable 
Position to Modify 
Structure-based drug design is currently the most common method of identifying lead 
compounds which elicit desired activity. Traditionally, the development of lead compounds is 
centred around identifying a target macromolecule implicated with the disease in question, such 
macromolecules may include enzymes, receptors or nucleic acids. Once a suitable target is 
identified, drugs may be designed with a structure that suitably interacts with the target 
macromolecule to produce the desired outcome. The desired outcome of chemotherapeutics is 
to elicit antiproliferative and cytotoxic effects in cancerous cells.  
In the case of TMZ 1, methyl diazonium ions 13 released through prodrug activation, methylate 
DNA bases preventing replication and initiating antiproliferative effects. Although it is well 
documented that the methyl diazonium ion 13 bonds to the target (DNA) eliciting the desired 
antiproliferative effects, the efficiency of TMZ’s ability to activate and achieve this aim is 
questionable due to negligible patient benefit. Therefore an aim of this study was to optimise 
the activity of TMZ by modifying its chemical structure.  
Modifications that perturb or change the mechanism by which TMZ elicits its effects can be a 
successful approach. Modifications at position 3 determine the group that is ultimately 
transferred to DNA. Lunt et al., 1987 found chloroethyl and methyl moieties elicited cytotoxicity 
exclusively. More recently, studies investigating bi-functional TMZ analogues have displayed 
some success in vitro (Ramirez et al., 2015). These analogues give rise to diazonium ions with 




Figure 2.2: Depicting the intramolecular trapping reaction of (2-[N-(2-diazonioethyl)-4-methyl-
anilino]ethanediazonium) 34 to form the corresponding azridinium ion 35. (Garelnabi et al., 2012) 
 
Bifunctional analogues 23, as discussed in the Chapter 1, have been shown to initiate inter-
strand cross links thus activating ATM/ATR pathways (Garelnabi et al., 2012; Ramirez et al., 
2015). Upon hydrolytic ring opening, producing compound 34, these analogues undergo an 
intramolecular trapping reaction, depicted in Figure 2.2, producing aziridinium species 35 that 
are responsible for alkylating nucleic acids and eliciting a cytotoxic effect. However, it is 
suggested that imidazotetrazines with the ability to cross-link DNA are unsuitable as 
chemotherapeutic agents due to the life-threatening myelosuppression they elicit in patients 
(Lunt et al., 1987; Neijt et al., 1989; Smyth et al., 1989). As a result, it is deemed that the methyl 
group at position 3 is useful to retain a mechanism of action that elicits cytotoxicity with 
tolerable side effects. Furthermore, as described in Chapter 1, the addition of alkyl groups at 
position 6 perturbs prodrug activation, reducing cytotoxic potency (Lunt et al., 1987). Similarly, 
structural modifications to the core of TMZ also prevent prodrug activation resulting in reduced 
activity (Cheng et al., 1986; Diana et al., 2002). The amide at position 8 however, holds more 
promise as a possible site that could increase activity. Multiple studies have described position 
8 modified analogues with increased cytotoxic potencies against numerous cell lines 
(Suppasansatorn et al., 2006; Liu et al., 2010; Svec et al., 2018; Marin-Ramos et al., 2018). In fact 
it is now widely recognised that the amide at position 8 on TMZ is not central to activity and can 
64 
 
tolerate modifications (Lowe et al., 1992; Svec et al., 2018). Consequently, position 8 was 
targeted as a site of modification with the view to yield analogues with increased anticancer 
effects. 
2.1.2. Rational Design of Analogues 
Since there are no definitive SARs proposed at position 8 on TMZ, the strategic design of 
compounds which may yield increased anticancer activity holds its own challenges. Although the 
exact role of this position is unknown, a number of hypothetical roles have been described in 
the literature. It is hypothesised that the position could play a role in exerting kinetic control 
over prodrug activation (Langnel et al., 2000; Svec et al., 2018); influencing transport properties 
of compounds by modifying their subsequent internalisation within cells; or influencing the non-
covalent interactions between intact prodrug and DNA (Langnel et al., 2000). Rational drug 
design was centred around these hypotheses with the aim of both synthesising superior 
analogues of TMZ alongside extending SAR at the position of modification.  
Since it is hypothesised that position 8 plays a role in non-covalent interactions with DNA, 
influencing the potency of the molecule (Langnel et al., 2000), it appears logical that a series of 
ester and amide analogues of TMZ would give a useful insight into SARs at this position. Esters 
and amide groups provide sites for hydrogen bond accepting (HBA) and hydrogen bond donating 
sites (HBD), respectively (Figure 2.3). Consequently, the effect of changing the hydrogen bonding 
character at position 8 will be investigated by synthesising analogues with respective ester and 
amide groups at this position. There have been a number of reviews that help support the 
strategy behind the use of esters and amides that tend to retain cytotoxic potency 
(Suppasansatorn et al., 2006; Liu et al., 2010; Marin-Ramos et al., 2018). Whereas, other position 
8 modifications such as cyano and nitro moieties resulted in analogues devoid of significant anti-
tumour activity (Lunt et al., 1987). Consequently, the synthesis of a series of ester and amide 





Figure 2.3: Chemical structures and molecular models of ester and amide analogues of temozolomide.  
 
An earlier report regarding ester TMZ analogues at position 8, reviewed in section 1.6.3, failed 
to assess the antiproliferative effects of phenyl ester and amide groups. Systematic design of 8-
phenyl ester and amide TMZ analogues, with various aromatic substituents, should provide an 
insight into the implications of mesomeric and inductive effects of the molecule, (Figure 2.4). It 
is hypothesised that mesomeric effects of these groups could influence electron distribution 
within the molecule, subsequently impacting the kinetics of prodrug activation. Interestingly, 
post-design of analogues in the present study, Svec et al., 2018 confirmed the hypothesis that 
position 8 could exert kinetic control over pro-drug activation before the current work was 
published. However, the design of the analogues described in the present study could provide a 





Figure 2.4: Chemical structures and molecular models of phenyl ester and amide analogues of 
temozolomide. 
 
The addition of various ester and amide derivatives at position 8 will ultimately affect the 
lipophilicity of the molecule. As previously mentioned, it is hypothesised that position 8 could 
play a role in the bio-distribution and cellular internalisation of TMZ analogues into cells. The 
addition of short alkyl chains to esters and amides would serve to increase the lipophilicity of 
analogues, improving BBB penetration and cellular internalisation, (Figure 2.5). A similar effect 
is observed when comparing BBB penetration of morphine and heroin (Di and Kerns, 2016).  The 
addition two acetyl groups on morphine, yielding heroin, causes 100-fold increase in BBB 
penetration (Clark, 2003). It is hypothesised that by adding moieties at position 8 on TMZ could 




Figure 2.5: Chemical structures and molecular models of benzyl and phenethyl ester and amide 
analogues of temozolomide. X = O or NH. 
 
The series of TMZ analogues will include the most promising analogues from Liu et al., 2010 and 
Suppasansatorn et al., 2006. The inclusion of TMZ hexyl ester (Suppasansatorn et al., 2006) and 
TMZ 3-(dimethylamino)propyl ester (Liu et al., 2010) will provide a basis for comparing the novel 
analogues synthesised in this study, (Figure 2.6). Furthermore, in both these studies, 
antiproliferative evaluation was not carried out on glioma cell lines. During this study, the 
inclusion of TMZ hexyl ester and TMZ 3-(dimethylamino)propyl ester should provide a useful 
comparison since these analogues will be tested for the first time against glioma cell lines. 
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ES2 ES7  
Figure 2.6: Structures of TMZ hexyl ester (ES2) TMZ 3-(dimethylamino)propyl ester (ES7), first described 


















2.1.3. Summary of the Rational Design  
• Position 8 on the imidazole ring has been identified as the most promising position that 
yields analogues with superior antiproliferative activity compared to TMZ.  
• The precise role of position 8 of TMZ has still not been elucidated. However, it is 
hypothesised to be involved in the following: 
o Exerting kinetic control over prodrug activation. 
o Influencing transport properties of the drug. 
o Influencing non-covalent interactions between intact prodrug and DNA. 
 
Table 2.1: A summary of the considerations in the design of novel TMZ analogues. 
Modifications to be made at position 8 Rationale 
Modifications will utilise ester and amide 
linkages. 
Previous literature suggests increased 
activity in ester and amide TMZ analogues. 
Additionally provides HBA and HBD sites. 
Utilising phenyl ester and amide groups. Phenyl ester moieties are yet to be 
investigated at position 8 of TMZ. The 
inclusion of phenyl ester and amides, with 
various aromatic substituents, should 
provide an insight into the mesomeric and 
inductive effects. 
Utilising various alkyl chains within the ester 
/ amide moiety.  
The use of alkyl chains in the design of the 
molecule will increase lipophilicity, 
potentially improving cellular internalisation 
of analogues and the ability to penetrate the 
BBB. 
 
The aim of Chapter 2 will be to successfully synthesise and characterise a series of ester and 





2.3.1. Chemicals and Reagents 
Temozolomide was purchased from Carbosynth. Deuterated solvents, dimethyl sulfoxide-d6 and 
chloroform-d, for NMR analysis were purchased from GOSS Scientific. Ethyl acetate, ethanol, 
anhydrous tetrahyrofuran, anhydrous toluene, petroleum ether 40-60oC and dichloromethane 
were purchased from Fisher Scientific. Concentrated sulphuric acid, HPLC grade water, 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and anhydrous magnesium sulphate 
were purchased from Fisher Scientific. Sodium nitrite, thionyl chloride, anhydrous 
dimethylformamide, silica gel for column chromatography, 4-methoxyphenylethyl alcohol, 
phenol, aniline and 4-dimethylaminopyridine were purchased from Sigma Aldrich (now Merk). 
N,N'-dicyclohexylcarbodiimide was purchased from Alfa Aesar. p-Cresol, 2-phenylethanol, 4-
nitrophenylethyl alcohol, 4-methoxybenzyl alcohol, 4-methoxyphenol, 4-nitrophenol, 4-
chlorophenol, 4-hydroxybenzonitrile, 2-methoxyphenol, 3-dimethylamino-1-propanol, 2-
phenylethyl amine, p-anisidine, 4-methylbenzylamine and 4-chlorobenzylamine were 
purchased from Alfa Aesar. were purchased from Sigma Aldrich. p-Toluidine, 4-chloroaniline, 4-
aminobenzonitrile, hexylamine, o-anisidine and 4-methoxybenzylamine were purchased from 
Acros Organics. All reagents were commercially sourced and used without any further 
purification. 
2.3.2. Overview of Methods  
All solvents and reagents were used without any further purification. Reactions were monitored 
using silica gel coated TLC plates with fluorescent indicator (254 nm). Flash column 
chromatography, used for purification, was carried out using silica gel purchased from Sigma 
Aldrich. Specifications of the silica gel were; 60 Å pore size, 230-400 mesh particle size and 40-
63 μm particle size. 1H and 13C NMR spectra were recorded on either Bruker Fourier 300 (300 
MHz) or a Bruker Advance III 400 (400 MHz). All chemical shifts are relative to residual solvent 
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peaks (chloroform-d CDCl3, δH-7.26; δc-77.16); (DMSO-d6, δH-2.50; δc-39.52). J Values are 
calculated in Hz. IR spectra were recorded on Nicolet iS10 Spectrophotometer. Melting points 
were recorded on a Stuart SMP10 melting point apparatus and were uncorrected. High 
resolution mass spectrometry (HMRS) was obtained by Pharmidex by means of UHPLC-ToF-MS 
using electrospray ionisation on a Agilent 1290 UHPLC and Agilent 6550 QToF-MS. In the cases 
where more than one synthetic route was used, the most efficient route, in terms of yield, was 
reported. The assignment of carbon environments of 13C NMR spectra was aided by 13C dept-
135.  
2.3.3. Synthesis 
2.3.3.1. Preparation of Ester and Amide Analogues of Temozolomide Utilising Acyl Chlorides 
(Scheme 2.2) 
Synthesis of 3-Methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid 
(Temozolomide Acid 36) 
TMZ 1 (2.00 g, 10.3 mmol) was dissolved in conc. sulphuric acid (16 mL). Sodium nitrite (2.65 g, 
38.4 mmol) in water (10.4 mL) was added dropwise to the solution, keeping the temperature of 
the reaction mixture below 15 oC. The resulting mixture was left for 16 h. Ice-water (40 mL) was 
added to the mixture, precipitating out the desired product. The precipitate 36 was collected via 
filtration before being dried over phosphorus pentoxide for 48 h. Producing a white solid, 1.36 
g (68 % yield). 
 
M.p. = 181 oC (decomposition) (lit. = >180 oC); IR (cm-1) 3499 (O-H stretch), 3080 (C-H stretch), 
1764 (C=O stretch, COOH), 1686 (C=O stretch, CONH). 1H NMR (300 MHz, DMSO-d6), δH: 13.40 
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(bs, 1H, OH), 8.82 (s, 1H, N-CH), 3.87 (s, 3H, N-CH3). 13C NMR (75 MHz, DMSO-d6), δC: 162.28 (6), 
139.52 (2), 136.91 (5), 129.52 (3), 128.17 (4), 36.76 (1). HRMS calc’d for C6H5N5O3  [M+Na]+: 
218.0284. Found m/z: 218.0293. 
Synthesis of 3-Methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl chloride 
(Temozolomide Acyl Chloride 37) 
A mixture of temozolomide acid 36 (200 mg, 1.03 mmol), thionyl chloride (5 mL, 69 mmol) and 
dimethylformamide (1 drop) was heated under reflux for 3 h. The resulting mixture was 
evaporated under reduced pressure. Toluene (3 x 10 mL) was added and evaporated to dryness 
to yield, 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl chloride (37, TMZ acyl 
chloride), as a brown/orange solid 218 mg, (99 % yield). M.p. = 142 oC (lit. = 142 – 143 oC). 
 
General synthesis of target compounds ES1-ES7; AM1-AM11 
 
 
Scheme 2.2: (I) Sodium nitrite, conc. Sulphuric acid <15 oC; (II) thionyl chloride, dimethylformamide reflux; 
(III) appropriate alcohol / amine, THF, r.t. Ester and amide analogues are referred to as ES and AM, 
respectively. 
Note: All aromatic substituents are in the para- position unless otherwise stated. 
Commented [OI4]: These are incorrect 




Temozolomide acyl chloride (37, 218 mg, 1.02 mmol) was dissolved in tetrahydrofuran (10 mL). 
A solution of tetrahydrofuran (2 mL) and the appropriate alcohol or amine (≈1.05 mmol) was 
added dropwise and stirred for 3 h. The crude reaction mixture was absorbed onto silica, and 
purified by column chromatography using a solvent system of an appropriate ratio of light 
petroleum ether to ethyl acetate, to afford the desired title compounds.  
Ethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - ES1  
 
General procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. Ethanol (76 µL, 1 mmol, 
equiv. 1.2) was added dropwise to a solution of temozolomide acyl chloride (0.177 g, 0.83 mmol, 
equiv. 1.0) in THF (10 mL). EtOAc was used for flash column chromatography to afford 
compound ES1, light orange solid 145 mg, (79 % yield). M.p. 130 oC; IR (cm-1) 1716 (C=O stretch, 
COO), 1623 (C=O stretch, CONH). 1H NMR (300 MHz, DMSO-d6), δH: 8.85 (s, 1H, N-CH), 4.38 (q, J 
= 7.1 Hz, 2H, O-CH2), 3.88 (s, 3H, N-CH3), 1.33 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, DMSO-
d6), δC: 160.9 (6), 139.4 (2), 137.1 (5), 129.8 (3), 127.1 (4), 61.3 (7), 36.9 (1), 14.7 (8). HRMS calc’d 








Hexyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - ES2 
 
Procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. Hexanol (110 µL, 0.88 mmol, 
equiv. 0.88) was added dropwise to a solution of temozolomide acyl chloride (213 mg, 0.10 
mmol, equiv. 1.0) in THF (10 mL). EtOAc : petroleum ether (1:1, v/v) was used for flash column 
chromatography to afford compound ES2, yellow solid 105 mg (29 % yield); m.p. 76 oC; IR (cm-1) 
3114 (C-H stretch), 2956 (C-H stretch), 2921 (C-H stretch), 2854 (C-H stretch), 1755 (C=O stretch, 
COO), 1722 (C=O stretch, CONH). 1H NMR (300 MHz DMSO-d6), δH: 8.85 (s, 1H, N-CH), 4.34 (t, J 
= 7.1 Hz, O-CH2), 3.88 (s, 3H, N-CH3), 1.71 (quint, J = 7.1 Hz, 2H, CH2), 1.53 – 1.16 (m, 8H, (CH2)4), 
0.87 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz DMSO-d6), δC: 160.96 (6), 139.43 (2), 137.13 (5), 
129.80 (3), 127.12 (4), 65.16 (7), 36.84 (1), 31.30 (8), 28.63 (9), 25.51 (10), 22.50 (11), 14.36 (12). 
HRMS calc’d for C12H17N5O3  [M+Na]+: 302.1224. Found m/z: 302.1239. 
Phenethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - ES3 
 
Procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. 2-Phenylethanol (110 µL, 0.92 
mmol, equiv. 0.89) was added dropwise to a solution of temozolomide acyl chloride (222 mg, 
1.03 mmol, equiv. 1.0) in THF (10 mL). EtOAc : petroleum ether (1:1, v/v) was used for flash 
75 
 
column chromatography to afford compound ES3, off-white solid 137.4 mg. (44% yield); m.p. 
124 oC; IR (cm-1) 3067 (C-H stretch), 1740 (C=O stretch, COO), 1712 (C=O stretch, CONH), 1H NMR 
(300 MHz DMSO-d6), δH: 8.85 (s, 1H, N-CH), 7.38-7.19, (m, 5H, Ar), 4.55 (t, J = 7.5 Hz, 2H, O-CH2), 
3.89 (s, 3H, N-CH3), 3.05 (t, J = 7.5 Hz, 2H, CH2-Ar). 13C NMR (75 MHz DMSO-d6), δC: 160.9 (6), 
139.4 (2), 138.4 (9), 137.2 (5), 129.8 (3), 129.5 (11), 128.8 (10), 126.9 (4), 126.9 (12), 65.8 (7), 
36.9 (1), 34.9 (8). HRMS calc’d for C14H13N5O3 [M+Na]+: 322.0911. Found m/z: 322.0925. 
4-Nitrophenethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - 
ES4 
 
Procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. 2-(4-Nitrophenyl)ethanol 
(150.4 mg, 0.90 mmol, equiv. 0.96), in THF (2 mL), was added dropwise to a solution of 
temozolomide acyl chloride (201 mg, 0.94 mmol, equiv. 1.0)  in THF (10 mL). EtOAc was used for 
flash column chromatography to afford compound ES4, white solid 102.6 mg (27 % yield); m.p. 
187 oC; IR (cm-1) 3105 (C-H stretch), 1743 (C=O stretch, COO), 1708 (C=O stretch, CONH). 1H NMR 
(300 MHz, DMSO-d6), δH: 8.86 (s, 1H, N-CH), 8.15 (d, J = 8.3 Hz, 2H, Ar), 7.67 (d, J = 8.3 Hz, 2H, 
Ar), 4.63 (t, J = 6.4 Hz, 2H, O-CH2), 3.90 (s, 3H, N-CH3), 3.22 (t, J = 6.4 Hz, 2H, CH2-Ar). 13C NMR 
(75 MHz DMSO-d6), δC: 160.7 (6), 147.0 (12), 146.7 (9), 139.4 (2), 137.2 (5), 130.9 (10), 129.9 (3), 
126.7 (4), 123.8 (11), 65.0 (7), 36.9 (1), 34.6 (8). HRMS calc’d for C14H12N6O3 [M+Na]+: 367.0761. 






carboxylate - ES5 
 
Procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. 2-(4-Methoxyphenyl)ethanol 
(157.0 mg, 1.03 mmol, equiv. 1.0), in THF (2 mL), was added dropwise to a solution of 
temozolomide acyl chloride (220.8 mg, 1.03 mmol, equiv. 1.0)  in THF (10 mL). EtOAc : petroleum 
ether (1:1, v/v) was used for flash column chromatography. The crude product was subjected 
twice, to flash column chromatography to afford compound ES5, off-white solid 79.2 mg (22 % 
yield); m.p. 164 oC; IR (cm-1) 3126 (C-H stretch), 1745 (C=O stretch, COO), 1725 (C=O stretch, 
CONH). 1H NMR (300 MHz, DMSO-d6), δH: 8.85 (s, 1H, N-CH), 7.27 (d, J = 8.4 Hz, 2H, Ar), 6.85 (d, 
J = 8.4 Hz, 2H, Ar), 4.48 (t, J = 6.8 Hz, 2H, O-CH2), 3.89 (s, 3H, O-CH3), 3.71 (s, 3H, N-CH3), 2.98 (t, 
J = 6.8 Hz, 2H, CH2-Ar). 13C NMR (75 MHz DMSO-d6), δC: 160.9 (6), 158.3 (12), 139.4 (2), 137.2 (5), 
130.5 (9), 130.1 (3), 129.8 (10), 127.0 (4), 114.2 (11), 66.1 (7), 55.4 (13), 36.9 (1), 34.0 (8). HRMS 








4-Methoxybenzyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - 
ES6 
 
Procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. 4-Methoxybenzyl alcohol 
(122.5 mg, 0.89 mmol, equiv. 0.92), in THF (2 mL), was added dropwise to a solution of 
temozolomide acyl chloride (209.3 mg, 0.98 mmol, equiv. 1.0) in THF (10 mL). EtOAc : petroleum 
ether (3:2, v/v) was used for flash column chromatography to afford compound ES6, yellow solid 
111.4 mg (37 % yield); m.p. 170 oC, IR (cm-1) 3122 (C-H stretch), 2961 (C-H stretch), 2928 (C-H 
stretch), 1752 (C=O stretch, COO), 1719 (C=O stretch, CONH), 1615-692. 1H NMR (300 MHz, 
DMSO-d6), δH: 8.85 (s, 1H, N-CH), 7.44 (d, J = 8.4 Hz, 2H, Ar), 6.96 (d, J = 8.4 Hz, 2H, Ar), 5.36 (s, 
2H, O-CH2), 3.88 (s, 3H, O-CH3), 3.76 (s, 3H, N-CH3). 13C NMR (75 MHz DMSO-d6), δC: 160.8 (6), 
159.7 (11), 139.4 (2), 137.3 (5), 130.5 (3), 129.9 (9), 128.3 (8), 123.0 (4), 114.3 (10), 66.4 (7), 55.6 









carboxylate – ES7 
 
Procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. 3-Dimethylamino-1-propanol 
(103.6 µL, 1.03 mmol, equiv. 1), solubilised in THF (2 mL), was added dropwise to a solution of 
temozolomide acyl chloride (219.9 mg, 1.03 mmol, equiv. 1.0) in THF (10 mL). EtOAc was used 
for flash column chromatography to afford compound ES7, white solid 132.4 mg (46 % yield); 
m.p. 204 oC, IR (cm-1) 3074 (C-H), 2595-2483 (C-H), 1747 (C=O stretch, COO), 1719 (C=O stretch, 
CONH). 1H NMR (300 MHz, DMSO-d6) δH: 8.89 (s, 1H, N-CH), 4.43 (t, J = 6.2 Hz, 2H, O-CH2), 3.89 
(s, 3H, N-CH3), 3.20 (t, J = 6.2 Hz, 2H, CH2-N), 2.75 (s, 6H, N-CH3), 2.18 (quint, J = 6.2 Hz, 2H, CH2). 
13C NMR (100 MHz, DMSO) δ 160.2 (6), 138.9 (2), 136.8 (5), 129.4 (3), 126.3 (4), 62.1 (7), 53.8 











N-hexyl-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide - AM1 
 
Procedure for synthesis outlined in Section 2.3.3.1., Scheme 2.2. Hexan-1-amine (135.8 µL, 1.03 
mmol, equiv. 1.0) was added dropwise to a solution of temozolomide acyl chloride (219.9 mg, 
1.03 mmol, equiv. 1.0) in THF (10 mL). EtOAc was used for flash column chromatography to 
afford AM1, off-white solid 156.5 mg (55 % yield); m.p. 138 oC; IR (cm-1) 3295 (N-H stretch), 3118 
(C-H stretch), 2921 (C-H stretch), 2856 (C-H stretch), 1726 (C=O stretch, CONH), 1652 (C=O 
stretch, CONH). 1H NMR (400 MHz, Chloroform-d), δH: 8.40 (s, 1H, N-CH), 7.35 (t, J = 6.5 Hz, 1H, 
NH), 4.04 (s, 3H N-CH3), 3.51 (q, J = 6.5 Hz, 2H, CH2), 1.63 (quint, J = 4.5 Hz, 2H, CH2), 1.46-1.27 
(m, 6H, (CH2)3), 0.89 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (100 MHz Chloroform-d), δC: 159.3 (6), 138.8 
(2), 133.7 (5), 132.1 (4), 127.7 (3), 39.4 (7), 36.5 (8), 31.5 (9), 29.5 (10), 22.5 (11), 14.0 (12). HRMS 













Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. 2-Phenylethanamine (123 µL, 
0.98 mmol, equiv. 1.0) was added dropwise to a solution of temozolomide acyl chloride (209.4 
mg, 0.98 mmol, equiv. 1.0) in THF (10 mL). EtOAc was used for flash column chromatography to 
afford AM2, off-white solid 169.2 mg (58 % yield); m.p. 158 oC; IR (cm-1) 3312 (N-H stretch), 3082 
(C-H stretch), 1745 (C=O stretch, CONH), 1646 (C=O stretch, CONH). 1H NMR (400 MHz, DMSO-
d6), δH: 8.84 (s, 1H, N-CH), 8.54 (t, J = 5.9 Hz, 1H, NH), 7.36 – 7.16 (m, 5H, Ar), 3.87 (s, 3H, N-CH3), 
3.54 (q, J = 7.4 Hz, 2H, NH-CH2), 2.87 (t, J = 7.4 Hz, 2H, CH2-Ar). 13C NMR (100 MHz DMSO-d6), δ: 
160.0 (6), 139.8 (9), 139.7 (2), 134.9 (5), 130.8 (4), 129.1 (11), 128.9 (3), 128.8 (10), 126.6 (12), 











-Methyl-4-oxo-N-phenyl-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide - AM3 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. Aniline (93 µL, 1.03 mmol, equiv. 
1.0) was added dropwise to a solution of temozolomide acyl chloride (219.9 mg, 1.03 mmol, 
equiv. 1.0) in THF (10 mL).  EtOAc: petroleum ether (2:1, v/v) was used for flash column 
chromatography to afford AM3, light orange solid 110.3 mg (40 % yield); m.p. 189 oC; IR (cm-1) 
3356 (N-H stretch), 3118 (C-H stretch), 1734 (C=O stretch, CONH), 1684 (C=O stretch, CONH). 1H 
NMR (300 MHz, DMSO-d6), δH: 10.40 (s, 1H, NH), 8.96 (s, 1H, N-CH), 7.88 (d, J = 9.0Hz, 2H, Ar), 
7.36 (t, J = 6.0 Hz, 2H, Ar), 7.20 – 7.05 (t, J = 6.0 Hz, 1H, Ar), 3.89 (s, 3H, N-CH3). 13C NMR (75 MHz, 
DMSO-d6), δC: 158.8 (6), 139.6 (2), 138.9 (7), 135.6 (5), 130.6 (4), 129.1 (9), 129.0 (3), 124.4 (10), 











carboxamide - AM4 
 
Procedure for synthesis outlined in section 2.3.3.1, scheme 2.2. 4-Methoxyaniline (132.9 mg, 
1.09 mmol, equiv. 1.1), in THF (2 mL) was added dropwise to a solution of temozolomide acyl 
chloride (216.5 mg, 1.01 mmol, equiv. 1.0) in THF (10 mL). EtOAc : petroleum ether (2:1, v/v) 
was used for flash column chromatography to afford AM4, yellow solid (25 % yield); m.p. 192 
oC; IR (cm-1) 3376 (N-H stretch), 3119 (C-H stretch), 2937 (C-H stretch), 1746 (C=O stretch, 
CONH), 1684 (C=O stretch, CONH). 1H NMR (300 MHz, DMSO-d6), δH: 10.30 (s, 1H, NH), 8.95 (s, 
1H, N-CH), 7.79 (d, J = 9.1 Hz, 2H, Ar), 6.94 (d, J = 9.1 Hz, 2H, Ar), 3.89 (s, 3H, O-CH3), 3.75 (s, 3H, 
N-CH3). 13C NMR (75 MHz, DMSO-d6), δC: 158.4 (6), 156.1 (10), 139.7 (2), 135.5 (5), 132.0 (7), 
130.8 (4), 128.9 (3), 122.3 (8), 114.2 (9), 55.6 (11), 36.7 (1). HRMS calc’d for C13H12N6O3 [M+Na]+: 









carboxamide - AM5 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. 4-Chloroaniline (145.8 mg, 1.14 
mmol, equiv. 1.1), solubilised in THF (2 mL) was added dropwise to a solution of temozolomide 
acyl chloride (217.0 mg, 1.02 mmol, equiv. 1.0) in THF (10 mL).  EtOAc was used for flash column 
chromatography to afford AM5, brown solid 140.7 mg (45 % yield); m.p. 200 oC; IR (cm-1) 3359 
(N-H stretch), 3117 (C-H stretch), 1737 (C=O stretch, CONH), 1689 (C=O stretch, CONH). 1H NMR 
(400 MHz, DMSO-d6), δH: 10.59 (s, 1H, NH), 8.97 (s, 1H, N-CH), 7.93 (d, J = 8.8 Hz, 2H, Ar), 7.42 
(d, J = 8.8 Hz, 2H, Ar), 3.90 (s, 3H, N-CH3).13C NMR (100 MHz, DMSO-d6), δC: 158.4 (6), 139.1 (2), 
137.4 (7), 135.3 (5), 129.8 (3), 128.5 (9), 127.5 (4), 121.8 (8), 36.2 (1). HRMS calc’d for 










3-Methyl-4-oxo-N-(p-tolyl)-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide - AM7 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. p-Toluidine (102.2 mg, 0.95 
mmol, equiv. 0.96), solubilised in THF (2 mL) was added dropwise to a solution of temozolomide 
acyl chloride (212.1 mg, 0.99 mmol, equiv. 1.0) in THF (10 mL). EtOAc was used for flash column 
chromatography to afford AM7, yellow solid 164.7 mg (58 % yield); m.p. 209 oC; IR (cm-1) 3301 
(N-H stretch), 3114 (C-H stretch), 1735 (C=O stretch, CONH), 1672 (C=O stretch, CONH). 1H NMR 
(400 MHz, DMSO-d6) δH: 10.30 (s, 1H, NH), 8.94 (s, 1H, N-CH), 7.75 (d, J = 8.8 Hz, 2H, Ar), 7.16 (d, 
J = 8.8 Hz, 2H, Ar), 3.89 (s, 3H, N-CH3), 2.28 (s, 3H, Ar-CH3). 13C NMR (100 MHz, DMSO) δC: 158.6 
(6), 139.6 (2), 136.4 (10), 135.5 (5 or 7), 133.4 (5 or 7), 130.7 (4), 129.5 (9), 128.9 (3), 120.7 (8), 










carboxamide – AM8 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. o-Anisidine (115.3 µL, 1.01 
mmol, equiv. 0.99), solubilised in THF (2 mL) was added dropwise to a solution of temozolomide 
acyl chloride (220.8 mg, 1.03 mmol, equiv. 1.0) in THF (10 mL). EtOAc was used for flash column 
chromatography to afford AM8, yellow solid 268.7 mg (87 % yield); m.p. 193 oC; IR (cm-1) 3370 
(N-H stretch), 1741 (C=O stretch, CONH), 1677 (C=O stretch, CONH). 1H NMR (400 MHz, DMSO-
d6) δH: 9.78 (s, 1H, NH), 8.95 (s, 1H, N-CH), 8.40 (d, J = 8.8 Hz, 1H, Ar), 7.14 (d, J = 8.8 Hz, 2H, Ar), 
7.01 (m, 1H, Ar), 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3). 13C NMR (100 MHz, DMSO) δC: 157.6 (6), 
148.8 (12), 139.5 (2), 135.4 (5), 130.0 (4), 129.2 (3), 127.5 (7), 124.7 (10), 121.2 (9), 119.6 (8), 











carboxamide – AM9 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. 4-Methoxybenzylamine (136.0 
µL, 1.04 mmol, equiv. 1.00), solubilised in THF (2 mL) was added dropwise to a solution of 
temozolomide acyl chloride (223.1 mg, 1.04 mmol, equiv. 1.0) in THF (10 mL). EtOAc was used 
for flash column chromatography to afford AM9, off-white solid 199.7 mg (61 % yield); m.p. 193 
oC. IR (cm-1) 3371 (N-H stretch), 3126 (C-H stretch), 1735 (C=O stretch, CONH), 1696 (C=O stretch, 
CONH). 1H NMR (400 MHz, DMSO-d6) δ: 8.99 (t, J = 6.3 Hz, 1H, NH), 8.85 (s, 1H, N-CH), 7.27 (d, J 
= 8.8 Hz, 2H, Ar), 6.88 (d, J = 8.8 Hz, 2H, Ar), 4.42 (d, J = 6.3 Hz, 2H, NH-CH2), 3.86 (s, 3H, O-CH3), 
3.72 (s, 3H, N-CH3). 13C NMR (100 MHz, DMSO) δC: 159.5 (6), 158.1 (11), 139.1 (2), 134.5 (5), 
131.5 (4), 130.3 (3), 128.7 (9), 128.4 (8), 113.6 (10), 55.0 (7), 41.5 (12), 36.1 (1). HRMS calc’d for 









carboxamide - AM10 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. 4-Methylbenzylamine (130.0 
µL, 1.02 mmol, equiv. 0.98), solubilised in THF (2 mL) was added dropwise to a solution of 
temozolomide acyl chloride (220.8 mg, 1.03 mmol, equiv. 1.0) in THF (10 mL). Ethyl acetate 
solvent system was used for flash column chromatography to afford AM10, off-white solid 168.5 
mg (54 % yield); m.p. 152 oC. IR (cm-1) 3397 (N-H stretch), 3102 (C-H stretch), 1736 (C=O stretch, 
CONH), 1665 (C=O stretch, CONH). 1H NMR (400 MHz, DMSO-d6) δH: 9.01 (t, J = 6.4 Hz, 1H, NH), 
8.86 (s, 1H, N-CH), 7.22 (d, J = 4.0 Hz, 2H, Ar), 7.12 (d, J = 4.0 Hz, 2H, Ar), 4.44 (d, J = 6.4 Hz, 2H, 
NH-CH2), 3.86 (s, 3H, N-CH3), 2.27 (s, 3H, Ar-CH3). 13C NMR (100 MHz, DMSO) δC: 159.6 (6), 139.1 
(2), 136.5 (11), 135.7 (5 or 8), 134.5 (5 or 8), 130.3 (4), 128.7 (10), 128.4 (3), 127.3 (9), 41.8 (7), 









carboxamide – AM11 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. 4-Chlorobenzylamine (122.0 µL, 
1.00 mmol, equiv. 0.97), solubilised in THF (2 mL) was added dropwise to a solution of 
temozolomide acyl chloride (220.1 mg, 1.03 mmol, equiv. 1.0) in THF (10 mL). EtOAc : petroleum 
ether (2:1, v/v) was used for flash column chromatography to afford AM11, off-white solid 154.3 
mg (47 % yield); m.p. 148 oC. IR (cm-1) 3288 (N-H stretch), 1735 (C=O stretch, CONH), 1651 (C=O 
stretch, CONH). 1H NMR (400 MHz, DMSO-d6) δH: 9.15 (t, J = 6.3 Hz, 1H, NH), 8.87 (s, 1H, N-CH), 
7.41 – 7.33 (m, 4H, Ar), 4.47 (d, J = 6.3 Hz, 2H, NH-CH2), 3.87 (s, 3H, N-CH3). 13C NMR (100 MHz, 
DMSO) δC: 159.7 (6), 139.1 (2), 138.6 (8), 134.6 (5), 131.3 (4 or 11), 130.1 (4 or 11), 129.2 (9), 









Synthesis of the target compound AM6 
Temozolomide acyl chloride 32 (218 mg, 1.02 mmol) was dissolved in tetrahydrofuran (10 mL). 
A solution of tetrahydrofuran (2 mL) and the appropriate amine (≈1.05 mmol) was added 
dropwise and stirred for 3 h. The precipitate formed was filtered and washed with 
tetrahydrofuran to afford the desired title compound AM6. Residual tetrahydrofuran was 
evaporated under reduced pressure. 
 
N-(4-cyanophenyl)-3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-
carboxamide - AM6 
 
Procedure for synthesis outlined in Section 2.3.3.1, Scheme 2.2. 4-Aminobenzonitrile (124.2 mg, 
1.07 mmol, equiv. 1.1), solubilised in THF (2 mL) was added dropwise to a solution of 
temozolomide acyl chloride (216.3 mg, 1.01 mmol, equiv. 1.0) in THF (10 mL). Precipitate was 
filtered and wash THF to afford AM6, off-white solid 216.0 mg (73 % yield); m.p. 234oC; IR (cm-
1) – 3339 (N-H stretch), 3117 (C-H stretch), 2222 (C≡N stretch), 1740 (C=O stretch, CONH), 1689 
(C=O stretch, CONH). 1H NMR (400 MHz, DMSO-d6), δH: 10.75 (s, 1H, NH), 8.93 (s, 1H, N-CH), 8.10 
(d, J = 8.8 Hz, 2H, Ar), 7.81 (d, J = 8.8 Hz 2H, Ar), 3.90 (s, 3H, N-CH3). 13C NMR (100 MHz, DMSO-
d6), δC: 158.8 (6), 142.7 (7), 139.0 (2), 135.6 (5), 133.0 (9), 129.5 (4), 128.6 (3), 120.3 (8), 118.9 




2.3.3.2. Initial Preparation of Ester Analogues of Temozolomide Utilizing 
Dicyclohexylcarbodiimide (DCC) / Dimethylaminopyridine (DMAP) Coupling (Scheme 2.3) 
Initial general synthesis of target compounds ES8-ES11 
Temozolomide acid 36 (200 mg, 1.03 mmol) was solubilised in a mixture of tetrahydrofuran and 
dichloromethane (10 mL: 10 mL). The appropriate alcohol (≈1.05 mmol), dissolved in 
tetrahydrofuran (2 mL), was added dropwise to the solution. The mixture was then stirred for 
10 mins. A solution of dicyclohexylcarbodiimide (DCC) (255 mg, 1.24 mmol) in dichloromethane 
(2 mL) was added along with a catalytic amount of 4-dimethylaminopyridine (DMAP). The 
reaction was stirred for 3 h. The precipitated urea by-products were filtered, and the resulting 
filtrate was evaporated under reduced pressure. To the resulting off-white/yellow solid, 
acetonitrile (5 mL) was added and the mixture subjected to 15 min of sonication. The residual 
precipitated urea by-product was again filtered, and the filtrate was evaporated under reduced 
pressure. To the resulting off-white/yellow solid was treated with acetonitrile (5 mL) and the 
process of sonication and filtering was repeated until a yellow oil was afforded. The yellow oil 
was subjected to flash column chromatography using a solvent system of an appropriate ratio 
of light petroleum ether to ethyl acetate, to remove any excess alcohol. The resulting off-
white/yellow powder was solubilised in dichloromethane (5 mL) and triturated with petroleum 
ether and dried to afford the desired title compounds. Although compounds ES8-ES11 were 





Scheme 2.3: (I) Sodium nitrite, conc. sulphuric acid <15 oC; (II) dicyclohexylcarbodiimide, 4-
dimethylaminopyridine, tetrahydrofuran : dichloromethane (1:1), ArOH, r.t. Ester analogues are referred 
to as ES. 
Note: All aromatic substituents are in the para position unless otherwise stated. 
 
2.3.3.3 Preparation of Ester Analogues of Temozolomide Utilising 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC.HCl) / 4-Dimethylaminopyridine (DMAP) Coupling 
(Scheme 2.4)  
General synthesis of target compounds (ES12-ES14) 
Temozolomide acid 36 (200 mg, 1.03 mmol) was solubilised in mixture of tetrahydrofuran and 
dichloromethane (10 mL: 10 mL v/v). The appropriate alcohol was added (≈1.05 mmol) dropwise 
to the solution. The mixture was then stirred for 10 mins. A solution of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC.HCl) (305 mg, 1.60 mmol) in dichloromethane (2 mL) 
was added along with a 4-dimethylaminopyridine (DMAP) (1 mg). The reaction was stirred for 3 
h. The crude reaction mixture was absorbed onto silica, and purified by flash column 
chromatography using a solvent system of an appropriate ratio of light petroleum ether to ethyl 
acetate, to remove any excess alcohol. The product was solubilised in dichloromethane (20 mL) 
and washed with brine (3 x 30 mL) and water (30 mL). The dichloromethane layer was dried over 
anhydrous sodium sulphate and the solvent was evaporated under reduced pressure to afford 





Scheme 2.4:  (I) Sodium nitrite, conc. sulphuric acid <15 oC; (II) 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, 4-dimethylaminopyridine, tetrahydrofuran : dichloromethane (1:1), 
ArOH. r.t. Ester analogues are referred to as ES. 
Note: All aromatic substituents are in the para position unless otherwise stated. 
 
Optimised synthesis of target compounds (ES8-ES11) 
Temozolomide acid 36 (600 mg, 3.07 mmol) was solubilised in mixture of tetrahydrofuran and 
dichloromethane (30 mL: 30 mL v/v). The appropriate alcohol was added (≈3.10 mmol) dropwise 
to the solution. The mixture was then stirred for 10 min. A solution of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC.HCl) (950 mg, 4.97 mmol) in dichloromethane (6 mL) 
was added along with a catalytic amount of DMAP (1 mg). The reaction was stirred for 3 h. The 
crude reaction mixture was absorbed onto silica, and purified by flash column chromatography 
using a solvent system of an appropriate ratio of light petroleum ether to ethyl acetate, to any 
remove excess alcohol. The product was solubilised in dichloromethane (40 mL) and washed 
with brine (3 x 40 mL) and water (40 mL). The dichloromethane layer was dried over sodium 











Procedure for synthesis outlined in Section 2.3.3.3., Scheme 2.4. 4-Methoxyphenol (427.8 mg, 
3.45 mmol, equiv. 1.11), in THF (6 mL), was added dropwise to a solution of temozolomide acid 
(607.4 mg, 3.101mmol, equiv. 1.0) in DCM and THF (30 mL: 30 mL, v/v). EDC.HCl (955.9 mg, 5.00 
mmol, equiv. 1.61) was added along with a catalytic amount of DMAP (approx. 1 mg). EtOAc : 
petroleum ether (2:1, v/v) was used for flash column chromatography. The resulting solid 
solubilised in DCM (20 mL) and washed with brine (3x30 mL) and water (30 mL). The DCM layer 
was dried over sodium sulphate and the solvent was removed under reduced pressure to afford 
ES8, off-white solid 489.8 mg (50 % yield); m.p. 172oC; IR (cm-1) 3117 (C-H stretch), 1739 (C=O 
stretch)*. 1H NMR (300 MHz, DMSO-d6), δH: 8.96, (s, 1H, N-CH), 7.22 (d, J = 9.0 Hz, 2H, Ar), 7.03 
(d, J = 9.0 Hz, 2H, Ar), 3.92 (s, 3H, Ar-OCH3), 3.79 (s, 3H, N-CH3). 13C NMR (75 MHz DMSO-d6), δC: 
159.0 (6), 157.5 (10), 143.8 (7), 138.5 (2), 136.3 (5), 128.8 (3), 128.6 (4), 122.3 (8), 114.5 (9), 55.6 
(11), 36.8 (1). HRMS calc’d for C13H11N5O4 [M+Na]+: 324.0703. Found m/z: 324.0713.   





4-Nitrophenyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - 
ES9 
 
Procedure for synthesis outlined in Section 2.3.3.3, Scheme 2.4. 4-Nitrophenol (453.0 mg, 3.26 
mmol, equiv. 1.03), in THF (6 mL), was added dropwise to a solution of temozolomide acid (615.2 
mg, 3.15 mmol, equiv. 1.0) in DCM and THF (30 mL: 30 mL, v/v). EDC.HCl (962.1 mg, 5.03 mmol, 
equiv. 1.59) was added along with a catalytic amount of DMAP (approx. 1 mg). EtOAc : 
petroleum ether (3:2, v/v) was used for flash column chromatography. The resulting solid 
solubilised in DCM (20 mL) and washed with brine (3x30 mL) and water (30 mL). The DCM layer 
was dried over sodium sulphate and the solvent was removed under reduced pressure to afford 
ES9, white solid 488.1 mg (49 % yield); m.p. 190 oC, IR (cm-1) 3154 (C-H stretch), 3114 (C-H 
stretch), 1754 (C=O stretch, COO), 1727 (C=O stretch, CONH). 1H NMR (300 MHz, DMSO-d6), δH: 
8.98 (s, 1H, N-CH), 8.38 (d, J = 9.0 Hz, 2H, Ar), 7.66 (d, J = 9.0 Hz, 2H, Ar), 3.94 (s, 3H, N-CH3). 13C 
NMR (75 MHz DMSO-d6), δC: 158.6 (6), 155.3 (7), 145.8 (10), 139.3 (2), 138.3 (5), 130.4 (3), 126.0 
(9), 125.2 (4), 123.7 (8), 37.1 (1). HRMS calc’d for C12H8N6O5 [M+Na]+: 339.0448. Found m/z: 






4-Chlorophenyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - 
ES10 
 
Procedure for synthesis outlined in Section 2.3.3.3. Scheme 2.4. 4-Chlorophenol (409.5 mg, 3.18 
mmol, equiv. 1.03), in THF (6 mL), was added dropwise to a solution of temozolomide acid (605.1 
mg, 3.10 mmol, equiv. 1.0) in DCM and THF (30 mL: 30 mL, v/v). EDC.HCl (950.0 mg, 4.97 mmol, 
equiv. 1.60) was added along with a catalytic amount of DMAP (approx. 1 mg). EtOAc : 
petroleum ether (4:3, v/v) was used for flash column chromatography. The resulting solid 
solubilised in DCM (20 mL) and washed with brine (3x30 mL) and water (30 mL). The DCM layer 
was dried over sodium sulphate and the solvent was removed under reduced pressure to afford 
ES10, white solid 442.3 mg (44 % yield); m.p. 164 oC; IR (cm-1) 3089 (C-H stretch), 1733 (C=O 
stretch). 1H NMR (400 MHz, DMSO-d6), δH: 8.97 (s, 1H N-CH), 7.56 (d, J = 9.0 Hz, 2H, Ar), 7.38 (d, 
J = 9.0 Hz, 2H, Ar), 3.93 (s, 3H, N-CH3). 13C NMR (100 MHz DMSO-d6), δ: 158.7 (6), 148.8 (7), 138.8 
(2), 137.5 (5), 130.3 (4), 129.8 (3), 129.6 (9), 125.2 (10), 123.7 (8), 36.6 (1). HRMS calc’d for 
C12H8N5O3Cl [M+Na]+: 328.0208. Found m/z: 328.0219.     





4-Cyanophenyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - 
ES11 
 
Procedure for synthesis outlined in Section 2.3.3.3., Scheme 2.4. 4-Hydroxybenzonitrile (392.1 
mg, 3.29 mmol, equiv. 1.06), in THF (6 mL), was added dropwise to a solution of temozolomide 
acid (602.8 mg, 3.09 mmol, equiv. 1.0) in DCM and THF (30 mL: 30 mL, v/v). EDC.HCl (962.1 mg, 
5.03 mmol, equiv. 1.63) was added along with a catalytic amount of DMAP (approx. 1 mg). EtOAc 
: petroleum ether (7:5, v/v) was used for flash column chromatography. The resulting solid 
solubilised in DCM (20 mL) and washed with brine (3x30 mL) and water (30 mL). The DCM layer 
was dried over sodium sulphate and the solvent was removed under reduced pressure to afford 
ES11, white solid 287.8 mg (30 % yield); m.p. 192 oC; IR (cm-1) 3146 (C-H stretch), 3110 (C-H 
stretch), 2224 (C≡N stretch), 1759 (C=O stretch, COO), 1730 (C=O stretch, CONH). 1H NMR (300 
MHz, DMSO-d6), δH: 9.00 (s, 1H, N-CH), 8.01 (d, J = 8.8 Hz, 2H, Ar), 7.58 (d, J = 8.8 Hz, 2H, Ar), 
3.93 (s, 3H N-CH3). 13C NMR (75 MHz DMSO-d6), δC: 158.2 (6), 153.4 (7), 138.8 (2), 137.7 (5), 134.2 
(9), 129.9 (6), 124.8 (4), 123.3 (8), 118.3 (11), 109.1 (10), 36.6 (1). HRMS calc’d for C13H8N6O3  






Phenyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - ES12 
 
Procedure for synthesis outlined in Section 2.3.3.3., Scheme 2.4. Phenol (117.0 mg, 1.24 mmol, 
equiv. 1.23), in THF (2 mL), was added dropwise to a solution of temozolomide acid (201.0 mg, 
1.03 mmol, equiv. 1.0) in DCM and THF (10 mL: 10 mL, v/v). EDC.HCl (305.4 mg, 1.59 mmol, 
equiv. 1.55) was added along with a catalytic amount of DMAP (approx. 1 mg).  EtOAc : 
petroleum ether (4:3, v/v) was used for flash column chromatography. The resulting solid was 
solubilised in DCM (20 mL) and washed with brine (3 x 30 mL) and water (30 mL). The DCM layer 
was dried over anhydrous sodium sulphate and the solvent was removed under reduced 
pressure to afford ES12, off white solid 75.3 mg (27.0 % yield); m.p. 149 oC; IR (cm-1) 3143 (C-H 
stretch), 1737 (C=O stretch)*. 1H NMR (400 MHz, Chloroform-d), δH: 8.53 (s, 1H, N-CH), 7.51 – 
7.37 (m, 2H, Ar), 7.35 – 7.23 (m, 3H, Ar), 4.06 (s, 3H, N-CH3). 13C NMR (100 Chloroform-d), δC: 
158.7 (6), 150.2 (7), 138.4 (2), 136.3 (5), 129.5 (9), 128.8 (3), 128.4 (4), 126.3 (10), 121.5 (8), 36.8 
(1). HRMS calc’d for C12H9N5O3  [M+Na]+: 294.0597. Found m/z: 294.0606.     









    
Procedure for synthesis outlined in Section 2.3.3.3., Scheme 2.4. 2-Methoxyphenol (121.0 µL, 
1.10 mmol, equiv. 1.07), in THF (2 mL), was added dropwise to a solution of temozolomide acid 
(200.4 mg, 1.03 mmol, equiv. 1.0) in DCM and THF (10 mL: 10 mL, v/v). EDC.HCl (301.1 mg, 1.58 
mmol, equiv. 1.53) was added along with a catalytic amount of DMAP (approx. 1 mg). EtOAc : 
petroleum ether (4:3, v/v) for flash column chromatography. The resulting solid solubilised in 
DCM (20 mL) and washed with brine (3x30 mL) and water (30 mL). The DCM layer was dried over 
sodium sulphate and the solvent was removed under reduced pressure to afford ES13, orange 
solid 150.7 mg (49 % yield); m.p. 165 oC; IR (cm-1) 3153 (C-H stretch), 1737 (C=O stretch)*. 1H 
NMR (400 MHz, DMSO-d6), δH: 8.95 (s, 1H, N-CH), 7.32 (t, J = 7.7, 1H, Ar), 7.23 (ddd, J = 7.7, 8.2, 
1.6 Hz, 2H, Ar), 7.04 (t, J = 7.7 Hz, 1H, Ar), 3.92 (s, 3H, N-CH3). 13C NMR (100 MHz DMSO-d6), δC:  
158.3 (6), 150.8 (12), 138.9 (2), 137.4 (7), 129.7 (3), 127.3 (10), 125.3 (5), 122.8 (9), 120.7 (8), 
112.9 (11), 56.0 (13), 36.5 (1). HRMS calc’d for C13H11N5O4 [M+Na]+: 324.0703. Found m/z: 
324.0715.     






p-Tolyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - ES14 
 
 
Procedure for synthesis outlined in Section 2.3.3.3., scheme 2.4. p-Cresol (107.0 µL, 1.03 mmol, 
equiv. 1.0), in THF (2 mL), was added dropwise to a solution of temozolomide acid (204.2 mg, 
1.03 mmol, equiv. 1.0) in DCM and THF (10 mL: 10 mL, v/v). EDC.HCl (303.4 mg, 1.59 mmol, 
equiv. 1.51) was added along with a catalytic amount of DMAP (approx. 1 mg). EtOAc : 
petroleum ether (2:1, v/v) was used for flash column chromatography. The resulting solid 
solubilised in DCM (20 mL) and washed with brine (3x30 mL) and water (30 mL). The DCM layer 
was dried over sodium sulphate and the solvent was removed under reduced pressure to afford 
ES14, off-white solid 81.5 mg (28 % yield); m.p. 164 oC; IR (cm-1) 3122 (C-H stretch), 1734 (C=O 
stretch)*. 1H NMR (400 MHz, Chloroform-d) δH: 8.51 (s, 1H, N-CH), 7.22 (d, J = 8.0 Hz, 2H, Ar), 
7.17 (d, J = 8.0 Hz, 2H, Ar), 4.05 (s, 3H, N-CH3), 2.37 (s, 3H, Ar-CH3). 13C NMR (100 MHz, CDCl3) δC 
158.8 (6), 148.0 (7), 138.4 (2), 136.3 (10), 136.0 (5), 130.0 (9 or 3), 128.8 (9 or 3), 128.5 (4), 121.2 
(8), 36.7 (1), 21.0 (11). HRMS calc’d for C13H11N5O3 [M+Na]+: 308.0754. Found m/z: 308.0764. 
 





2.4. Results and Discussion 
The aim of the present chapter was to synthesise a series of position-8-modified ester and amide 
analogues of TMZ. As previously stated, TMZ is highly unstable in neutral and basic solutions. 
The imidazotetrazine core undergoes ring opening due to nucleophilic attack by water at 
position C4 on the tetrazine ring (Scheme 2.1) (Denny et al., 1994). Also, ring opening is known 
to occur due to exposure to protic solvents (Stevens et al., 1984). As a result, where possible, 
synthesis of novel analogues utilised acidic conditions and aprotic solvents in order to prevent 
ring opening and to maximise yields.  
2.4.1. Preparation of Ester and Amide Analogues of Temozolomide Utilising Acyl 
Chloride Generation (Scheme 2.2) 
Historically, due to the relative instability of the tetrazine ring, modifications at position 8 were 
achieved through the reaction of various esters and amides containing 8-substituted diazoazoles 
38 with isocyanates (Scheme 2.5) (Lunt et al., 1987). However, a more efficient method for 
modifying position 8 on imidazotetrazines was described by Horspool et al. (1990), without 
disrupting the core of the molecule.  
 
 
Scheme 2.5: Reaction between 8-substituted diazoazoles and isocyanates to form 8-substituted 
imidazotetrazines. Reagents: (i) Sodium nitrite, aq. hydrochloric acid; (ii) Methyl isocyanate, 





Initial attempts at synthesising the target ester and amide analogues of TMZ followed the route 
described by Horspool et al. (1990) (Scheme 2.2). This first involved the conversion of the amide 
at position 8 on the imidazole ring to a carboxylic acid 36. The carboxylic acid group on TMZ acid 
is converted to the activated TMZ acyl chloride, thus allowing preferential nucleophilic attack of 
the imidazo carbonyl group on TMZ acyl chloride 37, by specific alcohols and amines, yielding 
the target analogues. Horspool et al. (1990) reported multiple methods of achieving the 
conversion of TMZ to TMZ acid, however the most successful route utilised nitrous acid to 
achieve hydrolysis of the carbamoyl group forming TMZ acid 36. A mechanism for the reaction 
is shown in Scheme 2.6. 
 
  
Scheme 2.6: Mechanism for the reaction between temozolomide and sodium nitrite / concentrated 




During the reaction outlined in Scheme 2.6, nitrous acid is formed upon the addition of sodium 
nitrite to concentrated sulphuric acid. The electron deficient nitrogen on nitrous acid is subject 
to nucleophilic attack by the amide nitrogen of TMZ. The subsequent loss of water from the 
intermediate 33 leads to the formation of a diazonium leaving group, allowing preferential 
nucleophilic attack of water to the carbonyl carbon 40, yielding the carboxylic acid 36. In 
practice, the reaction also produces nitrogen dioxide, from the reaction of sodium nitrite and 
concentrated sulphuric acid. Characterisation of the product using 1H and 13C NMR and IR 
spectroscopy of the reaction confirmed successful synthesis, (68% yield).    
 
 





The second reaction utilised in Scheme 2.2 was the conversion of TMZ acid 36 to the 
corresponding acyl chloride 37, using thionyl chloride and DMF 35. Here, DMF is utilised to 
catalyse the reaction. A mechanistic view of the DMF catalysed thionyl chloride reaction is 
shown in Scheme 2.7. Thionyl chloride reacts with DMF to form the Vilsmeier iminium salt 42, 
which subsequently reacts with TMZ acid 36 to produce the desired acyl chloride and reforming 
DMF 41, Scheme 2.8. However, it should be noted that the desired compound is also formed 
through a direct reaction of thionyl chloride and TMZ acid 36, shown in Scheme 2.8. To maximise 
the yield of the subsequent alcohol/amine quench, characterisation of TMZ acyl chloride 37 was 
limited to melting point analysis, which was cross-referenced with melting points quoted by 
Horspool et al. (1990) confirming synthesis. 
 
 
Scheme 2.8: A mechanism for the direct reaction of thionyl chloride and temozolomide acid 36, in the 
absence of dimethylformamide. 
 
 
TMZ acyl chloride 37 was subsequently quenched with various alcohols and amines to afford a 
variety of the desired analogues. A summary of the alcohols and amines used in the reaction are 
shown in Table 2.2. Reactions of amines with temozolomide acyl chloride 37 tended to afford a 
better yield compared to equivalent alcohols. The higher yields may be attributed to the lesser 
electronegativity of nitrogen compared to oxygen, meaning amines are much more effective 
nucleophiles than the equivalent alcohols. Table 2.2 also shows that phenols did not readily 
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react with TMZ acyl chloride 37. This effect was attributed to steric hindrance of the tetrazine 
ring on TMZ acyl chloride 37 and the aromatic ring of the alcohols. In addition, the lone pairs on 
oxygen in phenyl alcohols is less available for nucleophilic attack due to partial delocalisation 
into the aromatic ring. In an attempt to overcome the steric effects the reactions were also 
carried out under mild reflux 70 oC, with negligible success. As a result, a new approach was 
needed in order to synthesise the problematic target compounds. 
Table 2.2: Summary of the reactions between temozolomide acyl chloride 32 and various alcohols and 
amines using acyl chlorides. N/A refers to unsuccessful reactions. 


















































































2.4.2. Preparation of Ester Analogues of Temozolomide Utilizing 
Dicyclohexylcarbodiimide (DCC) / Dimethylaminopyridine (DMAP) Coupling 
(Scheme 2.3) 
In order to synthesise the sterically hindered target compounds an adaptation of the Steglich 
esterification reaction was utilised (Shervington et al., 2009). Scheme 2.10 depicts a mechanism 
for the reaction between dicyclohexylcarbodiimide (DCC) / 4-dimethylaminopyridine (DMAP, 
45) and temozolomide acid 36. DCC acts as a base and deprotonates the acid group of 
temozolomide acid 36. The lone pair on the oxygen of the acid group simultaneously attacks the 
imine carbon on DCC intermediate 43. DMAP then attacks the carbonyl carbon of the 
temozolomide acid forming a tetrahedral intermediate 44 in which DCC leaves as dicyclohexyl 
urea (DCU). The desired alcohol then attacks the carbonyl carbon forming another tetrahedral 
intermediate, in which DMAP 45 leaves affording the desired ester (Scheme 2.9).  
The DCU formed in the reaction between DCC / DMAP proved problematic during the initial 
attempts at purifying the target compounds using Scheme 2.3. DCU is relatively insoluble in most 
organic solvents allowing most of the impurity to be filtered off (Tsakos et al., 2015). However, 
trace amounts of DCU persist even after filtration. Initial attempts at separating the DCU via 
flash column chromatography were unsuccessful due to poor resolution of the impurity, 
resulting in its elution in numerous fractions including those with the desired product regardless 
of solvent system. Although DCU is relatively insoluble in most organic solvents it is partially 
soluble in DCM. The partial solubility of DCU and the high polarity of the target molecules, 
allowed high purity products to be achieved via trituration with DCM and light petroleum ether. 
Table 2.3 summarises the alcohols used in this reaction. The yields were relatively low due to a 
significant proportion of the product being sacrificed during the work up. However, reactions 
using phenol, p-cresol and 2-methoxyphenol could not be purified due to the products of these 
reactions exhibiting similar solubility properties to DCU in DCM, resulting in a large quantity of 






Scheme 2.9: A mechanism for the reaction between dicyclohexylcarbodiimide / dimethylaminopyridine 









Table 2.3: Summary of the reactions between temozolomide acid 36 and various alcohols and amines 
using DCC/DMAP. N/A refers to unsuccessful reactions. 
































2.4.3. Preparation of Ester Analogues of Temozolomide Utilising 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC.HCl) / 4-Dimethylaminopyridine (DMAP) 
Coupling (Scheme 2.4)  
The variation of the Steglich esterification adapted from Shervington et al. (2009) and outlined 
in Scheme 2.4, produced the desired sterically hindered esters, but due to difficulties in 
removing the DCU it was not a viable route when using phenol, 2-methoxyphenol or p-cresol. 
To resolve this problem, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC.HCl) was used as 
a direct replacement for DCC. The mechanism for the reaction of EDC.HCl / DMAP and TMZ acid 
36 is shown in Scheme 2.10. In this reaction 1-ethyl-3-(3-dimethylaminopropyl) urea (EDU) is 
formed as the by-product instead of DCU. Water-soluble EDU is easily removed by a simple 
aqueous work up. The yields for this reaction were an improvement on those obtained from 
Scheme 2.3, suggesting this approach to be a more viable option attempting to optimise yields 
or scaling up the reaction, Table 2.4. Consequently, Scheme 2.4 was investigated for the 
synthesis of ES8-ES11 analogues with the aim of improving yields. 


















Scheme 2.10: A mechanism for the reaction between 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide / 4-
dimethylaminopyridine and temozolomide acid 36. 
 
 
Due to the success of synthesising ester TMZ analogues using EDC.HCl / DMAP (Scheme 2.4), 
analogues ES8-ES11 were resynthesized using this route, with the aim of improving yields. Due 
to the straightforward aqueous work up, yields of ES8-ES11 were dramatically improved (Table 







Table 2.5: A comparison of yields for the synthesis of ES8-ES11 
































The current chapter discussed the synthesis and characterisation of a series of ester and amide 
analogues of TMZ. Ester and amide TMZ analogues were readily synthesised in acceptable yields, 
utilising TMZ acyl chloride generation (scheme 2.2) and EDC.HCl / DMAP coupling, (Scheme 2.4). 
A summary of the structures of the synthesised analogues is shown in Figure 2.7. The next stage 
of the work involved determining the antiproliferative properties of this series of TMZ analogues 
in the hope of identifying compounds with promising activity. 
 
Figure 2.7: Successfully synthesised ester and amide analogues of temozolomide. 



























The following chapter will focus on the antiproliferative evaluation of the compounds described 
in Chapter 2. Glial and glioma cell lines are the logical starting point for the antiproliferative 
evaluation of novel TMZ analogues. These cell lines have undergone specific mutations that de-
regulate the cell cycle leading to indefinite replication, while retaining some similar 
characteristics present in primary cells found in human glioma and in healthy glial tissue. 
Consequently, they provided the basis of an acceptable, cost-effective non-animal model for 
initially comparing the antiproliferative effects of the TMZ analogues described in Chapter 2. 
Although cell lines provide a model that simulates a primary human tumour, there are 
limitations that must be recognised when attempting to draw conclusions from results obtained 
using these cells. Glioma cell lines, including U87-MG, have been shown to exhibit different 
biological phenotypes compared with primary tumours. Differences in heterogenicity; 
epidermal growth factor receptor (EGFR) expression and cell replication rates between cell lines 
and primary tumours, all contribute to the limitations of glioma cell line investigations and limit 
the conclusions that can be made from the results, (Li et al., 2008). In order to provide a more 
accurate insight into the antiproliferative effects of TMZ analogues, patient-derived primary 
cultures can be used in place of cell lines. These cells exhibit cell phenotypes more reminiscent 
of cells found in primary human tumours, thus, providing the basis of a much more clinically-
relevant model compared with the use of cell lines (Ledur et al., 2017). Therefore, primary cells 
derived from patients suffering from GBM, can be used to more accurately determine the 
effectiveness of the most promising TMZ analogues, compared with the use of cell lines. 
Although in vitro models provide a cost effective, efficient means of assessing compounds they 
possess inherent disadvantages compared with animal models, (Aslantürk, 2018). Therefore, 
once lead TMZ analogues have been identified through in-vitro analysis, the next stage of 




The characteristics of each cell line used to assess the antiproliferative effects of the analogues 
is summarised in Table 3.1. Uppsala 87 Malignant Glioma (U87-MG), a cell line originally 
developed at The University of Uppsala from a male stage IV GBM patient, was initially used to 
evaluate the TMZ analogues (Allen et al., 2016). Analogues identified as possessing preferential 
antiproliferative activity, with regards to IC50, were then investigated further against 1321-N1, 
GOS-3 and SVGp12 cell lines. The 1321-N1 cell line was originally derived as a sub-clone of the 
1181-N1 cell line in 1972, which in turn was isolated from the parent line U-118 MG (Arnoldussen 
et al., 2018). These immortalised cells are representative of a grade II human astrocytoma. The 
GOS-3 line is a derivative of U-343-MG and represents a grade II/III human astro-
oligodendroglioma (Bady et al., 2012). The SVGp12 cell line was originally derived by transfecting 
primary foetal glial cells with simian virus 40 to achieve immortalisation (Henriksen et al., 2014). 
SVGp12 serves as a control cell line in the proceeding investigations described in the present 
chapter, allowing an assessment of the effect of the analogues on healthy cells. The sequential 
method of evaluation described above allowed for less active analogues to be eliminated earlier 
in the investigation, leading to a more efficient process. 
 
Table 3.1: A summary of cell lines used to assess the relative antiproliferative effects of TMZ analogues. 
Cell Line U87-MG GOS-3 1321-N1 SVGp12 
Grade Grade IV 
human 
glioblastoma 














Once the most promising analogues were identified using cell lines, the next stage of analysis 
was to assess the antiproliferative effects of these analogues against primary cells. Primary 
cultures were obtained from the Brain Tumour North West (BTNW) Tissue Bank in collaboration 
with The Royal Preston Hospital. The two primary cultures were BTNW914 and BTNW374 (Table 
3.2). The BTNW914 primary culture was derived from a 65 year old female GBM patient who 
exhibited 10 months survival after surgery. The BTNW374 culture was derived from a 33 year 
old female GBM patient who exhibited 8 months survival after surgery. 
Table 3.2: Characteristics and patient information of primary GBM cultures obtained from The Royal 
Preston Hospital. 
Primary Culture BTNW914 BTNW374 
Gender Female Female 
Age 65 33 
Disease State GBM (Grade IV) GBM (Grade IV) 
Survival Post 
Resection 
10 Months 8 Months 
Allred Score MGMT 
(Grade) 
(PS: 0) + (IS: 0) = TS: 0 (Negative) (PS: 5) + (IS: 3) = TS: 8 (Positive) 
  
 
Immunohistochemical (ICH) staining to assess MGMT expression was carried out by the 
Pathology Department at The Royal Preston Hospital. Allred scores from this assessment are 
shown in Table 3.2. Allred scores are expressed using both the proportional score (PS), (the 
proportion of MGMT expressing cells); and the intensity score (IS), (the average intensity of 
staining). The PS and the IS are then added together to give a total score (TS), the threshold for 
a sample to be deemed positive is >2, Table 3.3 (Harvey et al., 1999; Fitzgibbons et al., 2014). 
BTNW914 was found to be devoid of MGMT while BTNW374 was found to express high levels 
of MGMT. Consequently, analysis using these primary cultures allowed the analogues to be 
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tested with regards to the MGMT mediated resistance associated with methylating agents such 
as TMZ. 
Table 3.3: Allred score grading system. Proportional score (PS) and Intensity score (IS) are combined to 
give the total score (TS). TS scores between 0-2 are deemed to be negative, TS scores between 3-8 are 
deemed to be positive. (Harvey et al., 1999). 
Proportion of 
Positive Cells, % 
Proportion Score 
(PS) 
Average Intensity of 
Staining 
Intensity Score (IS) 
0 0 None 0 
<1 1 Weak 1 
1-10 2 Intermediate 2 
11-33 3 Strong 3 
34-66 4   
>67 5   
  
In the following study, the CellTiter-Glo® viability assay was used to assess the number of viable 
cells at the end of the experiments. CellTiter-Glo® allows adenosine triphosphate (ATP) levels to 
be measured using the enzyme luciferase and luciferin 46 (Niles et al., 2008). ATP is a known 
biomarker of viable cells (Crouch et al., 1993). Diminished cellular membrane integrity results in 
an abated ability to synthesise fresh ATP, while endogenous ATPases breakdown cellular ATP 
reserves. A reaction between luciferin 46 and ATP catalysed by luciferase and magnesium ions 
producing the luminescent product, oxyluciferin 47 (Scheme 3.1) (Riss et al., 2013).  
 
Scheme 3.1: The reaction between luciferin 46 and ATP, catalysed by luciferase and magnesium ions 
producing the luminescent product oxyluciferin 47. Adenosine monophosphate (AMP), pyrophosphate 
(PPi) and CO2 are also produced as by-products. 
 
Commented [OI7]: Change numbers 
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Upon addition of CellTiter-Glo®, the detergent present in the reagent lyses the cells, causing the 
release of intracellular ATP. ATPase inhibitors also present within the reaction mixture prevent 
breakdown of ATP and allow the reaction described as part of Scheme 3.1 to take place.  The 
strength of the luminescent signal from the reaction can then be used to estimate the 
concentration of ATP, which in turn is directly proportional to the number of viable cells (Crouch 
et al., 1993; Riss et al., 2013). The luminometric CellTiter-Glo® viability assay is a much faster 
and sensitive assay than its tetrazolium based counter parts, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Aslantürk, 2018). 
Additionally, ATP-based luminometric assays are less prone to artefacts, thus generating results 
that are more consistent. Consequently, CellTiter-Glo® was the preferred assay for the 
assessment of cell viability in this study.   
It is well documented that TMZ generates antiproliferative effects in both glioma cell lines and 
primary glioma cultures (Sankar et al., 1999; Perazzoli et al., 2015; Moiseeva et al., 2016; William 
et al., 2018). However, the mechanism of action and the pharmacokinetic profile of the drug 
must be carefully considered when designing in vitro investigations, to ensure results remain 
clinically significant. When designing a suitable in vitro model for the assessment of known or 
suspected methylating agents, such as the analogues described in the present work, a number 
of factors must be carefully considered. As discussed in Chapter 2, the ester and amide 
analogues of TMZ, synthesised as part of this study, were designed so as to not perturb the 
mechanism of prodrug activation and methylation. Therefore, upon exposure to an aqueous 
environment at physiological pH, it is reasonable to assume that the analogues degrade into 
modified MTIC degradants 48 and a methyldiazonium ion 13 (Scheme 3.2) (Denny et al., 1994). 
Thymine mismatch occurs through electrophilic addition of methyl groups to the O6-guanine 
adducts, producing O6-MeG. MMR machinery recognises the incorrect thymine inducing a futile 
cycle of insertion and deletion, initiating a double stranded break in the DNA. Once a sufficient 
number of double stranded breaks have occurred the ATM/ATR-Chk1 pathway is activated 
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leading to stabilisation of p53, generating an apoptotic response. Apoptosis in glioma cells, 
induced by temozolomide, occurs at least 120 h after treatment (Roos et al., 2007). 
Consequently, it is important that in vitro assays include an appropriate incubation time to allow 
time for apoptosis to occur. As a result, the antiproliferative determination of TMZ analogues 
was conducted over a period of 144 h (6 days). 
 
 
Scheme 3.2: Hypothesised degradation of 8-subsituted TMZ analogues 
 
 The aim of the current work will be to assess the antiproliferative effects of the TMZ analogues 
against a range of glioma cell lines and patient-derived primary cultures. From this information, 










3.2. Material and Methods 
3.2.1. Cell Lines and Primary Cultures. 
 The human glioma cell lines, U87-MG and 1321-N1 were purchased from The European 
Collection of Cell Cultures (ECCAC, UK). The GOS-3 glioma cell line was purchased from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DMSZ, Germany). The SVGp12 cell line was 
purchased from the American Type Culture Collection (ATCC). Full characterisation of cell lines 
is included in Table 3.4. Patient-derived primary GBM cultures, BTNW 374 and BTNW 914, were 
obtained from the BTNW tissue bank in collaboration with The Royal Preston Hospital. 
Characterisation and culture conditions of these cells is included in Table 3.5. The first phase of 
antiproliferative determination testing on all TMZ analogues was conducted against the U87-
MG cell line, due to it being the most malignant. The most promising analogues identified during 
the first phase of testing were then assessed against GOS-3 and 1321-N1 cell lines; with SVGp12 
serving as the control cell line, as part of the second phase of testing. The most promising 
analogues identified during the first and second phase of testing were then assessed against 
MGMT-positive and MGMT-negative patient-derived primary GBM cultures as part of the third 
phase of testing. All cells were received as frozen samples containing cells in appropriate 










Table 3.5: Characteristics of patient-derived primary cultures used to assess the antiproliferative effects of TMZ analogues. Note: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES). ICH staining to assess MGMT status was carried out by pathology staff from The Royal Preston Hospital using the Allred scoring system as described in Section 3.1. 
Patient-derived primary culture BTNW914 BTNW374 
Tissue Brain Brain 
Disease State Grade IV human glioblastoma Grade IV human glioblastoma 
Culture Conditions Nutrient Mixture F-10 Ham 
supplemented with 20 mM HEPES, 
10% FBS and 2 mM L-glutamine 
Nutrient Mixture F-10 Ham 
supplemented with 20 mM HEPES, 
10% FBS and 2 mM L-glutamine 
MGMT Status Negative  Positive 
 
Cell Line U87-MG GOS-3 1321-N1 SVGp12 
Tissue Brain Brain Brain Brain 
Disease State Grade IV human glioblastoma Grade II/III human astro-
oligodendroglioma 
Grade II human astrocytoma Healthy human foetal astroglial 
Culture Conditions  DMEM supplemented with 10% 
FBS and 2 mM L-glutamine 
DMEM supplemented with 10% 
FBS and 4 mM L-glutamine 
EMEM supplemented with 10% 
FBS, 2 mM L-glutamine, 1% 
NEAA, 1 mM sodium pyruvate 
EMEM supplemented with 10% 
FBS, 2 mM L-glutamine, 1% 
NEAA, 1 mM sodium pyruvate 
Supplier ECACC, UK DSMZ, Germany ECACC, UK ATCC, UK 
Table 3.4: Characteristics of cell lines used to assess the antiproliferative effects of TMZ analogues. Note: Foetal Bovine Serum Albumin (FBS); Dulbecco’s modified Eagle’s medium 




3.2.1.1. Media and Reagents Used for Cell Culture 
All medium and reagent preparation was completed under sterile conditions in a laminar flow 
hood. The medium was supplemented as recommended by the provider of the cell lines, as 
shown in Table 3.4 and Table 3.5. A full list of reagents used for the maintenance of the cell lines 
is detailed in Table 3.6. 
Table 3.6: A list of reagents and their relevant formulations used in cell culture. 
Reagent Formulation  Supplier  
Nutrient Mixture F-10 
Ham 
1.1 g/L glucose;  
20 mM HEPES;  
Containing phenol red; 
Containing sodium pyruvate. 
 Sigma Aldrich 
DMEM 4.5 g/L glucose; 
Containing phenol red; 
1.0 mM sodium bicarbonate. 
 Lonza 
EMEM Earle’s salt solution;  
Containing phenol red; 
2.2 mM sodium bicarbonate. 
 Lonza 
NEAA  Contains a 10 mM concentration 
of each non-essential amino acid 
(100X). 
 Lonza 
Hanks Balanced Salt 
Solution (HBSS) 
1.0 g/L glucose; 
Containing phenol red; 




L-glutamine L-Glutamine, supplied as 29.3 
mg/mL (200 mM) in 0.85% NaCl. 
 Lonza 
Sodium Pyruvate Pyruvic Acid Sodium Salt 100 mM.  Lonza 
Trypan Blue Trypan Blue Solution, 0.4% 
Phosphate Buffered Saline. 
 Hyclone 
FBS EU Grade. Origin: Brazil – Standard 
FBS. 





3.2.1.2. Thawing frozen cells 
U87-MG, 1321-N1, GOS-3 and SVGp12 cell lines were stored under liquid nitrogen in The 
University of Central Lancashire’s Tissue Bank. Cells were thawed following protocols 
recommended by the providers ECACC, ATCC and DSMZ. 
1. The frozen cryovial was placed immediately into a 37 oC water bath for 1-2 min to 
thaw. 
2. Cells were then pipetted aseptically into a 10 mL centrifuge tube with 5 mL of the 
appropriate supplemented medium at 37 oC. 
3. The cell suspension was centrifuged at 1000 rpm for 5 min. 
4. The supernatant was removed and 1 mL of fresh medium was added to resuspend 
the cell pellet. 
5. The cell suspension was then added to a 75 cm2 vented tissue culture-treated flask 
along with 10 mL of medium. 
6. The cells were then incubated at 37 oC and 5 % CO2 in a humidified incubator.  
7. The medium was changed every 48 h to replenish nutrients. 
Primary cultures obtained from The Royal Preston Hospital were thawed following protocols 
recommended by the Pathology Directorate. Cryostored vials of cells were collected from The 
Royal Preston Hospital and transported to The University of Central Lancashire on dry ice before 
being thawed. 
1. The frozen cryovial was placed immediately into a 37 oC water bath for 1-2 min to 
thaw. 
2. The 1 mL cell suspension was then transferred aseptically to a 25 cm2 unvented 
tissue culture-treated flask along with 9 mL of medium. 
3. The cells were then incubated at 37 oC in a humidified incubator for 24 h. 
4. The medium was then changed to remove cell debris and unadhered cells. 
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5. Half the medium was changed every 48 h to ensure nutrients were replenished 
whilst retaining essential growth factors. 
3.2.1.3. Subculture and Working Cell Stock Maintenance 
Cells were observed daily and subcultured upon reaching 70-80% confluence. Cells were 
periodically frozen in order to maintain working stocks of consistent passage number. All cell 
lines and primary cultures were subcultured using the following protocol: 
1. The cell culture medium was removed from the flask and replaced with 5 mL of HBSS 
(37 oC). The flask was gently agitated and the HBSS removed, so as to wash the cells, 
removing cell debris.  
2. 5 mL of the appropriate medium was added to the flask (Table 3.4). 
3. A sterile cell scraper was then used to detach the cells from the bottom of the flask. 
4. The resulting cell suspension was then transferred to a 10 mL centrifuge tube and 
was centrifuged at 1000 rpm for 5 min. 
5. The supernatant was removed and 1 mL of fresh medium was added to resuspend 
the cell pellet. 
6. A 10 µL aliquot of the cell suspension was then transferred to an Eppendorf tube for 
counting. Cells were counted and subcultured into a fresh 75 cm2  flask with 10 mL 
of fresh medium. 
In order to ensure working stocks of consistent passage number, cells were periodically frozen. 
Cells were frozen using the following protocol. 
1. A 900 µL cell suspension was obtained using the protocol described above. 
2. The 900 µL cell suspension was added dropwise to a cryovial containing 100 µL of 
DMSO. 




4. Cryovials were then stored under liquid nitrogen. 
3.2.1.4. Cell Counting 
A 10 µL aliquot of a 1 mL cell suspension was transferred to an Eppendorf, as described in Section 
3.2.4. The aliquot of cells was diluted with 20 µL of Trypan Blue. The cell solution was then added 
to a haemocytometer. Cells were counted using 4 outside squares and averaged, as shown in 









3.2.2. In-Vitro Antiproliferative Determination of the Compounds 
3.2.2.1. Drug Solution Preparation 
TMZ (98%) was purchased from Carbosynth. TMZ acid, along with ester and amide TMZ 
analogues were synthesised and characterised as part of Chapter 2. Each analogue was found 
to be >95% pure following 1H NMR analysis. Drugs were dissolved in DMSO to afford 200 mM 
stock solutions. Appropriate cell culture medium was then used in a series of dilutions to afford 
the working concentrations. Maximum working concentration used in experiments was 1 mM, 
ensuring the final DMSO concentrations did not exceed 0.5 % (v/v). The effect of DMSO at a 
Figure 3.1: A haemocytometer showing the 4 outside squares that were used to count the cells, 
highlighted in red. 
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concentration of 0.5% (v/v) over 6 days on each cell line and primary culture is shown in 
Appendix 1. The effect of DMSO at 0.5% (v/v) on the cell lines and primary cultures is negligible 
and indicates no decrease in viability. Consequently, any decreases in viability through exposure 
to analogues are attributed solely to the effect of the drug. 
3.2.2.2. Solubility Evaluation of TMZ Analogues 
The conversion of TMZ to ester and amide analogues affects the lipophilicity and subsequently 
the solubility of the analogues. Therefore it was essential to evaluate the solubility of TMZ 
analogues in medium prior to assessing their anticancer activity to ensure these analogues were 
in solution during incubation. All 25 analogues were prepared at concentrations ranging 
between 200 – 1000 µM in medium. Solutions were then visually inspected under a microscope. 
Analogues were then tested on cells at concentrations at which they were soluble. The results 
from solubility evaluation are shown in Appendix 3b. 
3.2.2.3. Protocol for In-Vitro Antiproliferation Assays 
Protocols outlined in Sections 3.2.2.3 and 3.2.2.4. were used to obtain a 1 mL cell pellet and 
calculate the concentrations of cells. Appropriate cell suspensions were then prepared. Cells 
were seeded in the appropriate media, in each well of a Costar 96-well plate at a density of 5 x 
102 immortalised cells; and 2 x 103 primary cells. The plates were incubated at 37 oC and 5% CO2 
in a humidified incubator for 24 h to allow cells to adhere. Each of the drugs was tested following 
the protocol outlined in Section 3.2.3.1., ensuring DMSO concentration was no greater than 
0.5% (v/v). Drug was added to the cells and incubated for 144 h. After incubation, the drug 
concentrations were removed and replaced with 100 µL of CellTiter-Glo® and 100 µL of media. 
The luminescence of each well was measured on GENios Pro plate reader. The results for each 
of the drug concentrations were expressed as a percentage of the control wells. For cell lines, 
the regression equation for a polynomial line of best fit of the order 2, was used to calculate the 
IC50. In the case of the in-vitro model used in the present study, the IC50 was defined as the 
concentration of drug that results in a 50% reduction in oxyluciferin production. For primary 
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cultures, cells were incubated with clinically relevant concentrations for 144 h. Viability was then 
expressed as a percentage of the control. Each experiment involving cell lines was carried out as 
a triplicate of triplicates. Experiments using patient derived-primary cultures were carried out in 
triplicate. 
 
3.2.2.4. Growth Curves 
Growth curves of the 4 cell lines used to assess the antiproliferative effects of TMZ analogues in 
the current study are shown in Figure 3.2. Cells were seeded each day for 8 days at 2000 cells 
per well using the protocol outlined in Section 3.2.6.3. On the 9th day of incubation cells were 
assessed using CellTiter-Glo®. Growth curves indicate that cells remain in the log phase of 
growth throughout the duration of the experiment.  
 
Figure 3.2: Growth curves of U87-MG, 1321-N1, GOS-3 and SVGp12 cell lines. The values shown are 



























3.3. Results and Discussion 
Prior to conducting antiproliferative determination of the TMZ analogues, summarised in Figure 
3.3, the solubility of each analogue in aqueous medium was evaluated. TMZ acid, ES1, ES2, ES3, 
ES7, ES12, ES13 and ES14 were found to be soluble in medium between 0-1000 µM. AM2 was 
found to be soluble up to 600 µM. ES8, ES9, ES10, ES11, AM1, AM3 and AM10 were found to be 
soluble between 0-200 µM. ES4, ES5, ES6, AM4, AM5, AM6, AM7, AM8, AM9 and AM11 were 
found to be insoluble at concentrations of 200 µM or above. Analogues that were found to be 
insoluble at 200 µM were eliminated from the investigation to allow focus on analogues with 
preferential solubility. The results of solubility evaluation of each analogue in aqueous medium 
are illustrated in Appendix 3B. The reduction in aqueous solubility of TMZ analogues, compared 
with TMZ, as expected due to the addition of lipophilic side chains. Amides were much less 
soluble than the corresponding esters, an effect attributed to additional hydrogen bond 
donating sites resulting in stronger intermolecular forces. In-vitro antiproliferation assays for 
each analogue were then conducted at concentrations at which the drugs were soluble. This 
approach ensured that the true activities of analogues were observed, preventing the viability 
of cells being compromised due to the mechanical stresses of percipitated drug.  
 
 
Figure 3.3: Summary of ester and amide analogues of temozolomide under investigation. 
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It is well acknowledged that TMZ elicits its mechanism of action through methylation of guanine 
forming O6-MeG, causing subsequent mismatch with thymine (Denny et al., 1994). Mismatch 
between thymine and O6-MeG is recognised by MMR, and is subsequently removed from the 
replication fork. In the absence of MGMT the guanine methylation is not repaired, resulting in a 
futile cycle of insertion and deletion, eventually triggering apoptosis. Apoptosis in glioma cells, 
induced by TMZ, occurs at least 120 h after treatment (Roos et al., 2007). Consequently, treated 
cells in in-vitro investigations were incubated for 144 h with the analogues in order to gain a 
more reliable IC50 value. The graph and polynomial regression equation used to calculate IC50 
values for analogues against each cell line are shown in Appendix 3C. 
To assess the antiproliferative potential of TMZ analogues depicted in Figure 3.3, initial 
screening was conducted against the U87-MG cell line, Table 3.7. For TMZ and TMZ acid the IC50 
was 696±79 and 662±42 µM, respectively. The equipotency observed between TMZ and TMZ 
acid against U87-MG is consistent with previous literature published using lymphoma cells 
(TLX9) (Tsang et al., 1990) and glioma cells (TJ899; TJ905 and SHG-44) (Suppasansatorn et al., 
2006). TMZ analogues ES1, ES3, ES7, ES13 and AM2, similar to TMZ acid, exhibited activity 
comparable to, or less than TMZ. ES7, an analogue originally described by Liu et al., 2010, was 
reported to exhibit very promising cytotoxic potential; however, testing was not inclusive tof 
glioblastoma cell lines providing the rationale of its inclusion in the present study (Liu et al., 
2010). Unfortunately, the compound was found to be less active than TMZ against U87-MG cells 









Table 3.7: IC50 evaluation (µM) of TMZ analogues against U87-MG cells. Values reported are IC50 ± SD, n=3. 
Analogue IC50 (µM) Analogue IC50 (µM) 
TMZ 696 ± 79 ES12 331 ± 47 
TMZ acid 662 ± 42 ES13 576 ± 91 
ES1 700 ± 109 ES14 376 ± 62 
ES2 409 ± 45 AM1 >200 
ES3 615 ± 96 AM2 548 ± 48 
ES4 - AM3 >200 
ES5 - AM4 - 
ES6 - AM5 - 
ES7 856 ± 20 AM6 - 
ES8 134 ± 7 AM7 - 
ES9 142 ± 3 AM8 - 
ES10 96 ± 3 AM9 - 
ES11 138 ± 7 AM10 139 ± 28 
  AM11 - 
 
A significant proportion of amide containing analogues and methyl/ethyl phenyl analogues, 
(ES4, ES5, ES6, AM1, AM3, AM4, AM5, AM6, AM7, AM8, AM9 and AM11) were insoluble in 
medium at concentrations greater than 200 µM. The maximum concentration that could be 
achieved in medium for analogues AM1 and AM3 was approximately 200 µM, at which IC50 
values could not be generated and so were eliminated from further studies. Interestingly, ester 
analogues (ES2, ES8, ES9, ES10, ES11, ES12 and ES14) exhibited 2 to 5-fold greater activity against 
the U87-MG cell lines compared to TMZ, and were subsequently taken forward to test against 
additional cell lines. The phenyl containing ester analogues ES8, ES9, ES10, ES11, ES12 and ES14 
(IC50 = 96 - 376 µM) were found to be the most potent, tested against the U87-MG cell line, 
compared with TMZ (IC50 = 696 µM). TMZ hexyl ester ES2 was originally described by 
Suppasansatorn et al., 2006 as a topical treatment for melanoma (Suppasansatorn et al., 2006). 
In the present work the potency of this analogue was assessed against glioblastoma cell lines, as 
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a result of its promising cytotoxic potency against melanoma cells. In the present study TMZ 
hexyl ester ES2 (IC50 = 409 µM), exhibited significantly increased potency against U87-MG cells 
compared to TMZ.  
Analogues ES2, ES8, ES9, ES10, ES11, ES12, ES14 and AM10 were selected to be taken forward 
due to promising activity shown against U87-MG cells. Additional testing involved 
antiproliferative determination of these analogues against 1321-N1, GOS-3 and SVGp12 cell, in 
order to gain a deeper understanding of their activity against the various grades of glioma and 
healthy glial cells. The results depicted in Table 3.8, show very similar trends and support the 
results obtained using U87-MG. The effectiveness of the analogues against human glial cells 
(SVGp12), suggest that these analogues did not have specificity for malignant cells.  
 
Table 3.8: IC50 evaluation (µM) of TMZ analogues against 1321-N1, GOS-3 and SVGp12 cells. Values 










The most noteworthy compounds found during the initial antiproliferative determination were 
ester analogues containing para-substituted aromatic moieties, containing methoxy, nitro, 
chloro and nitrile groups (ES8, ES9, ES10, ES11), which exhibited activity 4 to 5-fold greater than 
 IC50 (µM) 
Analogue U87-MG 1321-N1 GOS-3 SVGp12 
TMZ 696 ± 79 783 ± 40 696 ± 16 239 ± 6 
TMZ acid 662 ± 42 596 ± 26 504 ± 30 316 ± 2 
ES2 409 ± 45 269 ± 20 269 ± 6 182 ± 11 
ES8 134 ± 7 183 ± 1 183 ± 5 44 ± 2 
ES9 142 ± 3 104 ± 4 91 ± 1 39 ± 2 
ES10 96 ± 3 118 ± 11 54 ± 4 33 ± 1 
ES11 138 ± 7 103 ± 7 151 ± 4 36 ± 3 
ES12 331 ± 47 511 ± 10 691 ± 35 238 ± 6 
ES14 376 ± 62 238 ± 8 314 ± 38 215 ± 26 




TMZ, across each of the cell lines. The introduction of an ortho-substituted methoxy moiety 
(ES13) in place of corresponding para-substituted methoxy moiety (ES8) resulted in significantly 
reduced activity. Additionally, the unsubstituted phenyl analogue ES12 showed less activity than 
its substituted counter-parts (ES8, ES9, ES10, ES11). Interestingly, although analogue ES14, 
containing a methyl moiety in the para- position, displayed greater activity than the phenyl 
analogue ES12; it was still found to be significantly less active than analogues containing highly 
polarising aromatic groups. Consequently, the SAR of ester analogues containing para-
substituted aromatic moieties was probed further, through the analysis of Hammett constants 
(Figure 3.4).  Compound AM10 was eliminated from the study due to poor efficacy against 1321-
N1 and GOS-3 cell lines, where IC50 values could not be obtained.  
 
 
Figure 3.4: Hammett plot showing the relationship between -logIC50 vs Hammett Constant. 
 
Analysing the relationship between the Hammett constants and IC50 values revealed analogues 
containing highly polarising groups tended to confer increased activity. However, the lack of a 
linear relationship between the Hammett constants and log IC50, for para-substituted phenyl 
ester TMZ analogues, suggests that changing the substituent at the para- position of the phenyl 
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ester moiety effects more than one physiochemical property that contributes to potency. It has 
been recently established that modifications at position 8 of the imidazole ring can influence the 
rate of prodrug activation, it would be reasonable to suggest that modifying the substituent on 
the phenyl ester moiety could possibly affect the rate at which these prodrugs produce methyl 
diazonium ions (Svec et al., 2018; Yang et al., 2019). Svec et al. (2018) reported that the addition 
of electron donating groups, such as methyl and phenyl moieties, increased aqueous stability 
and potency. However, it is still unknown what the optimum half-life of a methylating 
imidazotetrazine prodrug should be to maximize efficiency. Consequently, the determination of 
stability in an aqueous environment of the phenyl ester analogues would be an intriguing aspect 
of future work (see Chapter 5). Another physiochemical property that may contribute to potency 
is the lipophilicity of the compounds. Analogues with increased lipophilicity could internalise 
into cells more efficiently, increasing their activity. Figure 3.5 summarises the relationship 
between LogP, calculated using Crippen’s Fragmentation (CS ChemDraw Ultra 8.0 software) 
(Ghose and Crippen, 1987), and IC50 against U87-MG cells. It is clear from Figure 3.5 that a 
moderate correlation between LogP and potency exists (R2 = 0.2665). However, the variation in 
IC50s within analogues that share similar LogP values again suggests more than one 




Figure 3.5: A graph showing moderate correlation between -logIC50 against U87-MG cells and estimated 
LogP. 
 
When considering the addition of alkyl chains to esters, it was observed than in the instance of  
the ethyl containing analogue ES1 and the hexyl containing analogue ES2, a longer alkyl chain 
increased potency against U87-MG cells, 700 ± 109 µM versus 409 ± 45 µM (Figure 3.6). The 
increase in potency observed was attributed an increase in lipophilicity, allowing for greater 
accumulation of ES2 in the cells.  However, when considering analogues ES12 and ES3, 
containing phenyl and phenylethyl moieties respectively, it was found that the addition of an 
alkyl chain reduced potency against U87-MG cells, 331 ± 47 µM versus 615 ± 96 µM. These 
results were in direct contradiction with the comparison between ES1 and ES2, where the 
addition of an alkyl chain increased potency, again suggesting modifications affect more than 































Figure 3.6: Structures of ES1, ES2, ES3 and ES12, containing various lengths of alkyl chains. 
Due to the significantly increased potency of phenyl ester TMZ analogues, it was important to 
assess the effectiveness of the most promising analogues in the presence and absence of MGMT. 
Patient-derived primary GBM cultures, BTNW914 (MGMT -) and BTNW374 (MGMT +), obtained 
from The Brain Tumour North West Tissue Bank, were used to assess analogues (ES8, ES9, ES10, 
ES11, ES12, and ES14) at clinically obtainable concentrations. The results from these 
investigations are shown in figure 3.7 and 3.8. 
In order to maximise the relevance of the results in this study, the analogues were assessed at 
concentrations that were clinically obtainable. For TMZ, peak plasma levels were found to be 
60-75 µM following a 200 mg/m2 oral dose (Ostermann et al., 2004; Aoki et al., 2007). Brain-
tumour concentrations of TMZ are estimated to be around 20% of the plasma concentration, 
equivalent to approximately 15 µM, (Ostermann et al., 2004; Portnow et al., 2009). However, 
since TMZ is a prodrug and is not biologically active until it has degraded into AIC and the 
methyldiazonium ion, these concentrations may not accurately reflect active drug levels within 
the tumour. In fact, the levels are likely to be higher than what is observed in these studies and 
as a mixture of TMZ, MTIC and methyl diazonium ions could be present in the tumour, all of 
which have cytotoxic properties or cytotoxic potential, (Ostermann et al., 2004). It must be 
noted that the authors acknowledge that modified TMZ analogues may not share the same 
biodistribution as TMZ. However, as there is no known data on the biodistribution of these novel 
analogues, the use of clinically-relevant concentrations of TMZ as a means to compare novel 





Figure 3.7: Cell Viability of BTNW914 (MGMT -) after treatment by TMZ and phenyl TMZ ester analogues 
at various clinically relevant concentrations. Values reported are cell viability (%) ± SD, n=3. 
 
 
Figure 3.8: Cell Viability of BTNW374 (MGMT +) after treatment by TMZ and phenyl TMZ ester analogues 






























































DMSO 0.5% 15 µM 75 µM 200 µM
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At clinically relevant concentrations of 15 and 75 µM, TMZ was found to reduce the viability of 
MGMT devoid cells by around 20% (Figure 3.7). The relatively modest reduction in viability 
supports the findings that patients treated with TMZ gain a modest therapeutic benefit (Stupp 
et al., 2005; Chamberlain, 2010). Results clearly indicate that TMZ is only effective against 
MGMT-devoid GBM cells at concentrations that are not clinically achievable, following a 200 
mg/m2 oral dose. Interestingly, analogues containing the methoxy, nitro, choro and nitrile 
phenyl esters (ES8, ES9, ES10 and ES11) generate IC50’s at concentrations that are clinically 
relevant in the tumour (<15 µM), thus suggesting these analogues could have the potential to 
generate a significant clinical effect in patients suffering from GBM devoid of MGMT, compared 
to TMZ. The phenyl esters containing para-substituted nitro and nitrile moieties (ES9 and ES11), 
were observed to be the most potent phenyl ester analogues tested, resulting in a reduction in 
viability of >90% after treatment at 75 µM. Phenyl ester analogues ES12 and ES14 were also 
found to be significantly more effective than TMZ, inducing a significant reduction in viability of  
greater than 50% at 75 µM against MGMT devoid GBM cells. However, these two analogues 
were found to be less potent than the analogues ES8, ES9, ES10 and ES11 that contain highly 
polarising groups.  
Figure 3.8 shows the activity of the most promising analogues against BTNW374 cells, a MGMT+ 
expressed patient-derived primary culture. As expected, the repair of cytotoxic O6-methylations 
by MGMT appeared to show TMZ resistance. The MGMT expressing cells demonstrated similar 
resistance to TMZ acid and phenyl ester ES12, suggesting that these analogues possibly generate 
activity via a similar mechanism to that of TMZ. Interestingly, the 4-methoxy, 4-nitro, 4-chloro, 
4-nitrile and p-cresol phenyl esters (ES8, ES9, ES10, ES11 and ES12, respectively), generated 
significant activity at 75 µM, independent of the MGMT status. Since the imidazotetrazine ring 
has remained unchanged in these analogues, it is plausible to assume that methylation still 
contributes to activity in TMZ sensitive cells. However, as these analogues retain activity against 
TMZ resistant cells that express MGMT, it is plausible to conclude that an additional mechanism 
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of action is involved, distinct from methylation (Ferluga et al., 1972; Selassie et al., 2005; Kadoma 























In the current chapter, the antiproliferative effects of the synthesised ester and amide analogues 
of TMZ have been evaluated against specified glioma cell lines and patient derived primary 
cultures. Phenolic ester analogues of TMZ (ES8, ES9, ES10 and ES11) were found to possess upto 
5-fold increased potency compared with TMZ, against the specified GBM cell lines. Additionally, 
lead phenolic esters were found to induce significant antiproliferative effects against TMZ-
resistant MGMT-positive primary cells. These results indicate that phenolic TMZ esters could 
provide an exciting alternative treatment for patients diagnosed with GBM, and could possibly 
have the potential to induce a greater therapeutic benefit to patients, compared with TMZ. 
However, further work must be completed in order to ascertain how the lead TMZ esters would 
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In light of the in-vitro activity of phenolic TMZ esters, (ES8, ES9, ES10, ES11, ES12 and ES14), it 
was important to establish the stability of these analogues in an environment mimicking that of 
the physiological system. The presence of ester moieties in the lead analogues poses the 
question of analogue stability when subjected to esterase enzymes. Hydrolysis of the ester 
would yield TMZ acid and the corresponding alcohol (Scheme 4.1). From the results presented 
in the previous chapter it is now known that TMZ acid is less active than the intact esters. The 
esters therefore needed to be examined as rapid hydrolysis of the ester bond may result in a 
loss of activity. 
 
 
Scheme 4.1: Suspected scheme of esterase mediated degradation of phenolic TMZ esters. 
  
Esterases are found primarily in the liver and gastrointestinal (GI) tract in mammalian systems, 
consequently playing a pivotal role in drug metabolism, although they are found throughout the 
body (Timoumi et al., 2019). These enzymes are responsible for the hydrolytic metabolism of 
numerous drug substrates, including esters, carbamates, thioesters and amides (Laizure et al., 
2013). Traditionally, ester prodrugs serve as vehicles for the active portion of the drug which 
offers increased lipophilicity to enhance oral absorption and cellular penetration (Montella et 
al., 2012). As previously mentioned one of our hypothesises for the increased activity of the lead 
compounds in the present study is the increased cellular uptake as a result of increased 
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lipophilicity. Since the analogues described in the present study act on cancerous brain tissue, it 
is important to ascertain the stability of our lead ester analogues when subjected to esterases, 
to have an idea regarding the behaviour of these analogues on their journey towards the site of 
action. 
The most common carboxylesterases found in humans are human carboxylesterase 1 and 
human carboxylesterase 2 (hCE1 and hCE2, respectively) (Laizure et al., 2013). Mammalian 
carboxylesterase enzymes are found primarily in cells of the liver and GI tract but are found in 
other tissues throughout the body (Taketani et al., 2007). The enzymes reside in the cytoplasm 
and endoplasmic reticulum of cells, contributing to the hydrolysis of various endogenous and 
exogenous substrates (Imai et al., 2006). hCE1 is primarily found within the liver while hCE2 is 
found predominantly in the small intestine (Hatfield et al., 2011). Although both hCE1 and hCE2 
are promiscuous towards a wide range of ester substrates, one predominates over the other 
depending on the ester substrate (Fukami and Yokoi, 2012; Laizure et al., 2013). Esters 
containing large acyl groups and small alcohol groups are the preferred substrates of hCE1, while 
hCE2 has a preference for esters with small acyl groups and bulkier alcohol groups (Taketani et 
al., 2007; Vistoli et al., 2010).  
HCEs are a member of the α/β-hydrolase protein family. This family of proteins include a number 
of functionally diverse enzymes each containing an alpha/beta-hydrolase fold domain 
responsible for their catalytic action. Enzymes of this family, containing this domain include 
esterases, lipases, dehalogenases, peroxidases and hydrolases. More specifically hCEs are 
known as serine hydrolases. The active site of hCEs is a catalytic triad of glutamine, histidine and 
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serine, found at the intersection of the alpha/beta, regulatory and catalytic domains, which are 
critical for activity (Figure 4.1) (Fleming et al., 2007; Wang et al., 2018). 
 
 
Figure 4.1 General 3D structure of hCEs. The catalytic triad is shown in the centre of the molecule; 
glutamine (yellow), histidine (blue) and serine (red). Adapted from Wang et al. (2018). 
  
The mechanism by which esterases hydrolyse ester bonds involves a two step base-catalysed 
reaction which, revolves around a catalytic triad of amino acids (Wang et al., 2018) (Scheme 4.2). 
The first step of the mechanism involves histidine acting as a base, catalysing the nucleophilic 
attack of the serine alcohol to the carbonyl of the ester substrate 49 (Imai et al., 2006; 
Hosokawa, 2008). Pivotal to the reaction is the hydrogen bonds formed between glycine 
residues within the active site and the ester substrate 50 (Montella et al., 2012). The collapse of 
the tetrahedral intermediate causes the breaking of the ester forming an acyl-serine 
intermediate and release of the alcohol 52 (Imai, 2006). The second step of the mechanism 
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involves the base catalysed attack of water to the acyl-serine intermediate, similar to the first 
step of the reaction 53. Again, the tetrahedral intermediate collapses initiating the release of 




Scheme 4.2: A mechanism showing phenolic TMZ ester hydrolysis by the catalytic triad, glutamine, 




In the present work porcine liver esterase (PLE) was used to assess stability of the ester bond in 
the phenolic esters. As discussed previously, specific isoenzymes such as hCE1 and hCE2 have 
different substrate preferences and therefore hydroylse different esters at different rates 
(Fukami and Yokoi, 2012; Laizure et al., 2013). Therefore, the use of individual specific 
isoenzymes, such as hCE1 or hCE2 may not give a truly accurate representation of ester 
hydrolysis in-vivo. Additionally, at this preliminary stage of investigation the cost of purchasing 
hCE isoenzymes to evaluate lead TMZ analogues was deemed not appropriate. As a result, PLE 
was used in favour of hCE1 or hCE2, as it contains numerous isoenzymes providing an acceptable 
cost-effective representation of an in-vivo environment, instead of focusing on individual hCE 
isoenzymes (Brüsehaber et al., 2009). This chapter will focus on esterase mediated hydrolysis of 
TMZ analogues, ES8, ES9, ES10, ES11, ES12 and ES14, that were highlighted as the lead 
compounds from antiproliferative determination studies, described Chapter 3. It was hoped that 
the results of esterase mediated degradation would give an indication of the metabolic stability 
of the ester bonds within each of the analogues, thus detailing their suitability as potential 
chemotherapeutic agents for the treatment of GBM.  
  
Commented [OI9]: Methylphenidate is the active 





Acetonitrile (HPLC grade ≥99.9%), water (HPLC grade ≥99.9%), acetic acid (HPLC grade ≥99.7%), 
citric acid monohydrate (HPLC grade), dimethyl sulfoxide (reagent grade) were purchased from 
Fisher Scientific. Sodium phosphate dibasic (HPLC grade ≥99.0%), sodium acetate (HPLC grade 
≥99.0%) and porcine liver esterase were purchased from Sigma Aldrich. 4-Nitrophenol (reagent 
grade >97%), 4-chlorophenol (reagent grade >98%), 3-hydroxybenzonitrile (reagent grade 
>97%) and 4-methoxyphenol (reagent grade >99%) were purchased from Alfa Aesar. Phenol 
(reagent grade >99%) and p-cresol (reagent grade >98%) were purchased from Sigma Aldrich. 
All reagents that were purchased from external suppliers were used without further purification.  
4.2.2. Instrumentation and HPLC Method 
4.2.2.1. Instrumentation  
A HPLC system that consisted of a Jasco PI-2089 plus quaternary gradient pump, Jasco AS-1555 
intelligent autosampler and a Jasco MD-1510 diode array multiwavelength detector was used 
for analysis. These three components were linked to a Dell Optiplex 790 computer system using 
a Jasco LC-Net II/ADC. Chromatograms were acquired and processed using Chromnav software. 
 
4.2.2.2. HPLC Method 
HPLC was carried out on an isocratic reverse phase system. The esters were separated from their 
esterase mediated degradation products, namely TMZ acid and the corresponding phenolic 
alcohol. Samples were injected using an autosampler from crimp-top sample vials using a 
Rheodyne injector with a 100 µL loop. Separation was achieved using a Waters Symmetry Shield 
RP C18 column (4.6 x 250 mm), containing particles equivalent to 5 micron. Detection of TMZ acid 
and TMZ esters (ES8, ES9, ES10, ES11, ES12 and ES14) was carried out at 325 nm. Detection of 
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4-methoxyphenol and 4-chlorophenol was carried out at 225 nm. Detection of 4-nitrophenol, 4-
hydroxybenzonitrile, phenol and p-cresol was carried out at 325 nm, 250 nm, 270 nm and 225 
nm, respectively. The mobile phase consisted of a sodium acetate buffer (20 mM) and 
acetonitrile (60:40, v/v). The pH of the resulting mixture was then adjusted to pH 4.5 using acetic 
acid. The analysis of the samples was performed over a period of <20 min at 1 mL / min at 
ambient temperature. 
 
4.2.2.3. Preparation of the Mobile Phase and Standards used for Validation 
The mobile phase was made up in batches 2000 mL (1200 mL sodium acetate buffer (20 mM): 
800 mL acetonitrile). The sodium acetate buffer was prepared by solubilising sodium acetate 
(3.282 g) in 2000 mL of HPLC grade water to achieve a final concentration of 20 mM. To ensure 
imidazotetrazines remained stable the pH of the sodium acetate/ MeCN mixture was adjusted 
to pH 4.5 by the addition of acetic acid. 
10 mg of each of the sample was solubilised in mobile phase (100 mL) to afford the 
concentrations displayed in Table 4.1. Samples were diluted to provide working concentrations 









Table 4.1: Concentrations of standard solutions used for the validation of the HPLC method. Standard 
solutions were obtained by solubilising 10 mg of each analyte in 100 mL of mobile phase. 
Analyte Concentration (mg / 100 
mL) 
Concentration (µM) 
TMZ Acid 10.01 513.2 
ES8 9.99 331.8 
4-Methoxyphenol 10.04 808.8 
ES9 10.03 317.3 
4-Nitrophenol 10.03 721.0 
ES10 10.07 330.1 
4-Chlorophenol 9.97 775.3 
ES11 10.01 301.1 
4-Hydroxybenzonitrile 10.07 845.3 
ES12 10.09 372.2 
Phenol 10.18 1081.7 
ES14 10.10 354.3 
P-Cresol 10.00 924.7 
  
 
4.2.3. Method Validation 
The method was validated using repeatability, reproducibility linearity, lower limit of detection 
(LLOD) and lower limit of quantification (LLOQ). Protocols set by The International Council for 
Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) in ICH 
Q2(R1) Validation of Analytical Procedures: Text and Methodology were used to validate the 






Stock solutions were diluted with mobile phase to 20% of the original concentration, yielding 
approximately 2 mg / 100 mL for each of the compounds listed in Table 4.1. Each of the prepared 
solutions was injected 6 times and the peak areas (PA) recorded. The relative standard deviation 
(RSD) for the 6 determinations was calculated.  
 
4.2.3.2. Reproducibility  
Five separate solutions of approximately 2 mg / 100 mL were prepared from each of the 
standards in Table 4.1, as described above. Each of five solution were injected twice and the 
average PA recorded. The RSD was calculated for the 5 determinations. 
 
4.2.3.3. Linearity  
Solutions of each of the standards were diluted from their respective stock solutions to afford 
concentrations approximately 2, 4, 6, 8, 10 mg / 100 mL. Each sample was injected twice and 
the mean PA was recorded. Calibration curves were then drawn for each compound. The 
coefficient of determination (R2) and regression equations were calculated to assess the 
relationship between PA and concentration. 
 
4.2.3.3. LLOD and LLOQ 
Standards of each compound were diluted in a systematic fashion, injecting each sample twice 
until the system could no longer detect a peak. Using the information gained from these 
dilutions the LLOD and LLOQ were determined. The LLOQ is defined as the lowest concentration 
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that gives rise to a peak that can be quantified with acceptable accuracy and precision. Whereas 
the LLOD is defined as the lowest detectable concentration.  
4.2.4. General Protocol for Monitoring the Stability of Lead Phenolic TMZ 
Analogues after Exposure to Porcine Liver Esterase 
A disodium phosphate, citric acid buffer (pH 6) was prepared by adding 63.15 mL of disodium 
phosphate (Na2HPO4·12H2O, 200 mM) to 36.85 mL of citric acid (100 mM).  A stock solution of 
80 mg of each of the TMZ esters (ES8, ES9, ES10, ES11, ES12, ES14) were prepared by dissolving 
in 100 mL of DMSO. Before preparing the esterase reactions, all reagents were incubated at 
37oC. The control reaction, without enzyme, was prepared by adding 3000 µL of buffer to the 
reaction vessel along with 56.25 µL of the 80 mg /100 mL stock solution. The test reaction, with 
enzyme, was prepared by adding 2999 µL of buffer to the reaction vessel along with 56.25 µL of 
TMZ ester. The final concentration of TMZ esters in the reaction vessels was 1.47 mg / 100 mL. 
Porcine liver esterase (1 µL) was added to the test reaction at 0 min. Both the control and test 
reactions were then incubated at 37 oC. Aliquots of 200 µL were transferred from the reaction 
vessels to 1 mL Eppendorf tubes, at 3 min intervals for 30 min. To terminate the reaction, each 
Eppendorf contained 200 µL of acetonitrile. Eppendorf tubes were vortexed for 30 s before 
being subjected to centrifugation at 13,000 rpm for 10 min. The supernatant (200 µL) was 









4.3. Results and Discussion 
4.3.1. Method Development 
Standard HPLC analytical methods for the analysis of TMZ, use an acidified buffer to aid with the 
stability of the imidazotetrazine core (Gilant et al., 2012; Khan et al., 2016; Khosa et al., 2018). 
The composition of the mobile phases used in HPLC methods developed for TMZ analysis, usually 
comprise of 80-95% aqueous solvent, (Reyderman et al., 2004). Consequently, initial attempts 
to develop a HPLC method for the analysis of phenolic TMZ esters utilised an 80:20 mixture of 
sodium acetate buffer and acetonitrile (pH 4.5) (Kapcak and Satana-Kara, 2018). However, as 
TMZ esters exhibit increased hydrophobicity, elution times of TMZ esters using this method 
were found to be upwards of 40 min, which was not practical. As a result, the composition of 
the mobile phase was optimised in order to reduce elution times. By increasing the proportion 
of organic solvent to 40 %, resulting in elution times that ranged between 6 and 18 min for TMZ 
esters.  
 
Figure 4.2: TMZ acid and ester analogues of TMZ (ES8, ES9, ES10, ES11, ES12, ES14) analysed using HPLC 
(sodium acetate buffer: MeCN 60:40, v/v, pH 4.5). 
152 
 
Table 4.2. reports the relative retention times of TMZ esters and their corresponding alcohols 
using the method outlined in Section 4.2.2. Retention times confirm acceptable resolutions 
between esters and their corresponding alcohols indicating that esters and corresponding 
alcohols can be readily quantified. 
 
Table 4.2: Retention times of TMZ esters and their corresponding alcohols using the HPLC method 
outlined in section 4.2.4. 
Analyte Retention Time (min) 














4.3.2. Method Validation 
To assess the precision of the analytical method, each analyte described in Table 4.1 was tested 
for repeatability at a concentration of approximately 2 mg / 100 mL. Full results are displayed in 
Appendix 4a. A summary of the RSD over 6 injections for each analyte is shown in Table 4.3. As 
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stated by the ICH (2018), if the RSD is calculated to be below 2%, the results from replicate 
analysis (n = 6) is acceptable. Results shown in Table 4.3. indicate that the method achieved 
suitable precision for each of the analytes in question, with calculated RSD less than 2 %. 
 
Table 4.3: A summary of the repeatability results of TMZ esters and their corresponding alcohols. Each 
sample was analysed over 6 determinations. Data for each of the solutions was averaged and the 
standard deviation and RSD calculated. 
Analyte (concentration µM) Average PA ± SD (n = 6) RSD (%, n = 6) 
TMZ Acid (103 µM) 969551 ± 1427 0.15 
ES8 (66 µM) 822203 ± 4874 0.59 
4-Methoxyphenol (162 µM) 622902 ± 1056 0.17 
ES9 (63 µM) 938538 ± 7072 0.75 
4-Nitrophenol (144 µM) 1479936 ± 11571 0.78 
ES10 (66 µM) 7924253 ± 1785 0.23 
4-Chlorophenol (155 µM) 1319539 ± 13022 0.99 
ES11 (68 µM) 888369 ± 5353 0.10 
4-Hydroxybenzonitrile (196 µM) 2989778 ± 16199 0.54 
ES12 (74 µM) 916108 ± 1311 0.14 
Phenol (251 µM) 352648 ± 489 0.14 
ES14 (71 µM) 713596 ± 9205 1.29 
P-Cresol (185 µM) 865262 ± 13405 1.55 
  
 
To assess the reproducibility of the method, six separate solutions of each of the analytes were 
prepared at approximately 2 mg / 100 mL. Each solution was injected twice and the average PA 
recorded. The standard deviation and RSD were calculated between each of the six samples. 
Complete results are displayed in Appendix 4b. A summary of the results for each analyte is 
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shown in Table 4.4. The RSD between each of the prepared six solutions was found to be less 
than 2 %. 
Table 4.4: A summary of the reproducibility of TMZ esters and their corresponding alcohols. Six separate solutions, 
each injected twice and the average PA recorded. Data for each of the solutions was averaged and the standard 
deviation and RSD calculated. 
Analyte (concentration µM) Average PA ± SD (n = 6) RSD (%, n = 6) 
TMZ Acid (103 µM) 960779 ± 7081 0.74 
ES8 (66 µM) 818994 ± 7225 0.88 
4-Methoxyphenol (162 µM) 618674 ± 3518 0.57 
ES9 (63 µM) 932685 ± 8704 0.93 
4-Nitrophenol (144 µM) 1476042 ± 10895 0.74 
ES10 (66 µM) 792449 ± 4402 0.56 
4-Chlorophenol (155 µM) 1320243 ± 9102 0.69 
ES11 (68 µM) 885105 ± 10545 1.19 
4-Hydroxybenzonitrile (196 µM) 2990155 ± 16916 0.57 
ES12 (74 µM) 957062 ± 15013 1.57 
Phenol (251 µM) 369266 ± 5635 1.53 
ES14 (71 µM) 715080 ± 11354 1.59 
P-Cresol (185 µM) 866773  ± 13556 1.56 
 
In order to confirm that the method gave a response that was directly proportional to the 
concentration of the analyte in question, linearity determinations were carried out. In Table 4.5, 
a summary of the regression equations for each analyte is included along with the coefficient of 
determination (R2). An R2 value of 1 indicates perfect positive linear relationship between 
response and analyte concentration. All analytes assessed exhibited R2 values above 0.9975, 
indicating an excellent relationship between response and analyte concentration. Graphical 
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representations of the relationship between response and analyte concentration are shown in 
Appendix 4c.   
 
Table 4.5: Summary of regression analysis from linearity investigations of each analyte. 
Analyte  Regression Equation Coefficient of 
Determination (R2) 
TMZ Acid  Y = 9549x 0.9993 
ES8  Y = 12464x 0.9996 
4-Methoxyphenol  Y = 3842x 0.9996 
ES9  Y = 14840x 0.9999 
4-Nitrophenol  Y = 10124x 0.9991 
ES10  Y = 12360x 0.9999 
4-Chlorophenol  Y = 8282x 0.9990 
ES11  Y = 13179x 1.0000 
4-Hydroxybenzonitrile  Y = 17653x 1.0000 
ES12  Y = 12488x 0.9998 
Phenol  Y = 1651x 0.9992 
ES14  Y = 5534x 0.9975 
P-Cresol  Y = 11115x 0.9989 
 
In order to determine the LLOQ and LLOD of the analytical method, stock solutions of each 
analyte were diluted and injected sequentially. Figure 4.3 shows an example of this process using 
ES8 and TMZ acid as examples. Please refer to Table 4.2. for relative retention times of analytes. 
This process was repeated for each analyte and the chromatograms are reported in Appendix 
4d. Using Figure 4.3, injection A, a solution containing TMZ acid (320 nM) and ES8 (207 nM), was 
determined to be the LLOQ, generating quantifiable peaks. Injection C, a solution containing 
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TMZ acid and ES8 at concentrations of 80 nM and 52 nM, was determined to be the LLOD. A 




Figure 4.3: An example of how the LLOQ and LLOD were determined. Injection B, (320 nM and 207 nM of TMZ acid (2.25 
min) and ES8 (9.75 min), respectively), was estimated to be the LLOQ for both TMZ acid and ES8. Injection D, (80 nM and 52 





TMZ Acid (320 nM); ES8 (207 nM) 
TMZ Acid (160 nM); ES8 (104 nM) 
TMZ Acid (80 nM); ES8 (52 nM) 
TMZ Acid (40 nM); ES8 (26 nM) 




Table 4.6: Summary of the LLOD and LLOQ for each analyte. 
Analyte  LLOQ (nM) LLOD (nM) 
TMZ Acid  320 80 
ES8  207 52 
4-Methoxyphenol  1010 505 
ES9  198 99 
4-Nitrophenol  451 113 
ES10  206 103 
4-Chlorophenol  969 485 
ES11  133 67 
4-Hydroxybenzonitrile  83 21 
ES12  145 36 
Phenol  490 122 
ES14  221 111 
P-Cresol  1156 577 
  
   
The observed acceptable robustness and linear response of the analytical method described in 
Section 4.2.3 clearly indicated its suitability for monitoring the hydrolysis of the lead TMZ ester 
by PLE. The sensitivity of the method for imidazotetrazine analytes was acceptable at pH 4.5 
with no visible trace of chemical hydrolysis of the imidazotetrazine core. The formation of TMZ 
acid and the corresponding alcohol; alongside the simultaneous disappearance of the TMZ ester 






4.3.3. Hydrolysis of TMZ esters when subject to porcine liver esterase  
The rate of hydrolysis for each of the phenolic TMZ esters, ES8, ES9, ES10, ES11, ES12 and ES14 
when treated with PLE, was determined as per the analytical method outlined in Section 4.2.4. 
As stated in Section 4.2.4, PLE reactions were terminated by quenching with acetonitrile which 
deactivates the enzyme. In the case of the present investigation, the use of acetonitrile as the 
quenching reagent, afforded recoveries of the un-hydrolysed TMZ esters in the region of 86 to 
98 %. TMZ ester recovery was calculated by expressing the observed concentration of ester in 
the control reactions as a percentage of the determined ester concentration.  In order to ensure 
degradation of the esters was specific to ester hydrolysis and not hydrolysis of the 
imidazotetrazine core, reactions were carried out at pH 6. The validation of the analytical 
method also involved investigating the stability of the imidazotetrazine ring whilst ensuring PLE 
retained a significant level of activity. These findings were in keeping with work published by 
Junge and Heymann (1979), who found PLE to have a broad pH optima (pH 6-8). 
 
An example of a typical enzyme reaction profile is shown in Figure 4.4; depicting the gradual 
hydrolysis of ES11, after exposure to PLE, in addition to the production of TMZ acid and 4-
hydroxybenzonitrile. After establishing that the ester was breaking down into its corresponding 
TMZ acid and alcohol, each analyte was readily quantified. Figure 4.5 shows the quantified 















Figure 4.4: A series of chromatograms showing degradation of ES11 into its corresponding TMZ acid and 4-hydroxybenzonitrile. Each series of chromatograms shows a different 
wavelength, allowing all analytes to be visualised. A: Breakdown of ES11 and the formation of 4-hydroxybenzonitrile (250 nm). B: Breakdown of ES11 and the formation of TMZ 











Figure 4.5: Hydrolysis of TMZ ester (ES11) into the corresponding TMZ acid and 4-hydroxybenzonitrile 
over time. ES11 and TMZ acid (325 nm); 4-hydroxybenzonitrile (250 nm) 
 
It is evident from Figure 4.5. that a slightly higher concentration of the acid and alcohol was 
produced, compared to the starting concentration of ES11, a phenomenon that was observed 
consistently across each of the esters tested. This discrepancy is likely accounted for by the 
recovery rates of the various esters (86-98%), as previously mentioned, or ester hydrolysis 
occurring during the preparation of the time t = 0 min sample. Another possible explanation is 
interference from other reaction components with the TMZ acid peak, as evidenced in Figure 
4.4. As these smaller peaks cause overlap, the true concentration of TMZ acid cannot be 
accurately quantified and is likely overestimated (by the software), explaining the discrepancy 
observed. Graphs similar to Figure 4.5. were constructed for the hydrolysis of each TMZ ester 

































Figure 4.6: Structures of phenolic TMZ esters assessed for esterase mediated stability. 
 
 
Table 4.7: The time taken for PLE to hydrolyse 50 % of phenolic TMZ esters. 
TMZ Ester Time taken to hydrolyse 
50 % of the ester (min) 







Results depicted in Table 4.7 indicate that 50 % of each of the TMZ esters was hydrolysed by PLE 
in the first 14 min of exposure. In fact, 50 % of TMZ esters containing para- nitro, chloro, phenyl 
and tolyl groups (ES9, ES10, ES12 and ES14), were hydrolysed within the first 4.2 min of PLE 
exposure (Table 4.7; Figure 4.6). TMZ esters containing para- methoxy and nitrile groups (ES8 
and ES11) conferred increased stability, with 50 % hydrolysis being achieved in 7.3 and 13.7 min, 
respectively. The phenolic TMZ esters analysed displayed rapid hydrolysis upon exposure to PLE. 
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In the present experiments, a concentration of 7.85 µg / mL of PLE was used. In comparison, 
work by Höllerer et al. (2018), observed 21 % di-(2-ethylhexyl)phthalate hydrolysis after 48 h of 
exposure to 1.3 µg / mL of PLE. Similarly, (Shervington et al., 2009) reports 24-37 % hydrolysis 
of various chlorambucil esters over a 24 h period, after exposure to 9.1 µg / mL PLE. Evidence 
from these two studies suggest a marked fragility of the ester bonds within the phenolic TMZ 
esters described in the present study. It is thought that this fragility could have a negative impact 
on the purposed therapeutic potential of these analogues. 
When considering the para- substituted aromatic substituents of TMZ esters, it would be 
expected that strong electron withdrawing groups would confer a faster rate of hydrolysis 
(Figure 4.6). Despite ES9 and ES11 containing nitro and nitrile aromatic substituents, 
respectively, which share similar electron withdrawing properties, they displayed unexpectedly 
different rates of hydrolysis. The time taken for 50 % hydrolysis to be achieved for ES11 (para-
nitrile) was 13.7 min, compared with 4.2 min for ES9 (para-nitro). This significant difference in 
rate brings the results obtained from this study into question. Similarly, ES10, ES12 and ES14 do 
not fit the expected trend in terms of electron withdrawing and donating effects of substituents. 
It is well documented that in ester hydrolysis of ethyl benzoates, the rate of hydrolysis is directly 
proportional to the electronic effects of the substituents on the aromatic ring, an effect that 
should be mirrored in the present investigation (Clayden, 2012). As a result, the unexpected 
findings from the present investigations, involving the hydrolysis of the phenolic TMZ esters, 
needs further work. On evaluation, as the time intervals between samples were relatively short, 
reaction vessels were removed from the incubator regularly, in order to remove 200 µL aliquots 
of the reaction mixture. This may have caused reaction temperatures to be inconsistent, which 
in-turn may have impaired enzyme function. This operation required the operator to carry out 
the aliquoting, efficiently and consistently, throughout each stage of the analysis. It is therefore 
conceivable that results may have been skewed as a direct consequence of the varying 
temperature, which may explain the unexpected findings of the present investigations. Due to 
time constraints of the present PhD programme, sufficient repeats of the analysis could not be 
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carried out. This aspect of the work is currently being optimised by representatives of the 






















The present chapter investigated the stability of the most promising analogues, identified in 
Chapter 3, when exposed to PLE. The phenolic TMZ esters, ES8, ES9, ES10, ES11, ES12 and ES14, 
were found to be highly susceptible to hydrolysis by PLE, with all esters being 50% hydrolysed 
within 3-14 min of exposure. As a result, it is hypothesised that the potential therapeutic benefit 
of these analogues may not translate to an in-vivo model without careful consideration of drug 
delivery strategies. However, it was expected that there would be a strong correlation between 
the electron withdrawing / donating properties of the aromatic substituents and the hydrolytic 
rates of reaction. Consequently, these experiments are to be repeated by the research group, 
applying an optimised procedure, which will involve the use of a number of reaction bottles. A 
bottle will be removed at given time intervals before being processed and analysed 
systematically, thus, eliminating possible fluctuations in temperature. This should enable the 
achievement of more reliable data consistent with knowledge of the electronic effects of the 
















As described in Chapter 1, TMZ, the standard chemotherapeutic agent prescribed to GBM 
patients, has a limited therapeutic benefit, increasing median survival by a modest 2.1 months 
(Stupp et al., 2005; Chamberlain, 2010). In-vitro investigations conducted by Sankar et al. (1999) 
found TMZ to be ineffective against a number of primary cells at clinically significant 
concentrations, perhaps explaining the limited therapeutic benefit gained by GBM patients. 
Additionally, MGMT-mediated resistance also plays a pivotal role in patient response to TMZ, as 
discussed in Chapter 1. It was therefore the aim of the present work to synthesise novel 
analogues of TMZ, with a view to achieving analogues with increased potency. 
Following a comprehensive review of the literature, position 8 on the imidazole ring of TMZ was 
identified as the most promising position to modify in order to yield analogues with increased 
potency (Suppasansatorn et al., 2006; Liu et al., 2010; Marin-Ramos et al., 2018; Svec et al., 
2018; Yang et al., 2019). The rational design of analogues was based on three main concepts. 
Firstly, a series of ester and amide TMZ analogues were synthesised to assess the impact of HBD 
and HBA sites at position 8, provided by ester and amide groups. Secondly, the inclusion of 
phenyl esters and amides, with various aromatic substituents, would provide an insight into the 
mesomeric and inductive effects of these analogues. Thirdly, the addition of alkyl chains to ester 
moieties in order to assess the effect of increasing the lipophilicity of TMZ analogues. A rationale 
for the modification to the TMZ chemical structure is included in Section 2.2. 
The target esters and amides were readily synthesised utilising TMZ acyl chloride and EDC.HCl / 
DMAP coupling. Amide TMZ analogues were readily synthesised in acceptable yields via TMZ 
acyl chloride intermediate followed by reactions with various amines. This route is also suitable 
for the synthesis of ES1-ES7 ester analogues, following a reaction between TMZ acyl chloride 
and appropriate alcohols. However, reactions between phenyl alcohols and TMZ acyl chloride 
proved problematic due to steric effects. The use of dehydrating coupling agents such as DCC 
and EDC.HCl, allowed the direct coupling of TMZ acid to appropriate alcohols, yielding ester 
analogues ES8-ES14. However, the synthesis of analogues using DCC / DMAP coupling, produced 
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DCU as a by-product, which proved challenging to remove, resulting in a significant loss of the 
target analogues during purification. The use of EDC.HCl, in place of DCC, improved yields due 
to the generation of EDU, a water soluble by-product, that was removed by a simple aqueous 
work up. It was concluded that the use of EDC.HCl / DMAP coupling improved the method of 
synthesis for analogues ES8-ES14, resulting in improved yields. 
Upon the successful synthesis and characterisation of ester and amide TMZ analogues, the 
activity of each analogue was determined against specified cell lines and primary cultures. The 
full results are presented in Chapter 3. Unfortunately, many of the amides synthesised as part 
of the present study were found to be insoluble in medium, prompting their elimination from 
the study, thus, allowing analogues with preferential solubility to be focused upon. The most 
prominent finding from antiproliferative determination of TMZ analogues, was the exceptional 
in-vitro potency of phenolic TMZ esters, ES8, ES9, ES10, ES11, ES12 and ES14. During initial 
determination using various cell lines, the phenolic TMZ esters were found to exhibit activity up 
to 5-fold greater than TMZ, against specified glioma cell lines. Following this success, the activity 
of lead phenolic TMZ esters was probed further, using primary GBM cultures. The lead analogues 
were assessed against MGMT negative and MGMT positive primary cells. In the primary culture 
devoid of MGMT, TMZ only has a slight effect on the viability of cells at concentrations that may 
be clinically obtainable (15-75 µM) (Figure 5.1). The observed lack of efficacy could explain why 
TMZ only has negligible impact on patient survival rates (Stupp et al., 2005; Chamberlain, 2010). 
In contrast, the phenolic TMZ esters, containing highly polarising aromatic substituents, were 
found to induce a reduction in viability >50%, at clinically obtainable concentrations of TMZ (15-
75 µM) (Figure 5.1). The dramatic improvement in activity as a result of these analogues could 
translate to improved health care of patients, ultimately resulting in greater survival rates and 
quality of life. The primary culture, BTNW974, was derived from a female patient whose survival 
was 10 months, following resection. As TMZ did not elicit a significant reduction in viability at 
clinically relevant concentrations in these cells, it is unlikely that a therapeutic benefit was 
gained by this patient as a result of TMZ treatment. However, as phenolic ester analogues of 
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TMZ appeared to reduce viability at clinically relevant concentrations of TMZ, it is possible that 
this patient may have gained some benefit if treated with these analogues, providing all other 
physiological parameters for these TMZ esters is favourable. 
 
 
Figure 5.1: Cell Viability of BTNW914 (MGMT -) after treatment by TMZ and phenyl TMZ ester 
analogues at various clinically relevant concentrations. Values reported are IC50 ± SD, n=3. 
 
As expected, primary cultures expressing high levels of MGMT, exhibited resistance to TMZ 
(Figure 5.2). Interestingly, lead phenolic TMZ esters were able to reduce the viability of MGMT 
expressing cells. This suggests that either analogues may cause a greater influx of 
methyldiazonium ions within the cell and subsequent DNA methylation which could overwhelm 
repair pathways or possibly a mechanism of action distinct from methylation. It should be noted 
that the phenolic TMZ esters were less potent against MGMT-expressing primary cells, 
compared to MGMT-devoid primary cells. However, a significant decrease in viability was 


































Figure 5.2: Cell Viability of BTNW374 (MGMT +) after treatment by TMZ and phenyl TMZ ester analogues 
at various clinically relevant concentrations. Values reported are IC50 ± SD, n=3. 
 
Interestingly, both Svec et al. (2018) and Yang et al. (2019) have reported C8-subsituted 
analogues of TMZ, containing phenyl and imidazole moieties, respectively. These groups were 
directly attached to position 8 of the imidazole ring of the lead compounds from these studies. 
Each of these studies reports a marked increase in activity of respective title analogues. Lead 
analogues of the present study contain phenyl groups similar to that of analogues described by 
Svec et al. (2018). Phenyl groups attached to position 8 on the imidazole ring, directly or via an 
ester bond, present a marked increased activity irrespective of MGMT expression (Svec et al., 
2018). This evidence further supports the notion that the attachment of phenyl groups to this 
position has the potential to yield analogues of TMZ that elicit a greater therapeutic benefit to 
GBM patients. 
Up until recently, the implications of modifying position 8 of imidazotetrazines was unclear. 
However, in light of recent findings, reported in studies conducted by Svec et al. (2018) and Yang 































DMSO 0.5% 15 µM 75 µM 200 µM
170 
 
the rate of prodrug activation. However, the optimum rate of imidazotetrazine prodrug 
activation is still unknown. Nevertheless, as part of future work, the rate of prodrug activation 
should be assessed for the lead phenyl TMZ analogues, in order to assess whether or not the 
aromatic substituents have the ability to influence the rate at which the analogues degrade to 
methyl diazonium ions.  
The activity of lead phenolic esters ES8, ES9, ES10, ES11, ES12 and ES14, against MGMT positive 
cells, suggests a mechanism of action distinct from methylation. Each phenol is known to be 
responsible for a series of complex radical scavenging, antioxidising, and prooxidising effects, all 
of which can initiate cellular apoptosis (Ferluga et al., 1972; Elia et al., 1994; Chen et al., 2004; 
Selassie et al., 2005; Kadoma et al., 2010). Providing the phenolic TMZ esters 55, or one of the 
imidazole degradation products 56, retain the characteristics of the corresponding alcohols; it is 
conceivable that disruptions in the cellular balance between ROS generation and antioxidant 
generation could contribute to the antiproliferative effects observed in Figure 5.2. In addition to 
hydrolytic degradation, possibly producing a phenyl ester imidazole 56; the TMZ phenyl ester 55 
could readily degrade to TMZ acid and the corresponding phenyl alcohol 57, in the presence of 
esterases. Esterases are known to be present in GBM although they are generally found at lower 
concentrations in the brain compared with the rest of the body (Fabiani et al., 1970; Sanchez-
Diaz et al., 2017). The presence of phenyl ester imidazoles 56 is therefore less likley due to 
hydrolysis of ester bonds. It is more plausible that phenyl alcohols, degraded from the parent 
drug, could possibly contribute to the reduction in viability of MGMT expressing cells. However, 
it should be noted that the literature indicates that phenols do tend to be relatively well 
tolerated by cell lines in-vitro. In primary rat hepatocytes, 4-Nitrophenol has been found not to 
cause DNA damage at concentrations less than 700 µM (Elia et al., 1994). Similarly, 4-
chlorophenol has been shown to initiate apoptosis at relatively high concentrations of 
approximately 2 mM in mouse fibroblast cells (Chen et al., 2004). Since phenols tend to induce 
cytotoxic events at relatively high concentrations, it is unlikely that the cleaved alcohols are 
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responsible for the antiproliferative effects observed in the present study. Consequently, it 
would be appropriate to investigate the antiproliferative effects of the phenols, used to prepare 
the six lead TMZ esters, in order to confirm whether or not they contribute to activity. 
 
Figure 5.3: Structures produced by esterase mediated and pH mediated degradation of TMZ phenyl 
esters that could be responsible for disruptions in the cellular balance between ROS generation and 
antioxidant generation, resulting in activity. TMZ phenyl ester (55); Imidazole phenyl ester produced 
during pH mediated prodrug activation (56); Phenyl alcohols produced during esterase mediated 
degradation (57). 
 
Similarly, the TMZ acid has been consistently shown throughout antiproliferative determination 
studies to not be responsible for the increase in cytotoxicity, see data presented in Figure 5.1, 
5.2. However, it is unclear whether this is due to poor cellular membrane penetration, due to its 
polar nature. It is also plausible that the esters could act as vehicles for delivering TMZ acid into 
the cell. However, this does not explain the activity against MGMT positive cells or the variable 
activity between various esters. Therefore, it is the authors view that the increased cytotoxicity 
observed with the phenolic TMZ esters is possibly caused by a synergistic effect involving 
multiple mechanisms from compounds 55 or 57 (Figure 5.3). However, due to the novelty of the 
work, there is limited evidence to support this hypothesis, until mechanistic studies are carried 
out.    
Chapter 4 details the stability of lead TMZ analogues when subjected to esterase enzymes. 
Although these investigations are preliminary and need to be repeated, the results suggest a 
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marked fragility of the ester bonds in the lead analogues. In fact, 50% of the esters were 
hydrolysed by esterase enzymes within the first 3-14 min of exposure. The maximum intracranial 
concentration of TMZ is reported to be approximately 2 ± 0.8 h (Portnow et al., 2009). As a 
result, it is unlikely that the lead TMZ esters, that are highlighted in Chapter 3, would in fact 
reach the site of a brain tumour intact. It is therefore probable that TMZ esters would be 
hydrolysed into TMZ acid and the corresponding alcohol and the increased activity observed in-
vitro would be lost. Despite the obvious challenges the ester bonds pose, the exceptional in-
vitro activity displayed, irrespective of MGMT expression, by lead analogues (ES8, ES9, ES10, 
ES11, ES12 and ES14) should be investigated further. Future work involving in-vivo models 
should take into account the fragility of ester bonds, by incorporating a strategic delivery of 
analogues to the tumour site, in order to ensure the analogues are delivered to the tumour site 
intact. Such delivery options could possibly involve PEGylated liposomes, which have recently 
been shown to increase the uptake of TMZ to the brain by 4-fold, compared to a free drug 
solution (Vanza et al., 2018). Similarly, Kumari et al. (2017) reported significant success with 
lactoferrin nanoparticles, which again could present a viable option for the lead TMZ esters 
described in the present study.  
The evidence collected as part of the present study suggests that lead phenolic TMZ esters have 
potential to induce greater therapeutic effects in patients, which could contribute to greater 
survival rates compared to treatment with TMZ. The data collected also suggest that the lead 
analogues could elicit a therapeutic benefit in patients that present TMZ resistant GBM, as a 
result of MGMT expression. The results presented in this study are supported by the activity 
observed in similar phenyl containing TMZ analogues reported by Svec et al. (2018). Immediate 
future work should involve assessing whether the intact phenyl esters of TMZ are the active 
compounds or whether it is the hydrolysed carboxylate or phenyl alcohol that generate the 
cytotoxic effect. As stated in Chapter 4, the esterase mediated hydrolysis of the lead phenolic is 
to be repeated, using the improved method, thus yielding a more conclusive outcome. The 
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biodistribution of the lead compounds should also be assessed in an in-vivo model. This 
information should help improve our understanding of whether a strategic drug delivery system 
such as nanoparticles, encapsulating the esters, would be needed to maximise efficacy of lead 
analogues in an in-vivo model. In summary, it is plausible that the lead TMZ analogues, described 
as part of this chapter, have the potential to replace TMZ as a more effective treatment of GBM. 
However, as this work is very much in its infancy, a considerable amount of additional work will 
need to be undertaken in order to confirm the envisaged therapeutic benefit of the phenyl TMZ 
analogues (Figure 5.4).  
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Appendix to Chapter 3 
Appendix 3a: DMSO Controls for Cell Lines and Primary Cultures 
 
Appendix 1: The effect of DMSO at various concentrations on U87-MG, 1321-N1, GOS-3 and SVGp12 cell 




Appendix 2: The effect of DMSO at 0.5% DMSO on primary cultures, BTNW914 and BTNW374. The values 







































































Appendix 3b: Solubility Evaluation of TMZ, TMZ acid and Ester and Amide 
Analogues of TMZ 
3-Methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (TMZ) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 3: Solubility evaluation of TMZ. TMZ was found to be soluble in media, ranging from 0-1000 
µM. Images shown at x40 magnification. 
 
3-Methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid – (TMZ Acid) 
 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 4: Solubility evaluation of TMZ Acid. TMZ Acid was found to be soluble in media, ranging from 





Ethyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - (ES1) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 5: Solubility evaluation of ES1. ES1 (0-1000 µM) was found to be soluble in media. Images 
shown at x40 magnification. 
 
Hexyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES2) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 6: Solubility evaluation of ES2. ES2 was found to be soluble in media, ranging from 0-1000 µM. 





Phenethyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES3) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 7: Solubility evaluation of ES3. ES3 was found to be soluble in media, ranging from 0-1000 µM. 
Images shown at x40 magnification. 
 
2-(4-Nitrophenyl)ethyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES4) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 






2-(4-Methoxyphenyl)ethyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate (ES5) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 9: Solubility evaluation of ES5. ES5 was found to be insoluble in media. Images shown at x40 
magnification. 
 
(4-Methoxyphenyl)methyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate (ES6) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 







3-(Dimethylamino)propyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate (ES7) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 11: Solubility evaluation of ES7. ES7 was found to be soluble in media, ranging from 0-1000 
µM. Images shown at x40 magnification. 
 
(4-Methoxyphenyl) 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES8) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 12: Solubility evaluation of ES8. ES8 was found to be soluble in media, ranging from 0-200 µM. 





(4-Nitrophenyl) 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES9) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 13: Solubility evaluation of ES9. ES9 was found to be soluble in media, ranging from 0-200 µM. 
Images shown at x40 magnification. 
 
(4-Chlorophenyl) 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES10) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 14: Solubility evaluation of ES10. ES10 was found to be soluble in media, ranging from 0-200 






(4-Cyanophenyl) 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate - (ES11) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 15: Solubility evaluation of ES11. ES11 was found to be soluble in media, ranging from 0-200 
µM. Images shown at x40 magnification. 
 
Phenyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES12) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 16: Solubility evaluation of ES12. ES12 was found to be soluble in media, ranging from 0-1000 





(2-Methoxyphenyl) 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES13) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 17: Solubility evaluation of ES13. ES13 was found to be soluble in media, ranging from 0-1000 
µM. Images shown at x40 magnification. 
 
p-Tolyl 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylate – (ES14) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 18: Solubility evaluation of ES14. was found to be soluble in media, ranging from 0-1000 µM. 





N-Hexyl-3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM1) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 19: Solubility evaluation of AM1. AM1 was found to be soluble in media, ranging from 0-200 
µM. Images shown at x40 magnification. 
 
3-Methyl-4-oxo-N-phenethyl-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM2) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 20: Solubility evaluation of AM2. AM2 was found to be soluble in media, ranging from 0-600 





3-Methyl-4-oxo-N-phenyl-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM3) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 21: Solubility evaluation of AM3. AM3 was found to be soluble in media, ranging from 0-200 
µM media. Images shown at x40 magnification. 
 
N-(4-Methoxyphenyl)-3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM4) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 






N-(4-Chlorophenyl)-3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM5) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 23: Solubility evaluation of AM5. AM5 was found to be insoluble in media. Images shown at 
x40 magnification. 
 
N-(4-Cyanophenyl)-3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM6) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 






3-Methyl-4-oxo-N-(p-tolyl)imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM7) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 25: Solubility evaluation of AM7. AM7 was found to be insoluble in media. Images shown at 
x40 magnification. 
 
N-(2-Methoxyphenyl)-3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM8) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 







   
0 µM  200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 27: Solubility evaluation of AM9. AM9 was found to be insoluble in media. Images shown at 
x40 magnification. 
 
3-Methyl-4-oxo-N-(p-tolylmethyl)imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide – (AM10) 
   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 
Appendix 28: Solubility evaluation of AM10. AM10 was found to be soluble in media, ranging from 0-200 






   
0 µM 200 µM 400 µM 
   
600 µM 800 µM 1000 µM 














Appendix 3c: Graphs to Show the Antiproliferative Determination of Each 
Analogue Against Various Cell Lines 
The following figures indicate the relationship between concentration of each drug and the 
viability of cells following 6 days of incubation. Each experiment was carried out in triplicate and 




Appendix 30: IC50 evaluation of temozolomide. Temozolomide (0-1000 µM) inhibits growth of U87-MG, 
1321-N1, GOS-3 and SVGp12 cell lines with IC50 values of 696±79, 783±40, 698±15, 239±6, respectively. 
The data values displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 
values are as follows: U87-MG - y = 3E-06x2 - 0.075x + 99.73; 1321-N1 – y = -7E-05x2 – 0.0091x + 101.52; 










































Appendix 31: IC50 evaluation of temozolomide acid. Temozolomide acid (0-1000 µM) inhibits growth of 
U87-MG, 1321-N1, GOS-3 and SVGp12 cell lines with IC50 values of 662±42, 596±26, 504±30 and 316±2, 
respectively. The data values displayed are mean ± SD, (n=3). Polynomial regression equations used to 
calculate IC50 values are as follows: U87-MG - y = 5E-05x2 - 0.0437x + 102.45; 1321-N1 – y = -3E-05x2 – 
0.0762x + 106.14; GOS-3 – y = 8E-06x2 – 0.1121x + 104.6; SVGp12 – y = 0.0001x2 – 0.2014x + 103.65. 
 
 
Appendix 32: IC50 evaluation of ES1. ES1 (0-1000 µM) inhibits growth of U87-MG cell line, with an IC50 of 
700.55±108.59 µM. The data values displayed are mean ± SD, (n=3). This compound was eliminated from 
further testing due to poor potency compared to TMZ. Polynomial regression equations used to calculate 









































































Appendix 33: IC50 evaluation of ES2. ES2 (0-1000 µM) inhibits growth of U87-MG, 1321-N1, GOS-3 and 
SVGp12 cell lines, with IC50 values of 409±45, 269±20, 400±4 and 182±11 µM, respectively. Polynomial 
regression equations used to calculate IC50 values are as follows: U87-MG - y = 6E-05x2 - 0.165x + 106.22; 
1321-N1 – y = 0.0001x2 – 0.2361x + 106.26; GOS-3 – y = 5E-05x2 – 0.1607x + 105.61; SVGp12 – y = 
0.0002x2 – 0.2499x + 88.783. 
 
Appendix 34: IC50 evaluation of ES3. ES3 (0-1000 µM) inhibits growth of U87-MG cell line, with an IC50 of 
615±96 µM. The data values displayed are mean ± SD, (n=3). This compound was eliminated from further 
testing due to poor potency compared to TMZ. Polynomial regression equations used to calculate IC50 




































































Appendix 35: IC50 evaluation of ES7. ES7 (0-1000 µM) inhibits growth of U87-MG cell line, with an IC50 of 
856±20 µM. The data values displayed are mean ± SD, (n=3). This compound was eliminated from further 
testing due to poor potency compared to TMZ. Polynomial regression equations used to calculate IC50 
values are as follows: U87-MG - y = 5E-06x2 - 0.0601x + 96.801. 
 
Appendix 36: IC50 evaluation of ES8. ES8 (0-200 µM) inhibits the growth of U87-MG, 1321-N1 GOS-2 and 
SVGp12 cell lines, with IC50 values of 103±6, 183±0.4, 155±5 and 44±2 µM, respectively. The data values 
displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 values are as 
follows: U87-MG - y = 0.0005x2 - 0.4367x + 99.595; 1321-N1 – y = 0.0021x2 – 0.0888x + 101.84; GOS-3 – y 






































































Appendix 37: IC50 evaluation of ES9. ES9 (0-200 µM) inhibits growth of U87-MG, 1321-N1, GOS-3 and 
SVGp12 cell lines, with IC50 values of 142±3, 106±7, 96±1 and 39±2 µM, respectively. The data values 
displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 values are as 
follows: U87-MG - y = 0.0004x2 - 0.3712x + 94.096; 1321-N1 – y = 8E-05x2 – 0.5382x + 105.16; GOS-3 – y 
= -5E-05x2 – 0.5355x + 101.94; SVGp12 – y = 0.0044x2 – 1.3207x + 95.15. 
 
Appendix 38: IC50 evaluation of ES10. ES10 (0-200 µM) inhibits growth of U87-MG, 1321-N1, GOS-3 and 
SVGp12 cell lines, with IC50 values of 96±3, 118±11, 54±4 and 33±1 µM, respectively. The data values 
displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 values are as 
follows: U87-MG - y = 0.001x2 - 0.548x + 94.53; 1321-N1 – y = 4E-05x2 – 0.5247x + 108.65; GOS-3 – y = 









































































Appendix 39: IC50 evaluation of ES11. ES11 (0-200 µM) inhibits growth of U87-MG, 1321-N1, GOS-3 and 
SVGp12 cell lines, with IC50 values of 142±5, 103±7, 151±4 and 36±3 µM, respectively. The data values 
displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 values are as 
follows: U87-MG - y = 0.0003x2 - 0.3693x + 97.245; 1321-N1 – y = 0.0005x2 – 0.5609x + 102.24; GOS-3 – y 
= 0.0001x2 – 0.3431x + 104.75; SVGp12 – y = 0.0048x2 – 1.3464x + 89.42. 
 
Appendix 40: IC50 evaluation of ES12. ES12 (0-1000 µM) inhibits growth of U87-MG, 1321-N1, GOS-2 and 
SVGp12 cell lines, with IC50 values of 331±47, 510±10, 691±34 and 238±6 µM, respectively. The data 
values displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 values are 
as follows: U87-MG - y = 9E-05x2 - 0.1601x + 93.085; 1321-N1 – y = 1E-06x2 – 0.1093x + 105.6; GOS-3 – y 








































































Appendix 41: IC50 evaluation of ES13. ES13 (0-1000 µM) inhibits growth of U87-MG cell line, with an IC50 
of 567±92 µM. The data values displayed are mean ± SD, (n=3). This compound was eliminated from 
further testing due to poor potency compared to TMZ. Polynomial regression equations used to calculate 
IC50 values are as follows: U87-MG - y = 7E-05x2 - 0.1577x + 99.012. 
 
Appendix 42: IC50 evaluation of ES14. ES14 (0-1000 µM) inhibits growth of U87-MG, 1321-N1, GOS-3, 
SVGp12 cell lines, with IC50 values of 376±62, 238±8, 314±38 and 215±26 µM, respectively. The data values 
displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 values are as 
follows: U87-MG - y = 7E-05x2 - 0.1577x + 99.012; 1321-N1 – y = 0.0002x2 – 0.2584x + 101.99; GOS-3 – y = 















































































Appendix 43: IC50 evaluation of AM1. AM1 (0-200 µM) inhibits growth of U87-MG cell line. IC50 could not 
be generated from the data without extrapolating past measured data points. The data values displayed 
are mean ± SD, (n=3). This compound was eliminated from further testing due to poor potency compared 
to TMZ. 
 
Appendix 44: IC50 evaluation of AM2. AM2 (0-600 µM) inhibits growth of U87-MG cell line, with an IC50 
of 548±48. The data values displayed are mean ± SD, (n=3). This compound was eliminated from further 
testing due to poor potency compared to TMZ. Polynomial regression equations used to calculate IC50 

































































Appendix 45: IC50 evaluation of AM3. AM3 (0-200 µM) inhibits growth of U87-MG cell line. IC50 could not 
be generated from the data without extrapolating past measured data points. The data values displayed 




Appendix 46: IC50 evaluation of AM10. AM10 (0-200 µM) inhibits growth of U87-MG, 1321-N1, GOS-2 
and SVGp12 cell lines. The IC50 values for U87-MG and SVGp12 are 139±28 and 79±6, respectively. IC50 
values for 1321-N1 and GOS-3 could not be generated, due to a lack of activity. The data values 
displayed are mean ± SD, (n=3). Polynomial regression equations used to calculate IC50 values are as 
follows: U87-MG - y = 0.0007x2 - 0.4251x + 95.586; 1321-N1 – y = -0.0008x2 – 0.0422x + 103.57; GOS-3 – 



































































Appendix to Chapter 4 
Appendix 4a: Repeatability of TMZ acid, TMZ esters and Corresponding Alcohols 
Using HPLC 











Appendix 47: Repeatability of TMZ acid (103 µM) over 6 injections. 
 
 





























Appendix 49: Repeatability of 4-methoxyphenol (162 µM) over 6 injections. 
 
 































Appendix 51: Repeatability of 4-nitrophenol (144 µM) over 6 injections. 
 
 































































Appendix 55: Repeatability of 4-hydroxybenzonitrile (169 µM) over 6 injections. 
 
 





























Appendix 57: Repeatability of phenol (251 µM) over 6 injections. 
 
  















































Appendix 4b: Reproducibility of TMZ acid, TMZ esters and Corresponding Alcohols 
Using HPLC 
TMZ Acid (103 µM) 
  
Sample PA1 PA2 AVG PA 
1 970246 970389 970317.50 
2 968042 971509 969775.50 
3 967882 969240 968561.00 
4 954308 954020 954164.00 
5 959385 961683 960534.00 







Appendix 60: Reproducibility of TMZ Acid (103 µM). 
 
 
ES8 (66 µM) 
   
Sample PA1 PA2 AVG PA 
1 813894 826976 820435.00 
2 820152 820481 820316.50 
3 825462 825951 825706.50 
4 814193 814975 814584.00 
5 826795 825095 825945.00 













4-Methoxyphenol (162 µM) 
  
Sample PA 1 PA2 AVG PA 
1 623139 622380 622759.50 
2 624173 623183 623678.00 
3 621095 623442 622268.50 
4 613151 616580 614865.50 
5 618205 623060 620632.50 







Appendix 62: Reproducibility of 4-methoxyphenol (162 µM). 
 
  
ES9 (63 µM) 
   
Sample PA1 PA2 AVG PA 
1 936223 935362 935792.50 
2 945668 946376 946022.00 
3 927576 940022 933799.00 
4 941346 906787 924066.50 
5 928203 915913 922058.00 














4-Nitrophenol (144 µM) 
  
Sample PA1 PA2 AVG PA 
1 1476342 1472228 1474285.00 
2 1496376 1490570 1493473.00 
3 1465367 1478730 1472049.00 
4 1491848 1441278 1466563.00 
5 1472751 1458248 1465500.00 











ES10 (66 µM) 
   
Sample PA1 PA2 AVG PA 
1 792054 794655 793354.50 
2 794323 792464 793393.50 
3 790458 790595 790526.50 
4 786808 785570 786189.00 
5 797483 801775 799629.00 













4-Chlorophenol (155 µM) 
  
Sample PA1 PA2 AVG PA 
1 1336524 1303198 1319861.00 
2 1321441 1331901 1326671.00 
3 1308566 1315605 1312086.00 
4 1313775 1315605 1314690.00 
5 1341691 1328644 1335168.00 







Appendix 66: Reproducibility of 4-chlorophenol (155 µM). 
 
  
ES11 (68 µM) 
  
Sample PA1 PA2 AVG PA 
1 883197 884466 883831.50 
2 892625 898000 895312.50 
3 888821 888193 888507.00 
4 892401 895825 894113.00 
5 881495 883476 882485.50 














4-Hydroxybenzonitrile (169 µM) 
  
Sample PA1 PA2 AVG PA 
1 2964287 2971625 2967956.00 
2 3001984 3014323 3008154.00 
3 2983782 2990218 2987000.00 
4 3001127 3015080 3008104.00 
5 2970794 2977672 2974233.00 




  SD 16915.98 
  
RSD 0.57% 
Appendix 68: Reproducibility of 4-hydroxybenzonitrile (169 µM). 
 
 
ES12 (74 µM)  
   
Sample PA1 PA2 AVG PA 
1 968115 970613 969364.00 
2 972963 973955 973459.00 
3 976836 976486 976661.00 
4 966892 973323 970107.50 
5 938898 940028 939463.00 















Phenol (251 µM)  
   
Sample PA1 PA2 AVG PA 
1 375439 376867 376153.00 
2 373240 375059 374149.50 
3 375517 376571 376044.00 
4 374022 373780 373901.00 
5 362477 362882 362679.50 







Appendix 70: Reproducibility of phenol (251 µM). 
 
 
ES14  (71 µM) 
  
Sample PA1 PA2 AVG PA 
1 698166 729880 714023.00 
2 715688 720746 718217.00 
3 703956 700006 701981.00 
4 705671 706018 705844.50 
5 728550 740391 734470.50 














P-Cresol (185 µM) 
 
Sample PA1 PA2 AVG PA 
1 864988 862337 863662.50 
2 884100 846344 865222.00 
3 881069 871643 876356.00 
4 844419 855450 849934.50 
5 854528 860594 857561.00 
























Appendix 4c: Linearity Investigations of TMZ esters and Corresponding Alcohols 
Using HPLC 
 
Appendix 73: A calibration curve to assess the relationship between TMZ acid concentration and 
response (peak area). 
 
 


























































Appendix 75: A calibration curve to assess the relationship between 4-methoxyphenol concentration and 

































































Appendix 77: A calibration curve to assess the relationship between 4-nitrophenol concentration and 

































































Appendix 79: A calibration curve to assess the relationship between 4-chlorophenol concentration and 

































































Appendix 81: A calibration curve to assess the relationship between 4-hydroxybenzonitrile concentration 





































































































































































































4-Methoxyphenol (2020 nM) 
4-Methoxyphenol (1010 nM) 
4-Methoxyphenol (505 nM) 
4-Methoxyphenol (203 nM) 
Appendix 86: Determining the LLOQ and LLOD of 4-methoxyphenol. Injection B, 4-methoxyphenol (6.0 mins; 1010 nM), was 






























ES9 (198 nM); 4-nitrophenol (901 nM) 
ES9 (99 nM); 4-nitrophenol (451 nM) 
ES9 (50 nM); 4-nitrophenol (225 nM) 
ES9 (25 nM); 4-nitrophenol (113 nM) 
Appendix 87: Determining the LLOQ and LLOD of ES9 and 4-nitrophenol. Injection A, (198 nM and 901 nM of ES9 (12.25 min) 
and 4-nitrophenol (10.5 min), respectively), was determined to be the LLOQ for ES9. Injection B, (99 nM and 451 nM of ES9 
and 4-nitrophenol, respectively), was determined to be the LLOD for ES9 and the LLOQ for 4-nitrophenol. Injection C, (50nM 




























ES10 (52 nM) 
ES10 (103 nM) 
ES10 (206 nM) 
ES10 (413 nM) 
Appendix 88: Determining the LLOQ and LLOD of ES10. Injection B, ES10 (17.5 mins; 206 nM), was estimated to be the LLOQ. 




























4-Chlorophenol (121 nM) 
4-Chlorophenol (243 nM) 
4-Chlorophenol (485 nM) 
4-Chlorophenol (969 nM) 
Appendix 89: Determining the LLOQ and LLOD of 4-chlorophenol. Injection A, 4-chlorophenol (14.8 mins; 969 nM), was 





























ES11 (34 nM) 
ES11 (67 nM) 
ES11 (133 nM) 
ES11 (266 nM) 
Appendix 90: Determining the LLOQ and LLOD of ES11. Injection B, ES11 (8.5 mins; 133 nM), was estimated to be the LLOQ. 




























4-Hydroxybenzonitrile (11 nM) 
4-Hydroxybenzonitrile (21 nM) 
4-Hydroxybenzonitrile (41 nM) 
4-Hydroxybenzonitrile (83 nM) 
Appendix 91: Determining the LLOQ and LLOD of 4-hydroxybenzonitrile. Injection A, 4-hydroxybenzonitrile (6.8 mins; 133 nM), 





























ES12 (18 nM) 
ES12 (36 nM) 
ES12 (73 nM) 
ES12 (145 nM) 
Appendix 92: Determining the LLOQ and LLOD of ES12. Injection A, ES12 (9.1 mins; 145 nM), was estimated to be the 




























Phenol (61 nM) 
Phenol (122 nM) 
Phenol (245 nM) 
Phenol (490 nM) 
Appendix 93: Determining the LLOQ and LLOD of phenol. Injection A, phenol (7.0 mins; 490 nM), was estimated to be the 




























ES14 (56 nM) 
ES14 (111 nM) 
ES14 (221 nM) 
ES14 (443 nM) 
Appendix 94: Determining the LLOQ and LLOD of ES14. Injection B, ES14 (13.75 mins; 221 nM), was estimated to be the 








P-Cresol (144 nM) 
P-Cresol (289 nM) 
P-Cresol (577 nM) 
P-Cresol (1156 nM) 
Appendix 95: Determining the LLOQ and LLOD of p-cresol. Injection A, p-cresol (9.6 mins; 1156 nM), was estimated to be 
the LLOQ. Injection C, p-cresol (9.6 mins; 289 nM), was estimated to be the LLOD. Analysis at 225 nm. 
